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Abstract 
Emotional functioning is a key component of both healthy and abnormal development in 
children and adolescents. It entails the experience, expression and regulation of emotions as 
well as emotional disorders. Although both the experience and the regulation of emotions 
change across the lifespan, they do so at an especially intense and rapid rate throughout 
childhood and adolescence. It is therefore crucial to investigate the role of different aspects of 
emotional functioning in various domains in these populations. Moreover, the onset of most 
emotional disorders occurs in adolescence, and prevalence rates of anxiety and depressive 
disorders are especially high during this period of life.  
For the purpose of this thesis, three components of emotional functioning were 
studied, using various methods across several domains. The first aim was to examine the role 
of emotion regulation in chronic pain (Koechlin, Coakley, Schechter, Werner, & Kossowsky, 
2018, Study I). For this purpose, a systematic literature search was conducted and studies 
meeting specific criteria were then synthesized to investigate whether emotion regulation 
might enhance existing frameworks of chronic pain. In addition, associations between two 
broad categories of emotion regulation (namely antecedent- and response-focused emotion 
regulation) and chronic pain were explored. Emotion regulation depends to a great extent on 
emotional reactivity, i.e. the individual threshold required for emotional reactions – 
experiencing more and more intense emotions can complicate adequate emotion regulation. 
Hence, the second aim of this study was to analyze how emotional reactivity influences the 
occurrence of adjustment problems in adolescents who experience stressful life events in their 
childhood years (Koechlin, Donado, Berde, & Kossowsky, 2018, Study II). In order to 
achieve this second aim, a large longitudinal dataset was used and several covariates, among 
them emotional reactivity, were analyzed with the aim of predicting adjustment problems in 
956 children who had experienced some or many stressful life events. Finally, as the 
prevalence rates of emotional disorders are high in adolescence, the third aim was to examine 
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the efficacy and safety of a common intervention, namely two classes of antidepressants, 
selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake 
inhibitors (SNRIs). In order to address this aim, a meta-analytic approach was chosen, and all 
randomized, double-blind, placebo-controlled trials of SSRIs and SNRIs in children and 
adolescents younger than 18 years who had been diagnosed with an emotional disorder were 
included (Locher, Koechlin et al., 2017).  
Study I showed that in the included reports, emotion regulation was rarely directly 
associated with pain intensity or pain-related disability. Rather, the relationship between both 
groups of emotion regulation strategies (antecedent- and response-focused) and chronic pain 
seemed to be mediated by psychological factors such as high emotionality, anxiety, or 
negative mood. This raises questions for future research, such as whether interventions that 
target emotion regulation specifically have the potential to relieve symptoms of chronic pain 
and emotional disorders simultaneously. Study II found that adjustment problems were best 
predicted by high emotional reactivity and many stressful life events. The results of this study 
point to the potential that emotional reactivity holds for the prevention and treatment of 
adjustment problems in adolescence. Study III revealed that even though antidepressants were 
more effective than a placebo in treating common emotional disorders in children and 
adolescents, these effects were small and disorder-specific. The results of this analysis present 
multiple avenues for further research, such as the underlying differences and similarities in 
emotional disorders that might help explain the difference in response to antidepressants and 
placebo.  
Patterns of emotional functioning develop in childhood, but may persist into 
adulthood, which highlights the importance of adaptive emotional functioning. This thesis 
sheds light on how emotional functioning influences chronic pain and the occurrence of 
adjustment problems in the face of stressful life events, and examines a common treatment for 
emotional disorders. Future research should focus on age-specific changes in emotional 
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functioning and how these influence chronic pain, emotional disorders and other domains. 
This approach would allow researchers to tailor interventions and prevention to age-specific 
needs and abilities.  
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Theoretical Background 
Emotional Functioning 
Emotions are basic features of human functioning (Shonkoff & Phillips, 2000). As such, they 
play a key role in both mental health and illness throughout the entire lifespan: maladaptive 
emotional functioning is thought to be a critical feature in nearly all mental disorders (Sloan, 
2006) and hence emotional work is central to a range of psychotherapeutic approaches (e.g., 
Harned, Banawan, & Lynch, 2006; Mennin, 2006; Suveg, Kendall, Comer, & Robin, 2006). 
Definitions of emotional functioning vary, but all note that emotional functioning entails the 
experience, expression and regulation of positive and negative emotions as well as symptoms 
of emotional problems such as anxiety, depression and aggressive behavior (Gross & John, 
2003; Kessler, Turner, & House, 1989; Vriend et al., 2013). Emotional functioning can thus 
be understood as an umbrella term that includes more specific concepts such as emotion 
regulation (Vriend et al., 2013), awareness and expression of emotions (Tolstikova, 2010), 
and psychological symptoms such as depression and anxiety symptoms (Jackson, Misiti, 
Bridge, Daniels, & Vannatta, 2015). Emerging patterns of emotional functioning in childhood 
are maintained into adulthood, hence childhood emotional functioning may provide an early 
indicator of long-term health risk in adulthood (DeSteno, Gross, & Kubzansky, 2013; Repetti, 
Taylor, & Seeman, 2002). 
This thesis examines three different aspects of emotional functioning from different 
perspectives, namely emotion regulation, emotional reactivity, and emotional disorders. 
Content and methodology across both childhood and adolescence are considered. 
When talking about emotional functioning, it is important to clarify what is meant by 
an emotion. A distillation of major points of convergence across researchers is depicted in 
Figure 1.  
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Figure 1. The process model of emotion generation (Gross, 1998b) 
 
Figure 1 shows that an emotional cue (such as a facial expression, bodily posture or a 
situation that is characteristic of a certain emotion, e.g., a funeral) is always evaluated and the 
elicited emotional responses are influenced by an individual’s goals and by what is 
meaningful to that individual. As such, emotions are flexible response sequences that arise 
whenever a situation is evaluated as offering challenges or opportunities to the individual. 
Emotions are multi-faceted, they involve changes in the behavioral, experiential and 
physiological domains, and they initiate changes in subjective experience. The modulation of 
response tendencies determines the final shape of the emotional response (Gross, 1998b). 
Emotional responses seem to be organized across dimensions such as valence, arousal, and 
approach-avoidance (Koole, 2009).  
 
Emotion Regulation 
Closely linked to the generation and experience of emotions and considered to be an 
important domain of emotional functioning is the regulation of emotions. Emotion regulation 
describes how people try to influence which emotions they have, when they have them, and 
how they experience and express these emotions (Gross, 1998b). A helpful model when 
describing how emotion regulation can set in at every step of the temporal unfolding of the 
emotion generation process is the Process Model of Emotion Regulation conceptualized by 
Gross (2008; Figure 2).  
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Figure 2. The Process Model of Emotion Regulation  
 
The Process Model of Emotion Regulation broadly distinguishes between antecedent- 
and response-focused strategies, with the former referring to strategies that occur before the 
emotion is fully developed (hence their prospect of success is generally greater; Aldao, 2013), 
and the latter including strategies that appear once an emotion is fully developed and which 
thus focus mainly on the emotional expression (i.e., the emotional response). Strategies such 
as selection or modification of a situation, attentional deployment and cognitive change are 
considered antecedent-focused, while response modulation is regarded as response-focused. 
Emotion regulation strategies can be behavioral (such as directly selecting or modifying a 
situation: situation selection and situation modification), cognitive (such as distracting 
oneself, ruminating about aspects of the situation, or reappraising the situation altogether: 
attentional deployment and cognitive change), or they can focus on the experiential aspects 
(such as modulating the emotional response: response modulation). Emotion regulation may 
be adaptive or maladaptive; this is largely dependent on both the context and the individual 
applying the respective strategy. Rather than simply classifying certain strategies as adaptive 
or maladaptive, newer definitions focus on the flexibility of emotion regulation, i.e., 
successfully adapting the choice of emotion regulation strategies to contextual and social 
demands (Aldao, Sheppes, & Gross, 2015).  
The ability to regulate one’s emotions adaptively develops across childhood and 
adolescence. The first important step in this process is the growing ability of the young infant 
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(in the first two years of life) to express different emotional states and to label them verbally 
accordingly (Compas et al., 2014). This happens in close interaction with adults, especially 
with the primary caregivers. The importance of an emotional interaction between child and 
adult is exemplified by the still face experiment: in this experiment, the mother (or other 
primary caregiver), after an episode of emotionally expressive interaction with her child, puts 
on a still face, i.e., stops her emotional expressions altogether (Tronick et al., 1998). The usual 
reaction of the infant is an increasing level of distress that only fades once the mother starts 
interacting emotionally again. 
In toddlerhood, the ability to regulate emotions by the use of language (e.g., to talk 
oneself through a difficult situation or to ask for support) emerges (Petermann & Kullik, 
2011). During the preschool and elementary school years, children’s ability to regulate their 
emotions grows and they are increasingly able to manage their emotions according to 
contextual demands. During this time, children also learn to understand and use display rules, 
i.e., how intentionally to separate the emotional experience from their facial, vocal and/or 
behavioral expressions (Zeman, Cassano, Perry-Parrish, & Stegall, 2006). In middle 
childhood and adolescence, as a consequence of a heightened awareness of changing 
relationships with peers and parents and an understanding of the consequences of displayed 
emotions, children and adolescents become warier about which emotions they express in what 
context. In addition, self-conscious emotions such as pride or shame (that typically emerge for 
the first time in toddlerhood) might become more prevalent and more intense in adolescent 
years, as the awareness of being evaluated by the social environment increases (Zeman et al., 
2006). 
In their development of emotion regulation, children are largely influenced by their 
familial context. This occurs through several routes: through observation of how parents 
regulate their emotions, via parenting practices and behaviors (such as how parents react to 
emotions and whether they are controlling or hostile versus warm and caring towards the 
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child), and through the emotional climate within the family, which is reflected for example in 
the quality of parent-child attachment and the parental relationship (Bariola, Gullone, & 
Hughes, 2011; Morris, Silk, Steinberg, Myers, & Robinson, 2007). However, most studies to 
date on parental influence on the child’s emotion regulation development have focused on 
early childhood (Bariola et al., 2011; Dorn, Spindler, Kullik, Petermann, & Barnow, 2013), 
with much less data available for middle childhood and adolescent.  
  
With the increasing recognition of the importance of emotion regulation in adaptive 
development, its role in mental disorders has also attracted more attention (Mennin, 2006). 
Maladaptive emotion regulation has been found to play a crucial role in several mental 
disorders. A large meta-analysis that examined the relationship between six emotion 
regulation strategies (acceptance, avoidance, problem solving, reappraisal, rumination and 
suppression) and symptoms of four mental disorders (anxiety, depression, eating disorders, 
and substance-related disorders) found a large effect size for rumination (r=.49, 95% 
Confidence Interval (CI) = .45–.52), and medium to large effect sizes for avoidance (r=.38, 
95%CI=.33–.44), suppression (r=.34, 95%CI=.28–.39), and problem solving (r=-.31, 95%CI= 
-.36– -.25; Aldao, Nolen-Hoeksema, & Schweizer, 2009). Surprisingly, in this analysis, 
reappraisal and acceptance, two strategies that are part of various psychological interventions 
such as cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) 
showed only small to medium effect sizes (reappraisal: r=-.14, 95%CI= -.20– -.07; 
acceptance: r=-.19, 95%CI=-.40 – .05). The other results are in line with previous research 
that found rumination to be a key symptom of depression (Barnow, Aldinger, Ulrich, & 
Stopsack, 2013), avoidance to be especially prevalent in many anxiety disorders (Campbell-
Sills & Barlow, 2007) and suppression to be associated with behavioral problems in children 
(Cole, Zahn-Waxler, Fox, Usher, & Welsh, 1996). 
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Although inappropriate emotion regulation plays a role in a wide range of mental 
disorders (Gross, 2008), it was not considered a disorder in itself until the new version of the 
DSM, the DSM-V, was released in 2013, containing the new diagnosis Disruptive Mood 
Dysregulation Disorder. This disorder is characterized by severe, recurrent, and 
disproportionate temper outbursts three or more times a week, with a persistent irritable or 
angry mood between outbursts, and an onset of symptoms before age 10 (American 
Psychiatric Association, 2013). Disruptive Mood Dysregulation Disorder has emerged in the 
light of ever-increasing prevalence rates of bipolar disorder (and hence growing prescription 
rates of antipsychotics) in childhood, which have led some researchers to argue that this non-
episodic irritability could be considered a developmental presentation of mania (Leibenluft, 
2011; Rao, 2014). 
 
Emotional Reactivity 
Intertwined with emotion regulation is emotional reactivity, which refers to individual 
differences in arousability, i.e., the threshold required for (positive or negative) emotional 
reactions (Koleva, Krulichova, Bertolini, Caimi, & Garattini, 2005). Recent research has 
shown that more negatively emotionally reactive children are more susceptible to 
environmental influences (Belsky & Pluess, 2012) and rearing (Pluess & Belsky, 2010). 
Experiencing more and more intense emotions might also complicate the emotion regulation 
process.  
The Emotional Security Theory (Davies & Cummings, 1994) suggests that emotional 
security serves as a mediator between marital functioning and child adjustment. Within this 
theoretical framework, emotional insecurity may be reflected by high emotional reactivity, 
which is characterized by heightened fear, distress and vigilance, whereas an emotionally 
secure child perceives family bonds as positive and stable, even in stressful situations (Davies 
& Cummings, 1998). In the context of stressful environments, for example marital conflicts, 
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heightened emotional reactivity might be advantageous, as it elevates vigilance (Cummings, 
Schermerhorn, Davies, Goeke-Morey, & Cummings, 2006). However, in the long run, 
emotional insecurity has been shown to increase children’s risk of adjustment problems 
(Thompson, 2000). Emotional security is a result not only of the consistency of quality of care 
with which children are provided and their early attachment experiences, but is also likely to 
be influenced by other factors, such as child temperament (Waters, Weinfield, & Hamilton, 
2000), and the stability and quality of a child’s living conditions (Thompson, 2000).  
Interestingly, in the differential susceptibility framework, emotional reactivity is considered a 
plasticity factor, which means that it can render children more susceptible to both supportive 
and unsupportive environments (Belsky, 2013). Enhanced susceptibility is represented in the 
nervous system and appears to regulate parts of the brain that are important for fear, reward, 
and emotional reactivity (Ellis, Boyce, Belsky, Bakermans-Kranenburg, & van IJzendoorn, 
2011). Outcomes of such highly reactive phenotypes are bivariate, i.e., whether they increase 
risk or are protective is dependent on the context, especially on adversity, support and 
protection (Boyce & Ellis, 2005). For example, children with high emotional reactivity seem 
to benefit more from supportive rearing environments than less susceptible children (Ellis et 
al., 2011). What is more, when a group of babies between the ages of seven and 10 months 
experienced experimentally induced increases in maternal sensitivity, children high in 
emotional reactivity showed a greater impact on their attachment security than children with 
lower reactivity (Klein Velderman, Bakermans-Kranenburg, Juffer, & van IJzendoorn, 2006). 
Consequently, emotional reactivity in itself renders individuals more susceptible to 
environmental influences – “for better and for worse”, as Belsky and colleagues put it 
(Belsky, Bakermans-Kranenburg, & van IJzendoorn, 2007).   
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Emotional Disorders 
High emotional reactivity and maladaptive emotion regulation are key features of emotional 
disorders. Anxiety and depressive disorders are very prevalent in adolescence, with lifetime 
prevalence rates ranging from 11.2% (any mood disorder, i.e., major depressive disorder, 
dysthymia, and bipolar I or II) to 31.9% (any anxiety disorder, i.e., agoraphobia, generalized 
anxiety disorder, social phobia, specific phobia, panic disorder, posttraumatic stress disorder, 
and separation anxiety disorder) and around 10% in both groups experiencing severe 
impairment (defined as “a lot” or “extreme” impairment in daily activities, or “severe or very 
severe” distress, Merikangas et al., 2010). Between the ages of 13 and 18 years, the lifetime 
prevalence rate for any mood disorder increases almost two-fold (Merikangas et al., 2010). 
Across adolescence, comorbidity rates of anxiety disorders and depressive disorders are 
significant (Essau, Lewinsohn, Lim, Ho, & Rohde, 2018). Different explanations of why this 
is the case have been expressed by researchers over the last decades, including theories of a 
shared underlying factor (i.e., negative affect) that links the two disorders (Tripartite Model; 
Clark & Watson, 1991), or symptom-related impairment of one disorder as a risk factor for 
the development of the other (Cummings, Caporino, & Kendall, 2014). Maladaptive emotion 
regulation has been considered a core component of the development of emotional disorders 
(Ehrenreich, Goldstein, Wright, & Barlow, 2009). This shared contribution of emotion 
regulation has led to arguments to include emotion regulation as a sixth domain in the 
Research Domain Criteria (RDoC; Fernandez, Jazaieri, & Gross, 2016). The RDoC was first 
introduced by the US National Institute of Mental Health (NIMH) in 2009 and aims to 
develop a new research classification system for mental disorders, based on the five domains 
of negative valence (such as fear or threat), positive valence (such as motivation and 
responsiveness to reward), cognitive systems (such as attention and memory), systems for 
social processes (such as attachment and perception of self), and arousal/modulatory systems 
(such as arousal and sleep-wake rhythm; Cuthbert & Insel, 2013). Each domain can be 
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assessed and measured via several units of analysis, namely genes, molecules, cells, (brain) 
circuits, physiology, behavior, self-report, and paradigms. The introduction of RDoC was a 
reaction to the fact that boundaries between mental disorders are often not as rigid as 
suggested by categorical diagnostic systems such as the DSM or ICD, and underlying 
mechanisms overlap significantly, which is why the dimensional approach of the RDoC 
seems more useful (Casey et al., 2013). Fernandez and colleagues now propose to include 
emotion regulation as a sixth RDoC domain, as it “is the functional consequence of patterns 
of interaction among the five existing molecular RDoC domains – an emergent construct” 
(Fernandez et al., 2016, p. 431). Research into the role of emotional functioning across the 
lifespan is likely to benefit from a possible inclusion of emotion regulation in the RDoC. 
 
A range of interventions exist for emotional disorders, among them psychological 
interventions such as CBT and ACT, and pharmacotherapy, which show comparable effects 
on remission, dropouts, and depressive symptoms (Das et al., 2016). However, 
antidepressants have significant severe side effects, including suicidal thoughts and behaviors, 
leading in 2004 to the inclusion by the US Food and Drug Administration (FDA) of the 
“black box” warning on the labels of antidepressants for pediatric use. This remains a 
controversial issue because of contradictory findings when the data were re-analyzed (Stone, 
2014). The scant research on the efficacy of antidepressants for emotional disorders in 
pediatric populations reveals small to medium effect sizes for depression and medium to large 
effect sizes for anxiety disorders (Garland, Kutcher, Virani, & Elbe, 2016). In addition, as a 
result of a lack of evidence on the dosage, safety, and efficacy of medications for children and 
adolescents, more than half the medication used in hospitalized children is off-label (i.e., 
prescriptions that differ from the approved labeling with respect to dose, frequency, dosage 
form, route of administration, or indication for use in children) or unapproved (i.e., not 
approved at all, not approved or contraindicated for use in children; ’t Jong et al., 2000). One 
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reason for this situation is that enrolling children in clinical trials is more challenging than the 
enrolment of adults, because the threshold for gaining consent is often higher and more 
complex and – depending on the disease studied – the pool of eligible children is often small, 
as prevalence rates for many conditions are lower in children than in adults (Caldwell, 
Murphy, Butow, & Craig, 2004). Consequently, a recent network meta-analysis that looked at 
efficacy and tolerability of antidepressants in youth with a major depressive disorder rated the 
quality of evidence as very low in most comparisons (Cipriani et al., 2016). The authors 
concluded that all but one of the studied antidepressants did “not seem to be suitable as 
routine treatment options” (p. 882). Nevertheless, antidepressants are still considered the first-
line pharmacological treatment for emotional disorders, that is, for depressive disorders, 
anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder (Garland 
et al., 2016).  
 
Emotional Functioning in Chronic Pain 
Given the important role that emotional functioning plays in mental disorders, surprisingly 
little research exists on its role in chronic pain, even though there is a high comorbidity rate 
between emotional disorders and chronic pain (Bair, Robinson, Katon, & Kroenke, 2003; 
Goldenberg, 2010; Tegethoff, Belardi, Stalujanis, & Meinlschmidt, 2015; Tsang et al., 2008).  
The International Association for the Study of Pain (IASP) defines pain as an “unpleasant 
sensory and emotional experience with actual or potential tissue damage, or described in 
terms of such damage” (Merskey & Bogduk, 1994). This definition points to the important 
emotional component of pain. Indeed, studies both in healthy volunteers (Godinho, Magnin, 
Frot, Perchet, & Garcia-Larrea, 2006; Ruiz-Aranda, Salguero, & Fernandez-Berrocal, 2010) 
and in patients with chronic pain (Tsao et al., 2004) have demonstrated the influence of 
emotional state on pain perception, indicating that negative emotions tend to increase pain 
perception.  
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Pain is considered chronic if it persists or recurs for more than three months or when it 
persists past normal healing time (Treede et al., 2015). An estimated 20% of people 
worldwide are affected by chronic pain syndromes such as headache, chronic low back pain, 
and fibromyalgia (Goldberg & McGee, 2011). Chronic pain ranks amongst the disorders that 
cause the largest financial, medical and psychosocial burden for individuals and societies 
(Vos et al., 2012), and accounts for 15% to 20% of physician visits (Koleva, Krulichova, 
Bertolini, Caimi, & Garattini, 2005). Even though the etiology of most chronic pain 
conditions remains unknown, current hypotheses point to several mechanisms that contribute 
to its development, including genetic (Diatchenko et al., 2005), neurological (Tracey & 
Bushnell, 2009), social (Beck, 2008), and psychological factors (Carter & Threlkeld, 2012). 
One influential notion is that of central sensitization, which has been defined as an “increase 
in synaptic efficacy in nociceptive pathways in the central nervous system and/or reduced 
descending inhibition of pain leading to enhanced pain” (Bromberg, Schechter, Nurko, 
Zempsky, & Schanberg, 2014, p. 213. As a result of genetic susceptibility, repeated trauma, 
infections and inflammation, the central nervous system might become overly effective in 
transmitting pain signals and less effective in inhibiting them. For the upcoming ICD-11, the 
International Association for the Study of Pain Task Force has created a new category, 
chronic primary pain. Chronic primary pain is defined as pain in one or more bodily regions 
that persists or recurs for longer than three months and is associated with significant 
emotional distress or functional disability (Treede et al., 2015). Importantly, this new 
terminology emphasizes the key role of emotions in the context of chronic pain. The term 
primary pain was first introduced by Neil Schechter in a 2014 JAMA Pediatrics Viewpoint 
and it was aimed at a paradigm shift towards an understanding that “pain itself is the disease” 
(Schechter, 2014, p. 694).  
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Even though some current models of chronic pain include psychological factors and 
comorbidities (e.g., von Baeyer & Champion, 2011), many questions remain with regard to 
the relationship between emotion regulation and chronic pain.  
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Aims of the thesis 
This thesis aims to shed light on the role of emotional functioning, that is, emotional 
reactivity, emotion regulation, and emotional disorders, in various domains across childhood 
and adolescence. Therefore, three different aims were pursued: first, to examine the role of 
emotion regulation in chronic pain, looking specifically at the difference between antecedent- 
and response-focused emotion regulation strategies and their respective relationship with 
pain-related outcomes. As emotion regulation is closely related to (and in a sense dependent 
on) emotional reactivity, the second goal was to analyze how emotional reactivity influences 
the occurrence of behavioral adjustment problems in adolescents who have experienced 
stressful life events in childhood. Finally, the last aim was to test a common intervention for 
emotional disorders and to examine the safety and efficacy of second-generation 
antidepressants in pediatric populations. 
The three research projects described in this thesis were designed to provide insight 
into the following leading questions:  
 
(1) What is the role of emotion regulation in chronic pain? 
Study I A high comorbidity rate between emotional disorders and chronic pain (Bair et al., 
2003) and the fact that emotional state influences pain perception (Berna et al., 2010) point to 
a potentially important role played by emotion regulation in the development and 
maintenance of chronic pain. The Process Model of Emotion Regulation (Gross, 1998a, 
1998b) suggests that emotion regulation can set in at every step of the temporally unfolding 
process of emotion generation. The model divides emotion regulation strategies broadly into 
antecedent- or response-focused strategies, based on their appearance in the process of 
emotion generation. As antecedent-focused strategies set in before the emotion is fully 
developed, the prospect of their success is considered greater (Aldao, 2013). To date, only one 
review has looked at pain and emotion regulation and focused on overlapping neural circuits 
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between the two (Konietzny, Suchan, Kreddig, Hasenbring, & Chehadi, 2016). Thus, the goal 
of Study I was to synthesize the existing body of research on the relationship between 
antecedent- and response-focused emotion regulation strategies and chronic pain, and to 
investigate whether the construct of emotion regulation might enhance existing theoretical 
frameworks of chronic pain. As there is only a small number of studies that have investigated 
pediatric populations (only two were identified that matched the inclusion criteria), the search 
was expanded to all age groups. 
 
(2) Does emotional reactivity influence the occurrence of adjustment problems in adolescents 
with few or many stressful life events during childhood? 
Study II Emotional reactivity is considered an important vulnerability factor in the 
differential susceptibility framework (Belsky et al., 2007). Stressful life events such as abuse, 
neglect, low socioeconomic status, divorce or separation of parents, and exposure to violence 
are important risk factors for healthy development in children and adolescents (Shonkoff, 
Boyce, & McEwen, 2009). Stressful life events have been linked to anxiety and depression 
(Ge, Conger, & Elder, 2001), delinquent behavior (Vaux & Ruggiero, 1983) and rumination 
and emotional dysregulation (McLaughlin & Hatzenbuehler, 2009). However, family- and 
individual-level influences, such as a child’s attachment to the primary caregiver, the 
relationship between parents, a child’s emotional reactivity and friendship quality might 
increase or decrease the risk of adverse outcomes despite stressful life events. Hence, the goal 
of Study II was to look longitudinally at the influences of individual- (such as emotional 
reactivity) and family-level factors (such as parent-child interaction and parental relationship) 
on the relationship between exposure to stressful life events in childhood and clinically 
elevated adjustment problems in adolescence.  
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(3) How safe and efficacious are antidepressants in the treatment of emotional disorders in 
children and adolescents? 
Study III Even though the use of selective serotonin reuptake inhibitors (SSRIs) and 
serotonin-norepinephrine reuptake inhibitors (SRNIs) is still debated (Stone, 2014), they are 
considered first line pharmaceutical treatments for emotional disorders. To date, only one 
review has compared the efficacy and risk profile of antidepressants across emotional 
disorders in childhood and adolescence (Bridge et al., 2007); however, since then, 11 new 
studies on the use of SSRIs or SNRIs in pediatric populations with emotional disorders have 
been published. Interestingly, Bridge et al.’s (2007) review found disorder-specific effect 
sizes for SSRIs and second-generation antidepressants (namely nefazodone, venlafaxine and 
mirtazapine): between antidepressant-placebo effect sizes were largest for non-OCD anxiety 
disorders (Hedges’ g = 0.69), and modest for major depressive disorder (Hedges’ g = 0.20; 
Bridge et al., 2007). The goal of Study III was to update and extend this review in order to 
assess the efficacy and safety of SSRIs and SNRIs for the treatment of emotional disorders, 
alongside between-disorder variation in drug and placebo responses.  
 
  
	19 	
Methods 
Different methodological approaches were chosen to address the three aims. In the case of the 
first aim, a systematic literature search was conducted and the identified papers were then 
summarized narratively (Study I). This had the advantage of allowing researchers to look at 
all available evidence without being dependent on consistent outcomes and outcome 
measures. For the second aim, data from a large longitudinal dataset were analyzed (Study II). 
The variables of interest (especially emotional reactivity and adjustment problems) were 
individually assessed at multiple time points, which had the advantage of a reduced risk of 
recall bias. In order to address the third aim, a meta-analytic approach was chosen (Study III). 
Meta-analyses are well suited to questions concerning the efficacy and safety of a given 
intervention, as a more reliable result can be obtained by pooling evidence across all included 
studies (Borenstein, 2009). 
 
The role of emotion regulation in chronic pain: A systematic literature review (Study I) 
Search strategy and study selection. In this systematic literature review, we searched 
PubMed, Embase, PsycInfo, Web of Science, CINAHL and the Cochrane Central Database of 
Controlled Clinical Trials from inception through November 2016, using the key words 
“emotion regulation” and “chronic pain”. In order to be included, studies had to report an 
emotion regulation and a chronic pain measure and an association between the two constructs. 
The screening and selection process was conducted independently by two authors.  
Data Extraction. Information on study sample, pain diagnosis, pain measure, emotion 
regulation measure, and statistical association between pain and emotion regulation measure 
was extracted. Questionnaire items on each emotion regulation measure in every study were 
reviewed and measures were categorized as either antecedent- or response-focused emotion 
regulation.  
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Effects of childhood life events on adjustment problems in adolescence: A longitudinal study 
(Study II) 
 Sample. Data used for this study originated from the Study of Early Child Care and 
Youth Development (SECCYD), collected by the National Institute of Child Health and 
Development (NICHD). In this study, participants were recruited from hospitals and 
university centers across several locations in the United States at the time of the child’s birth 
in 1991 and followed until age 15. During this time, four study phases were conducted.  
 Outcome Measure, Main Predictor, and Covariates. The primary outcome of our 
analysis was the clinical elevation of adjustment problems at age 15. For this outcome, we 
used two broad groups of syndromes, internalizing and externalizing problems, created from 
subscales of the Child Behavior Checklist (CBCL; Achenbach & Ruffle, 2000) rated by the 
mother, and the Youth Self Report (YSR; Achenbach, 1991), rated by adolescents. Clinical 
elevation of adjustment problems, our primary outcome, was defined as the presence of high 
internalizing and/or externalizing problems (i.e., T-score of >60, which is one standard 
deviation above the mean). The main predictor used in this study was a measure of stressful 
life events. The mother of the child in the study completed a survey on stressful life events 
(Sarason, Johnson, & Siegel, 1978) at three time points during the child’s childhood and 
reported whether any of the 57 events had occurred during the last year. The list of events 
included routine happenings (e.g., a wedding in the extended family), major events (e.g., 
separation of parents) and catastrophic events (e.g., death of a family member). We looked at 
life events from three different perspectives, following the example of previous research using 
the same dataset (Lumeng et al., 2013). First, we categorized the total number of stressful life 
events as either “many” (upper quartile of total number of stressful life events) or “few” 
(lower three quartiles of total number of life events). In addition, we created a 
timing/chronicity variable to reflect the time points at which the child was in the upper 
quartile of the number of life events. This resulted in five categories, namely early exposure, 
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late exposure, single exposure, never, and always exposed. In a last step, we created four 
categories of stressful life events depending on the area of life that was most affected by 
them: parent/family physical or mental health and well-being; parental work, school, or 
financial stability; emotional aspects of relationships; and change in family structure, routine 
and caregiving.  
We included a number of covariates, among them demographic variables (child gender, 
race/ethnicity, maternal education, total income-to-needs ratio to assess financial stress), 
individual-level (i.e., mainly concerning the child, namely mother-child attachment, 
temperament, emotional reactivity, friendship quality) and family-level covariates (i.e., 
concerning the child and the child’s family, namely mother-child attachment, maternal 
separation anxiety, parent-child interaction, parental intimacy, maternal and paternal 
depression) that have been shown to modulate the effect of stressful life events on adjustment 
problems. All these covariates were measured at least twice during the study period.  
 Statistical Analyses. All analyses were performed using SAS 9.4 (SAS Institute; Cary, 
NC). Descriptive statistics were calculated for all demographic and study characteristics. Chi-
squared and Wilcoxon’s test were used to assess unadjusted associations of individual 
stressful life events, summary stressful life events variables, and all the covariates with 
adjustment problems in adolescence. For each of the covariates, we created summary 
variables using the SAS PROC TRAJ procedure. This group-based trajectory modeling 
assumes a certain number of discrete underlying groups in the population (Jones, Nagin, & 
Roeder, 2001). In the case of emotional reactivity of the child, the model identified two 
trajectories, namely high and low emotional reactivity.  
Multiple logistic regression analyses were used to evaluate the association of 
adjustment problems in adolescence (dependent variable) and the total number of stressful life 
events (independent variable) while controlling for demographics. The models were re-run 
using all the stressful life events categorical variables and stressful life events 
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timing/chronicity as independent variables. Finally, models including individual- and family-
level covariates were run. Adjusted odds ratios (ORs) and their 95% confidence intervals 
(95% CIs) were calculated for all models. Significance values of the final model were 
Bonferroni-adjusted for multiple comparisons, and p-values <0.01 were considered 
significant. Linear mixed models were used to evaluate differences in CBCL internalizing and 
externalizing trajectories over time between children with “few” and those with “many” 
stressful life events.  
Efficacy and safety of SSRIs, SNRIs and placebo in common psychiatric disorders: A 
comprehensive meta-analysis in children and adolescents (Study III) 
 Search strategy and study selection. For the purposes of this meta-analysis, we 
searched PubMed, Embase, PsycInfo, Cochrane, Web of Science, clinicaltrials.gov and 
fda.gov from inception through August 2016 and checked references of included studies as 
well as of previous reviews. We included randomized, double-blind, placebo-controlled trials 
of SSRIs and SNRIs in children and adolescents <18 years of age diagnosed with major 
depressive disorder, an anxiety disorder, obsessive-compulsive disorder, or posttraumatic 
stress disorder based on DSM-III, DSM-III-R, or DSM-IV-TR criteria.  
 Outcome measures and data extraction. The primary outcome as defined by authors 
(of the included studies) was chosen as the sole outcome measure for each study. Pre- and 
post-intervention data or mean change data had to be available. Outcomes had to be reported 
on a well-validated, disorder-specific scale (e.g., Children’s Depression Rating Scale – 
Revised, Multidimensional Anxiety Scale for Children, and Children’s Yale-Brown 
Obsessive Compulsive Scale) or on a general severity scale (i.e., Clinical Global Impression – 
Severity Scale). Only continuous outcome data were included. Extracted data included 
demographic information, dropout rates, adverse events, safety information, and baseline and 
end point assessment scores.  
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 Data analysis. Comprehensive Meta-Analysis V3 (Biostat; Englewood, NJ) and R 
3.2.1 (R Foundation; Vienna, Austria) were used for calculations and analyses. We calculated 
three effect sizes (Hedges’ g; Hedges & Olkin, 1985) for each included study. First, 
differences in mean change scores between groups were evaluated. Next, within-group pre-
post effect sizes for antidepressant and placebo were calculated. We chose to use random-
effects models rather than fixed-effect models as the included studies were heterogeneous and 
the number of studies for the sub-analyses was relatively small. Random-effects models 
assume that a combination of sampling error and true variance in effect sizes results in 
variations in effect sizes across studies included in a meta-analysis, while fixed-effect models 
act on the assumption that there is one true underlying effect size for all studies and any 
variation is to the result of sampling error (Borenstein, Hedges, Higgins, & Rothstein, 2010). 
Heterogeneity was assessed by calculating the Q statistic, the t2 and the I2. A statistically 
significant Q indicates systematic differences between studies, therefore rejecting the null 
hypothesis that all variation in effect is the result of random error (Huedo-Medina, Sánchez-
Meca, Marín-Martínez, & Botella, 2006). The I2 is a transformation of Q that indicates the 
proportion of observed variance across studies that is the result of real heterogeneity rather 
than sampling error (Higgins, Thompson, Deeks, & Altman, 2003). The t2 offers an estimate 
of the variance among true effect sizes (Higgins, 2008). In order to evaluate whether the risk 
of adverse events differed between antidepressant and placebo groups, risk ratios (RRs) for 
treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) were 
calculated. The RRs of SAEs were based on the percentage of patients with SAEs in each 
included study. With regard to RRs of TEAEs, we compared two commonly used reporting 
methods: percentage of patients with TEAEs in each group and mean number of TEAEs per 
patient across all reported symptoms.  
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Summary of the Results 
The role of emotion regulation in chronic pain: A systematic literature review (Study I) 
Our search identified 15 studies including a total of 2065 patients. Only two studies included 
pediatric populations, six studies had a female-only population, and only one study had a 
majority of male participants. All measures of emotion regulation were classified as either 
antecedent- (n=4) or response- (n=5) focused emotion regulation. A number of studies (n=5) 
used both antecedent- and response-focused measures and one study used a measure that 
could not be classified definitively.  
The group of studies of antecedent-focused emotion regulation did not show a direct 
influence of these strategies on pain. However, these emotion regulation strategies were 
correlated with high emotionality and negative mood. Hence, it is possible that adaptive use 
of antecedent-focused strategies may reduce pain vulnerability or pain experience indirectly 
by reducing high emotionality or negative mood, both known vulnerability factors for the 
development of chronic pain. 
Studies considering response-focused emotion regulation found a direct correlation 
between these strategies and pain or pain-related functioning in some cases, while in other 
cases these strategies related to symptoms of depression, a prevalent psychological 
comorbidity of chronic pain.  
Those studies that measured both groups of emotion regulation strategies found no 
direct relationship of either group of strategies to pain, but found response-focused strategies 
to be correlated with catastrophizing thoughts around pain, the likelihood of being 
hospitalized during pain crises, and the impact of the disease on patients’ everyday life.  
In summary, the studies included in this review rarely found direct associations 
between emotion regulation and pain. Rather, the relationship between (antecedent- or 
response-focused) emotion regulation and pain seemed to be mediated by psychological 
factors such as emotionality, anxiety or negative mood. Those studies looking exclusively at 
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response-focused emotion regulation strategies appeared to provide the best evidence for a 
strong relationship between maladaptive emotion regulation, psychological symptoms, and 
pain. 
  
Effects of childhood life events on adjustment problems in adolescence: A longitudinal study 
(Study II) 
Of the 1364 children and their families enrolled in the study, information from the YSR at age 
15 years was available for 956 subjects. A significant difference between mother- and 
adolescent-reports was found for the internalizing (11.0% vs. 11.3%, p<0.001) and 
externalizing (10.3% vs. 14.3%, p<0.001) subscales as well as for the ratings of adjustment 
problems (26.3% vs. 21.1%, p<0.001). All selected covariates, except temperament, showed a 
significant association with mother-reported adjustment problems in adolescence in the 
unadjusted analysis. However, for child-reported adjustment problems, only emotional 
reactivity (p=0.002) and maternal (p=0.004) and paternal (p=0.006) depression were found to 
be significant.  
Overall, children with adjustment problems at age 15 reported a higher total number of 
stressful life events (median=24, Interquartile Range (IRQ): 15–30 vs. median=19, IRQ: 12–
27, p<0.001) than children with no adjustment problems. Variables significantly associated 
with adjustment problems in adolescence were: total number of stressful life events, gender, 
maternal education level, emotional reactivity, friendship quality, and paternal (but not 
maternal) depression. There were no significant associations between timing/chronicity of 
stressful life events and adjustment problems. Stressful life events categorized as emotional 
aspects of relationships were significantly associated with child-reported adjustment 
problems, and marginally significantly associated with mother-reported adjustment problems. 
Of note was the finding that each additional stressful life event increased the odds ratio (OR) 
for adjustment problems in adolescence. Results from the model that included only children 
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with “many” life events showed that mother-reported adjustment problems were associated 
with high child emotional reactivity scores (OR=3.8, p=0.003). Similarly, results from the 
model that included only children with “few” stressful life events showed that mother-
reported adjustment problems were again associated with high child emotional reactivity 
(OR=2.0, p=0.006), but also with maternal education at child’s birth (high school education 
versus graduate studies; OR=3.3, p=0.002). Child-reported adjustment problems were 
associated with paternal (but not maternal) clinically significant versus low depression scores 
(OR=3.5, p=0.001).  
  
Efficacy and safety of SSRIs, SNRIs and placebo in common psychiatric disorders: A 
comprehensive meta-analysis in children and adolescents (Study III) 
Our search identified one unpublished and 35 published randomized, double-blind trials, 
including 6778 participants, that compared an SSRI or an SNRI against placebo in patients 
younger than 18 years with a diagnosis of an anxiety disorder (AD; n=10), a depressive 
disorder (DD; n=17), obsessive-compulsive disorder (OCD; n=8), or posttraumatic stress 
disorder (PTSD; n=1). As we only found one study on PTSD, no disorder-specific subgroup 
analyses were calculated for this disorder.  
The combined analysis between groups across all disorders yielded a small drug-
placebo difference (g=0.32; 95%CI, 0.25 to 0.40, p<0.001). In the between-group analysis 
stratified by disorder, anxiety disorders (g=0.56, 95%CI, 0.40 to 0.72, p<0.001) and 
obsessive-compulsive disorder (g=0.39, 95%CI, 0.25 to 0.54, p<0.001) did not differ 
significantly from each other (p=0.14), but both yielded significantly higher (AD vs. DD: 
p<0.001 and OCD vs. DD: p=0.02) drug-placebo differences than the DD group (g=0.20, 
95%CI, 0.13 to 0.27, p<0.001). The within-drug group analysis stratified by disorder yielded 
no significant difference (p=0.06) between studies of anxiety disorders (g=1.58, 95%CI, 1.35 
to 1.81, p<0.001) and depressive disorders (g=1.85, 95%CI, 1.7 to 2.0, p<0.001), yet both 
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yielded significantly larger drug responses (p<0.001) than studies of obsessive-compulsive 
disorder (g=1.01, 95%CI, 0.88 to 1.14, p<0.001). The within-placebo group analysis stratified 
by disorder yielded a large placebo response for studies of depressive disorders (g=1.57, 95% 
CI, 1.36 to 1.78, p<0.001), which was significantly larger (p<0.001) than the placebo 
response in studies of anxiety disorders (g=1.03, 95%CI, 0.84 to 1.21, p<0.001).  
 Side-effect analysis The two reporting methods of TEAEs (reporting method 1: 
percentage of patients with TEAEs, reporting method 2: mean number of TEAEs per patient 
across symptoms) differed significantly, indicating higher RRs for reporting method 2. 
Patients taking an antidepressant reported significantly more TEAEs (reporting method 1: RR, 
1.07, 95%CI, 1.01 to 1.12, p=0.01; reporting method 2: RR, 1.49, 95%CI 1.22 to 1.82, 
p<0.001) and SAEs (RR, 1.76, 95%CI, 1.34 to 2.32, p<0.001) compared to those taking the 
placebo.  
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Discussion 
This thesis pursued the main goal of improving our current understanding of the role of 
emotional functioning across different domains in childhood and adolescence. Emotional 
reactivity, emotion regulation and emotional disorders are part of emotional functioning. 
Therefore, the thesis had three different aims: to examine the role of emotion regulation in 
chronic pain; to analyze the role of emotional reactivity in the context of stressful life events; 
and to test a common intervention for emotional disorders in children and adolescents. 
Emotional (mal)functioning can be considered a shared underlying process of emotional 
disorders, and patterns of emotional functioning that emerge in childhood persist into 
adulthood, presenting as an early indicator of or risk factor for long-term health and 
adjustment (Repetti et al., 2002). Overall, emotional functioning has been found to be a key 
process of healthy development in children and adolescents, across several important 
domains. Emotional disorders show high prevalence rates, are a major public health concern, 
and predict long-term risk for various adverse outcomes. Therefore, the recognition of the 
importance of emotional functioning in childhood and adolescence as well as the proper 
treatment of emotional disorders is crucial.  
 
The role of emotion regulation in chronic pain: A systematic literature review (Study I) 
At first sight, the finding that emotion regulation is rarely directly correlated with pain 
intensity or pain-related might seem surprising. However, when examining it from a more 
integrated perspective, it seems plausible that emotion regulation serves as a key moderator 
that influences the overall wellbeing of patients with chronic pain via several psychological 
factors (such as negative emotionality and depressed mood). Current models of chronic pain 
development and maintenance point to several aspects that are potentially influenced by 
maladaptive emotion regulation, namely psychological vulnerability, comorbid psychological 
conditions and impaired pain regulatory systems (von Baeyer & Champion, 2011). 
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Furthermore, a recent study found some shared genetic components of emotion regulation and 
chronic widespread pain (Burri, Ogata, Vehof, & Williams, 2015). Having a comorbid 
emotional disorder might present as an additional stressor to patients with chronic pain and 
may increase their disability, but may also serve as a target well suited for interventions that 
aim to improve emotional functioning. Indeed, preliminary case and pilot studies on both 
adults and adolescents that have targeted emotional functioning report positive results (e.g., 
Allen, Tsao, Seidman, Ehrenreich-May, & Zeltzer, 2012; Gottschalk, Bleichhardt, 
Kleinstauber, Berking, & Rief, 2015). One of these studies, a case report of two adolescent 
patients with chronic pain and comorbid emotional disorders, used modules such as 
psychoeducation about emotions and pain, modification of emotion-driven behaviors, and 
flexibility in thinking during the course of treatment (Allen et al., 2012). Both patients 
showed improvements over at least some of the various domains of interest, such as pain, 
functional disability, emotion regulation, anxiety and depression. Another study extended 
CBT for adult patients with somatoform disorders (including pain) with emotion regulation 
training modules. The researchers focused on the impact of emotions on pain and 
psychological symptoms, explored how emotion regulation can help to change this impact, 
and found greater effect sizes for CBT with emotion regulation than for CBT alone for almost 
all treatment objectives. The group differences were not significant, however, possibly the 
result of small group sizes (Gottschalk et al., 2015). These promising first results argue for the 
inclusion of emotion regulation (and more broadly, emotional functioning) in current 
theoretical frameworks of chronic pain, which may help to further clarify why some people 
are more vulnerable to chronic pain (and comorbid emotional disorders) and how this 
knowledge can be implemented in new interventions.  
The new category of chronic primary pain, as suggested for the upcoming ICD-11 (Treede et 
al., 2015), takes the importance of emotional functioning (which includes emotion regulation) 
in patients with chronic pain into account: the diagnostic criteria for chronic primary pain 
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state that it is “characterized by significant emotional distress (anxiety, anger/frustration or 
depressed mood)” or functional disability (ICD-11 – Mortality and Morbidity Statistics, 
2018).  
 
Effects of childhood life events on adjustment problems in adolescence: A longitudinal study 
(Study II) 
Study II found a further aspect of emotional functioning, namely emotional reactivity, to have 
an important influence on the relationship between stressful life events in childhood and 
adjustment problems in adolescence. Interestingly, we found a significant difference between 
mother- and self-reported adjustment problems in adolescence, with adolescents rating 
themselves higher on the Youth Self Report than their mothers did on the Child Behavior 
Checklist. This is in line with previous research that found self-rated emotional disorders to 
be consistently higher compared to ratings of other informants (such as parents or teachers; 
van der Ende, Verhulst, & Tiemeier, 2012). When the emotional development across 
childhood and adolescence is taken into account, this finding makes sense: it is in middle 
childhood and during adolescence that children become warier with regard to which emotions 
they display in what context, and self-conscious emotions (such as pride or shame) become 
more intense and more prevalent (Zeman et al., 2006). Hence, adolescents might want to hide 
symptoms of emotional disorders from their parents. With regard to the development of 
adjustment problems in adolescence, Study II found emotional reactivity to be among the 
most important predictors. In the differential susceptibility framework (Belsky, 2013), 
emotional reactivity is thus considered a vulnerability factor that, depending on positive or 
negative influences from the environment, may lead to either adaptive or maladaptive 
outcomes. Indeed, when we closely examined possible protective factors against adjustment 
problems for children in the group with “many” stressful life events, low emotional reactivity 
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was one of them. In a very stressful environment, it might be advantageous to have a higher 
threshold for emotional reactions, in order to avoid constant emotional distress. 
 
Efficacy and safety of SSRIs, SNRIs, and placebo in common psychiatric disorders: A 
comprehensive meta-analysis in children and adolescents (Study III) 
In the treatment of emotional disorders, SSRIs and SNRIs are considered first- and second-
line pharmacological treatment choices. Interestingly, Study III found effect sizes of 
antidepressants to be larger for anxiety disorders than for depressive disorders. This disorder-
specific difference in drug-placebo response might be attributable to the large placebo 
response in depressive disorders, which in turn might be explained by the greater 
demoralization and hence greater sensitivity to change in patients with depressive disorders 
when compared to patients with anxiety disorders (Cohen et al., 2008). It might also be 
because of the heterogeneous phenotype of depressive disorders that makes prediction of 
treatment effect challenging (Kessler et al., 2016). This was apparent in the DSM-5 field trials 
on major depressive disorder, which found a low test-retest reliability (kappa=0.28) for 
children, adolescents and adults (Regier et al., 2013). Furthermore, there is high comorbidity 
between anxiety and depression. As a consequence, the DSM-V Field trials tested a new 
diagnosis, namely “mixed anxiety and depression disorder” (Regier et al., 2013). When this 
disorder was tested in the DSM-5 Field Trials, it turned out to have an unacceptable rate of 
test-retest reliability (kappa: -0.04; Regier et al., 2013). In the case of these findings, new 
ways of looking at mental disorders are needed, as the current categorical perspective does 
not seem to capture the complexity of emotional disorders adequately. Hence, the US-
National Institute of Mental Health (NIMH) proposed the Research Domain Criteria (RDoC), 
a dimensional framework to describe mental disorders along several domains (Insel et al., 
2010). As has been proposed previously, emotional functioning, especially emotion regulation 
(Fernandez et al., 2016), could be included as a new domain in RDoC. This would facilitate 
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research into similarities and differences between emotional disorders on several units of 
analysis (Dillon et al., 2014). In addition, as a result of the high comorbidity of emotional 
disorders and chronic pain (Study I), inclusion of emotional functioning in RDoC would 
allow researchers to study shared underlying mechanisms. Studying processes instead of 
diagnoses could lead to the development of interventions that target these processes 
specifically and hence affect symptoms of emotional disorders and chronic pain 
simultaneously.   
As pharmacotherapy shows comparable effects on remission, dropouts, and depressive 
symptoms to psychological interventions such as CBT or ACT (Das et al., 2016), and taking 
into consideration the increased risk of serious adverse events in a course of treatment with 
antidepressants, a cautious and individual cost-benefit analysis is important before the start of 
treatment for emotional disorders.   
 
Limitations 
The results reported in this thesis have some limitations. Study I reflected the difficulties 
caused by a highly heterogeneous use of the term emotion regulation, which made the study 
search and selection process challenging. The same applied in the case of the chronic pain 
conditions included in the systematic review. The greatest limitation, however, was the small 
number of studies on pediatric samples: we found only two studies that included children and 
adolescents. With this research gap identified by our study, we decided to broaden the search 
to all age groups. Given that emotion regulation involves higher order cognitive processing, 
no generalization to broader pediatric samples can be made, especially not with regard to 
possible age-specific relationships between emotion regulation and chronic pain. An 
additional limitation of the included studies was the bias of female only studies (six of 15 
studies).   
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In Study II, the analyses were conducted using a community (not a clinical) sample. 
Hence, our outcome, adjustment problems in adolescence, represented differences within the 
norm that only in rare cases exceeded a clinical threshold. The same assumptions should 
therefore be tested on a clinical sample. Other than that, all information in our study relied on 
self-report by participating children and their mothers. Previous research has shown that 
depressed or anxious mothers tend to report more cases of child behavior problems than their 
healthy counterparts or the children themselves (Najman et al., 2000). This might have 
influenced our results, as a considerable number of mothers reported either depressive 
symptoms or symptoms of separation anxiety at some point during the study period.  
The limitations of Study III include the fact that none of the RCTs included in our 
analysis directly compared the effectiveness of SSRIs and SNRIs across disorders. Thus, we 
could only make indirect conclusions with regard to disorder specificity. Mean age and age 
distribution of participants varied among studies, which might have had an effect on the 
results, as the response to SSRIs and SNRIs has been shown to be lower in children than in 
adolescents (Bridge et al., 2007).  
 
Conclusions and Implications for Future Research  
Despite these limitations, the results of this thesis emphasize the importance of emotional 
functioning across various domains in childhood and adolescence. As emotional functioning 
develops across age, future research should focus on the age-specific influences of emotional 
functioning on chronic pain and emotional disorders. This would allow medical practitioners 
to tailor intervention and prevention to age-specific needs and abilities. The heterogeneous 
phenotype of emotional disorders, especially of depressive disorders, calls for new ways of 
studying these phenomena. Investigating within-comparisons might offer a new and 
interesting perspective, shedding light at how depressive symptoms change over time within a 
person and how these processes manifest. Examining emotional functioning using various 
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methods across different levels of analysis might also be a promising method (Dorn et al., 
2013; Fernandez et al., 2016). If a large number of people were to be studied in this fashion, 
conclusions could be drawn at the population level (Kendler & Aggen, 2017).  
Furthermore, individual patient-level analyses could help to explore the influence of 
individual characteristics on treatment effects, as they are – other than in meta-analyses – not 
based on aggregated data (Zhou et al., 2018). Here, the inclusion of more psychological 
factors, such as emotional functioning in RCTs would help to increase our knowledge of how 
these factors influence treatment outcomes.  
In the field of chronic pain, the new category of chronic primary pain (Schechter, 
2014; Treede et al., 2015) should be examined for its validity. Here, the focus should be on 
the role of emotional distress, which is now defined as a symptom of anxiety, 
anger/frustration and depression, but might be of better use if defined more broadly. In this 
way, other emotional symptoms that might interfere with patients’ wellbeing despite pain 
would not be missed.  
Children are not small adults (Foster & Lyall, 2015). Results from research in adult 
populations cannot and should not be transferred directly to pediatric populations. Hence, 
despite challenges posed by the enrollment of children in clinical trials (Caldwell et al., 2004), 
future researchers should make an effort to include children in order to do justice to 
developmental features that are specific to this age group.  
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A B S T R A C T
Objective: Emotion regulation (ER) includes a set of cognitive and attentional processes used to change or
maintain emotional state. A small but growing body of research suggests that maladaptive ER might be a risk
factor for the development of chronic pain. This review aims to summarize existing literature on the association
between ER and chronic pain, and to determine whether the construct of ER may further enhance our under-
standing of the risk and protective factors that may contribute to the onset and maintenance of chronic pain.
Methods: A systematic search was conducted using the search terms “chronic pain” and “emotion regulation.”
Studies that measured both constructs across all age groups were included.
Results: We found 15 studies that met our inclusion criteria. Nine studies were completed within the last five
years, suggesting that the evaluation of ER as it relates to pain is a new line of research. Studies that measured
“response-focused” ER found associations between maladaptive ER and pain. Studies that measured “antecedent-
focused” ER strategies were less likely to show a direct association with pain.
Conclusion: Maladaptive response-focused ER may be an important risk factor in the development and main-
tenance of chronic pain, as it is associated with pain and psychological comorbidities. Adding ER to chronic pain
investigations may help to further explain individual differences in the risk and protective mechanisms that are
known to influence chronic pain. Importantly, this line of research has potential to directly inform future in-
terventions for patients with chronic pain.
1. Introduction
Chronic pain is defined as any pain condition that exists for more
than three months, either continuously or recurrently [14,48]. Chronic
pain is estimated to effect 20% of the population and causes an en-
ormous burden to both individuals and the healthcare system [25].
Current models of chronic pain illustrate the complex interplay of
sensory, environmental, psychological, and pain regulatory risk factors
that shape the pain vulnerability of an individual ([55]; see Fig. 1).
Research on chronic pain seeks to disentangle the various risk and
protective influences of biological, psychological, and environmental
factors that are known to contribute to chronic pain disorders. Under-
standing these factors is critical to the development and implementa-
tion of targeted intervention.
Pain has long been defined as an “unpleasant sensory and emotional
experience” ([40]). The recognition of the sensory and psychological
components of pain have recently been strengthened by controlled la-
boratory studies that illustrate the link between emotional state and
pain perception, both in healthy volunteers (e.g. [24,43]) and in pa-
tients with chronic pain (e.g. [50]). Additionally, research using fMRI
has supported the notion that inducing negative mood can influence
subsequent pain ratings [11]. Beyond the research linking the sensory
and emotional experience of pain, patients with chronic pain have three
times the risk of being diagnosed with anxiety and depression as
compared to the general population [7,26,49]. Despite the multiple
links between pain and negative emotions, surprisingly little is known
about how emotion regulation styles may influence pain, pain-related
disability, and psychological comorbidities in chronic pain populations.
Emotion regulation (ER) describes a person's ability to modulate his
or her emotional state and expression, that includes influencing which
emotions people have, when they have these emotions, and how emo-
tions are experienced and expressed [1,31]. Assessment of ER thus
encompasses measurement of cognitive, behavioral, and psychophy-
siological responses to an event or stressor [18,56]. The regulation of
emotions has been the focus of various studies, among them studies in
the field of stress and coping research [31]. However, ER is different
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from coping on the one hand in that coping includes non-emotional
actions; ER on the other hand includes processes not traditionally
considered in the coping literature, such as maintaining or up-reg-
ulating positive emotions [15].
A helpful model of organizing the diverse cognitive and behavioral
strategies people use to regulate their emotions is the Process Model of
ER [30,34]. The Process Model of ER is based on the modal model of
emotion, which presents the core features of emotions and specifies that
ER can set in at every step of the emotion generation process: Emotion
arises in a situation that is meaningful to the individual and demands
attention, has a particular meaning and gives rise to a multifaceted,
embodied response (see Fig. 2). The Process Model broadly divides ER
into antecedent- and response-focused strategies. Antecedent-focused
strategies include situation selection, situation modification, attentional
deployment, and cognitive change, that set in before the emotion is
fully developed – hence their prospect of success is generally greater
[3]. Strategies such as avoiding a situation that potentially elicits ne-
gative emotions or shifting one's attention to thoughts of an upcoming
vacation to prevent boredom in a long work meeting are considered
antecedent-focused. In contrast, response-focused strategies emphasize
regulating the emotional response, especially its physiological and be-
havioral aspects, once the event has already onset [29,38]; holding
back one's tears in public is one example.
ER is considered maladaptive if it shows a negative short- and/or
long-term outcome, antagonizes personal goals or shows a lack of ER
flexibility (i.e., is inappropriate to contextual or social demands [5]).
Research on ER has studied how ER affects the individuals as well as the
people around them. This has yielded results linking maladaptive ER to
psychopathology (for a review see [4]), negative affect [9], learning
difficulties [17], memory deficits [19,42], and physiological stress re-
actions [13]. Importantly, research has demonstrated that training in
adaptive ER is effective for treating a range of psychological and psy-
chosocial difficulties. As a result, these skills and strategies are often
incorporated as a component part of cognitive behavioral therapy
treatment [10,27].
This systematic review synthesizes the existing body of research that
explores the relationship between ER and chronic pain. To our knowl-
edge, this is the first review to examine the ER – chronic pain re-
lationship. Our goal is to investigate whether the construct of ER may
enhance the existing theoretical frameworks of chronic pain, to increase
our understanding of individual-level risk and protective influences that
contribute to development and maintenance of chronic pain conditions.
Further, we seek to explore the associations between the two categories
of ER, antecedent- and response-focused strategies, and chronic pain.
Based on our understanding of the process model of ER, we hypothesize
that response-focused ER is more likely to have negative associations
with chronic pain as compared to antecedent-focused ER.
2. Methods
For this systematic review, we searched PubMed, Embase,
PsychInfo, Web of Science, CINAHL, and the Cochrane Central Database
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SYSTEMS
eg, prematurity, early life trauma
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CENTRAL NERVOUS SYSTEM
eg, somatic tissue injury, 
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Fig. 1. Antecedents and consequences of pain vulnerability [55].
Figure copyright © 2010, G.D. Champion and C. L. von Baeyer. Used with permission.
Fig. 2. The Process Model of Emotion Regulation [34].
Figure copyright © 2007 by The Guilford Press. Used with permission.
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of Controlled Clinical Trials using the key words “emotion regulation”
and ‘chronic pain’. For additional information on search terms, see
Table 1. In total, our search returned 2893 articles, of which 1041
duplicates were removed. The screening and selection process was
conducted by two authors independently (HK and CW). We included
studies that measured both ER and chronic pain using a cross-sectional,
observational, longitudinal, or interventional design across all age
groups and pain conditions, published from the earliest available record
from 1923 through November 2016. We excluded studies of acute and/
or experimentally induced pain, studies that did not report on the as-
sociations between ER and pain measures, and studies that assessed
coping or alexithymia instead of ER. Reviews, meta-analyses, disserta-
tions, posters, and conference abstracts were also excluded. Based on
abstract and title search, 48 papers were included in full text review
(see Fig. 3). We extracted information on study sample, pain diagnosis,
pain measure, ER measure, and statistical associations between pain
and ER measures. Further, we reviewed questionnaire items on each
measure of every study and categorized measures into antecedent- or
response-focused ER.
3. Results
The study selection procedure is summarized in Fig. 3. Our search
identified fifteen studies including a total of 2065 patients who met our
criteria. Two studies included pediatric populations, six studies had a
female-only population, and only one study had a majority of male
participants. The studies included in this review assessed patients with
one or more of the following pain conditions: fibromyalgia (n=5),
rheumatoid arthritis (n= 4), back pain (n=4), multiple pain sites
(n= 3), juvenile idiopathic arthritis (n= 1), pelvic pain (n=1), and
sickle cell disease (n=1). Characteristics of the included studies are
shown in Table 2. All measures of ER were classified as either ante-
cedent (n= 4)- or response (n=5)-focused ER. Several studies (N=5)
used both antecedent- and response-focused measures and one study
used a measure that could not clearly be classified. The statistics and
the multivariate and bivariate associations for the studies are reported
in the supplement (Table S1).
3.1. Antecedent-focused emotion regulation
Four studies measured ER strategies that were classified as ante-
cedent-focused (see Table 2). This included cognitive ER strategies such
as thought suppression or cognitive reappraisal.
This group of studies sought to determine how pain intensity or
pain-related functioning was influenced by cognitive ER strategies that
are typically employed prior to the full-blown emotional response. For
example, one study that was interested in participants' tendency to
employ cognitive change strategies, asked them to rate statements such
Table 1
Search terms.
PubMed (emotion regulat*[tiab] OR emotional regulat*[tiab] OR emotion dysregulat*[tiab] OR emotional dysregulat*[tiab] OR
emotional modulat*[tiab] OR emotion modulat*[tiab] OR emotion management[tiab] OR emotional management[tiab] OR
emotional competenc*[tiab] OR emotion comptetenc*[tiab] OR emotional expression[tiab] OR emotion expression[tiab] OR
emotional control[tiab] OR emotion control[tiab] OR emotional self-efficacy[tiab] OR emotional suppression[tiab] OR emotion
suppression[tiab] OR affect regulat*[tiab] OR affect dysreg*[tiab] OR effortful control[tiab] OR situation selection[tiab] OR
situation modification[tiab] OR attentional deployment[tiab] OR cognitive change[tiab] OR response modulation[tiab])
AND (“pain”[mesh] OR “Pain Measurement”[mesh] OR pain[tiab])
Embase ((emotion* NEXT/1 (regulat* OR dysregulat* OR modulat* OR management OR competenc* OR expression OR control OR ‘self
efficacy’ OR suppression)):ab,ti OR (affect* NEXT/1 (regulat* OR dysregulat*)):ab,ti OR ‘effortful control’:ab,ti OR ‘situation
selection’:ti,ab OR ‘situation modification’:ti,ab OR ‘attentional deployment’:ti,ab OR ‘cognitive change’:ti,ab OR ‘response
modulation’:ti,ab) AND (‘pain’/exp. OR ‘pain measurement’/exp. OR pain:ab,ti) AND [embase]/lim
PsycINFO DE (“Emotional Regulation” OR DE “Emotional Control”) OR TI ((emotion* W1 (regulat* OR dysregulat* OR modulat* OR
management OR competenc* OR expression OR control OR “self efficacy” OR suppression)) OR (affect* W1 (regulat* OR
dysregulat*)) OR “effortful control” OR “situation selection” OR “situation modification” OR “attentional deployment” OR
“cognitive change” OR “response modulation”) OR AB ((emotion* W1 (regulat* OR dysregulat* OR modulat* OR management
OR competenc* OR expression OR control OR ‘self efficacy’ OR suppression)) OR (affect* W1 (regulat* OR dysregulat*)) OR
‘effortful control’ OR ‘situation selection’ OR ‘situation modification’ OR ‘attentional deployment’ OR ‘cognitive change’ OR
‘response modulation’)
AND
DE (‘Pain Measurement’ OR ‘Pain’ OR “Back Pain” OR ‘Chronic Pain’ OR “Headache” OR “Myofascial Pain” OR “Neuralgia” OR
“Neuropathic Pain” OR “Pain Perception” OR “Pain Thresholds”) OR TI pain OR AB pain
CINAHL TI ((emotion* W1 (regulat* OR dysregulat* OR modulat* OR management OR competenc* OR expression OR control OR ‘self
efficacy’ OR suppression)) OR (affect* W1 (regulat* OR dysregulat*)) OR ‘effortful control’ OR ‘situation selection’ OR ‘situation
modification’ OR ‘attentional deployment’ OR ‘cognitive change’ OR ‘response modulation’) OR AB ((emotion* W1 (regulat* OR
dysregulat* OR modulat* OR management OR competenc* OR expression OR control OR ‘self efficacy’ OR suppression)) OR
(affect* W1 (regulat* OR dysregulat*)) OR ‘effortful control’ OR ‘situation selection’ OR ‘situation modification’ OR ‘attentional
deployment’ OR ‘cognitive change’ OR ‘response modulation’)
AND
MH (“Pain+” OR ‘Pain Measurement’) OR TI pain OR AB pain
Web of Science TS= (“emotion regulat*” OR “emotional regulat*” OR “emotion dysregulat*” OR “emotional dysregulat*” OR “emotional
modulat*” OR “emotion modulat*” OR “emotion management” OR “emotional management” OR “emotional competenc*” OR
“emotion comptetenc*” OR “emotional expression” OR “emotion expression” OR ‘emotional control’ OR “emotion control” OR
“emotional self-efficacy” OR “emotional suppression” OR “emotion suppression” OR “affect regulat*” OR “affect dysreg*” OR
‘effortful control’ OR ‘situation selection’ OR ‘situation modification’ OR ‘attentional deployment’ OR ‘cognitive change’ OR
‘response modulation’)
AND
TS=pain
Cochrane Central Database of Controlled
Clinical Trials
(‘emotion regulat*’ OR ‘emotional regulat*’ OR ‘emotion dysregulat*’ OR ‘emotional dysregulat*’ OR ‘emotional modulat*’ OR
‘emotion modulat*’ OR ‘emotion management’ OR ‘emotional management’ OR ‘emotional competenc*’ OR ‘emotion
comptetenc*’ OR ‘emotional expression’ OR ‘emotion expression’ OR ‘emotional control’ OR ‘emotion control’ OR ‘emotional
self-efficacy’ OR ‘emotional suppression’ OR ‘emotion suppression’ OR ‘affect regulat*’ OR ‘affect dysreg*’ OR ‘effortful control’
OR ‘situation selection’ OR ‘situation modification’ OR ‘attentional deployment’ OR ‘cognitive change’ OR ‘response
modulation’)
AND
pain
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as: “No matter how badly I feel, I try to think about pleasant things”
[36]. Findings from this group of studies suggest that while there might
not be direct associations between antecedent-focused ER and pain,
there was a link between antecedent-focused ER and depression, in that
thought suppression was positively correlated with more depressive
mood and major depressive disorder [22]. Additionally, there was an
association between high emotionality and reduced use of adaptive
antecedent-focused ER such as cognitive reappraisal [37]. In other
words, when patients had more negative emotions, they were less likely
to use cognitive reappraisal and thus experienced more pain. Similarly,
in the same group of patients, high pain was linked to lower mood [36].
Further, women with chronic pelvic pain reported to suppress their
thoughts and emotions more often compared to controls [46]. This
study also found that the tendency to suppress unwanted thoughts or
emotion was associated to more pain.
Thus, while antecedent-focused ER may not directly influence pain,
it is possible that adaptive use of these strategies may reduce pain
vulnerability or pain experience indirectly by reducing high emotion-
ality or negative mood, both known vulnerability factors for the de-
velopment of chronic pain.
3.2. Response-focused emotion regulation
Five studies measured response-focused ER. This included strategies
such as response modulation (i.e., influencing physiological, experi-
ential, or behavioral responding) and expression of emotions.
This group of studies sought to determine how pain intensity or
pain-related functioning was influenced by behavioral or experiential
ER that is typically employed after response tendencies have been
initiated. For example, one study investigated whether anger inhibition
or expression was related to concurrent pain and pain three hours after
anger inhibition or expression [12]. They found that both expression of
anger (such as slamming doors or shouting) and inhibition of anger
(such as hiding anger or keeping it to oneself) were correlated with pain
intensity, in that those participants who strongly expressed or inhibited
their anger experienced more pain. Similarly, in patients with more
problems controlling their emotional expression, for example, those
who had emotional outbursts or sudden and/or frequent mood changes,
pain interfered more with their physical activity, mood, relationships,
and sleep [8].
With regard to psychological comorbidities, a study that measured
participants' self-perceived ability to regulate emotions found that those
with low self-perceived ability to do so often also showed depressive
symptoms [35]. Interestingly, however, this self-perception was not
correlated with pain, but those patients who reported depression
symptoms also reported significantly more pain. Similarly, two studies
looked at the same sample of patients with rheumatoid arthritis, dis-
tinguished different styles of ER and tested if these different styles
would relate to dimensions of perceived health such as social and
physical functioning and disease activity. They found that none of the
ER styles was significantly related to physical functioning or disease
activity. However, ER styles were related to social functioning and
positive and negative affect [52]. Additionally, they tested if men and
women differ with regard to ER styles and perceived health and found
that indeed, women had higher scores than men on an ER style that is
best described in terms of attending to and intensely experiencing
emotions, and valuing emotions in daily life and decision making [53].
For women, the styles of ER found in this study explained 3% of the
Fig. 3. Flow chart.
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variance of disease activity, which means that a small part of difference
between individuals with regard to disease activity is explained by their
different styles of ER. This was not true for men, in turn, men reported
better physical functioning than women.
Thus, in some cases, response-focused ER was directly correlated
with pain and pain-related functioning, while in other cases these
strategies related to symptoms of depression, a prevalent psychological
comorbidity of chronic pain.
3.3. Antecedent- and response-focused emotion regulation
Five studies measured both antecedent- and response-focused ER.
This group of studies sought to determine how antecedent- and re-
sponse-focused ER strategies differ with regard to their relationship to
pain, pain-related disability, and disease impact. For example, one of
the few studies that examined a pediatric population asked their par-
ticipants and participants' parents to complete a baseline ER measure
prior to a one-month electronic diary study that assessed emotions and
pain thrice daily. The baseline ER measures asked for both antecedent-
and response-focused ER to deal with negative emotions, but no cor-
relation with pain intensity was found [16]. However, children that
reported more emotional ups and downs in the electronic diary also
reported more pain compared to those children with less emotional
variability.
Three studies that all measured both cognitive reappraisal and ex-
pressive suppression did not find significant correlations of pain with
either one of the ER strategies [51,54,57]. However, findings of these
studies suggest that while cognitive reappraisal and expressive sup-
pression do not directly influence pain, expressive suppression seems to
have a negative impact on patients' experience of their pain. For ex-
ample, one study found that participants who used more suppression of
their emotional expression also reported significantly more symptoms
of anxiety and depression [54]. In the same study, a significant positive
correlation between negative emotions, such as feeling upset or scared,
and pain was reported. Another study found that patients who em-
ployed more expressive suppression also had more catastrophic
thoughts around pain such as “When I'm in pain, I worry all the time
about whether the pain will end” (item from the Pain Catastrophizing
Scale PCS; [45]). These catastrophic thoughts were significantly posi-
tively correlated with pain intensity and pain-related disability [57].
Additionally, children with sickle cell disease who used expressive
suppression were more likely to be hospitalized due to pain crises
compared to those who employed less expressive suppression [51]. In
line with these findings, patients who reported often expressing their
feelings freely also reported less consequences of their pain such as
number days of work missed, physical impairment, and morning
tiredness [23].
Thus, most studies that measured both antecedent- and response-
focused ER found no direct relationship of either strategy to pain, but
found response-focused ER to be correlated with catastrophizing
thoughts around pain, likelihood of being hospitalized during pain
crises, and the impact the disease has in patients' everyday life.
One study measured ER that could not be classified as either ante-
cedent- or response-focused. Questions such as “When I experience a
positive emotion, I know how to make it last” or “I have control over
my emotions” were asked to determine participants' efficacy in ER [2].
Participants who rated themselves as being effective in regulating their
emotions also reported less negative affect and better quality of life. ER
efficacy was not correlated with pain-related disability, but positively
with self-efficacy in managing pain [2].
In sum, the studies included in this review rarely found direct as-
sociations between emotion regulation and pain intensity or pain-re-
lated disability. Rather, the relationship between ER (antecedent or
response-focused) and pain seemed to be mediated by psychological
factors such as emotionality, anxiety, or negative mood. The studies
that more closely explored response-focused ER seemed to provide the
best evidence for a strong relationship between maladaptive ER, psy-
chological symptoms, and pain.
4. Discussion
This systematic review examined the relationship between ante-
cedent- and response-focused ER and chronic pain. We found that ER is
a relatively new construct in the chronic pain literature and the direct
and indirect influences of ER and pain are not yet clearly defined. Most
studies in this review found indirect associations between ER and pain,
via other psychological factors. However, there were several studies
that found direct associations between maladaptive response-focused
ER and chronic pain, pain-related disability, and depressive symptoms.
This is in line with previous research that differentiated between
adaptive and maladaptive ER based on their relationship with psy-
chological symptoms and found antecedent-focused strategies (such as
cognitive reappraisal) to be more adaptive compared to response-fo-
cused strategies (such as expressive suppression; [4]). However, the
differentiation between adaptive and maladaptive ER is more precise
when it incorporates the idea of ER flexibility, i.e. the ability of an
individual to implement an ER strategy that matches the contextual
demands [5]. Maladaptive ER can thus be thought of as a limited range
of strategies inappropriately matched to changing social and contextual
demands. Suffering from chronic pain may present as a constant
stressor that increases the amount of negative affect one experiences
(due to missing days at work or school or not being able to actively
participate in social activities; Vos et al. [58]) and thus it might become
increasingly difficult to employ adaptive ER.
Even in cases where ER is not directly associated with pain intensity
or disability, it plays an important role in patients' overall well-being
and functioning, as it can be associated with symptoms of depression,
anxiety, stress [8,35,54], or quality of life [2]. All these factors might
then further worsen pain or limit functioning in this population. It is
therefore suggested to include ER in current models of chronic pain,
such as the one proposed by von Baeyer and Champion ([55]; see
Fig. 1). Based on Mayer and Bushnell's work [39], von Baeyer and
Champion differentiate between primary risk factors for chronic pain,
such as central sensitization, or autonomic nervous system activity, and
secondary risk factors, such as catastrophizing, and symptom-related
worries. While early gene-environment interactions may shape primary
risk factors, secondary risk factors may be more responsive to the cul-
tural, social, and medical environment and are thus commonly targets
of chronic pain interventions. The results of our systematic review
suggest that ER may be an important secondary risk factor that cuts
across different chronic pain syndromes.
Further, as a secondary risk factor, ER is a good target for training
modules within the treatment of chronic pain, as adaptive use of ER
strategies can be trained (e.g. [17,20,27]). Preliminary studies that
included ER in current treatment options for chronic pain report posi-
tive results, both in adolescents (e.g. [6]) and adults (e.g. [27]). In a
study of two case examples of patients with chronic pain and comorbid
anxiety or depression, the training of ER lead to improvements in at
least some of the domains of interest (pain, functional limitations, an-
xiety, ER, and others more; [6]). In a study that extended cognitive
behavioral therapy (CBT) with ER training and compared it to CBT
alone, CBT with ER training showed greater effect sizes for almost all
treatment objectives [27]. Hence, adding ER to current theoretical
frameworks of chronic pain may help to further clarify why some
people are more vulnerable to chronic pain than others and how this
knowledge can be implemented in new interventions.
Several limitations have to be considered when interpreting the
results of this review. We only found a small number of studies that
examined ER and chronic pain, and one major obstacle in conducting
this systematic review was that even in this small sample of literature
the term ER was used very heterogeneously. Besides the Process Model
of ER [30], there is significant variability in regards to how the term ER
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is operationalized. Some working definitions include (or do not clearly
exclude) alexithymia, coping style, emotional awareness, and emo-
tional intelligence. The variability in conceptualization of this term is
also evident in the wide range of measures developed to systematically
assess ER [18,56]. The studies included in this review used a range of
different questionnaires. However, in an attempt to clarify the subject,
only studies that explicitly measured ER were included. Similar chal-
lenges present themselves in the field of chronic pain. First, there are a
variety of pain sites and syndromes assessed within this review. Second,
study participants suffered from chronic pain conditions for time per-
iods that ranged between several months and more than a decade.
Living with chronic pain for such an extended period of time might lead
to more accentuated problems in the areas of social life, job, and
functioning in general [41]. Further, although we included all age
groups, only two of the 15 studies looked at pediatric populations.
Given that ER involves higher order cognitive processing, we certainly
cannot assume that our findings would generalize more broadly to
pediatric samples. Moreover, no statement can be made regarding age-
specific relationships between ER and chronic pain. Other significant
limitations include the bias of female only studies (6/15) in this review
and the cross-sectional design of most of the studies.
The results of this review are also limited in part by the standard
questionnaire format of all measures used for studies within this review.
In general, as ER is a phenomenon that includes cognitive, behavioral,
and physiological aspects, it is advisable to measure it using several
methods, such as psychophysiological and observational methods and
questionnaires [28,33,47]. Future studies should employ newer am-
bulatory assessment methods, such as ecological momentary assess-
ment [44]. Electronic diaries are one example for electronic momentary
assessment [18]. Fernandez and colleagues [21] proposed to include ER
as a new Research Domain Criteria (RDoC) domain. This would support
future research in the field of ER and chronic pain, as it would allow to
further understand not just the cognitive and behavioral, but also the
neural, genetic, and physiological systems that underlie the ER - chronic
pain relationship.
To our knowledge, this is the first review to systematically examine
the role of both antecedent- and response-focused ER in chronic pain.
Our results suggest that ER may be an important and understudied risk
factor that can have direct or indirect influences on pain, pain-related
disability, and psychological comorbidities in patients with chronic
pain. Further investigation is needed to more directly explore the role of
ER in chronic pain and importantly to ascertain if training in adaptive
ER strategies could provide direct symptom relief or even potentially
serve as a protective factor, reducing pain vulnerability in patients who
may have other identified risk factors for the development of chronic
pain.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jpsychores.2018.02.002.
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Supplementary Material 
 
sTable 1. Data Analysis and Results of Included Studies 
	
 First Author (Year) Data Analysis Result p-Value 
 
Antecedent-
focused emotion 
regulation 
strategies 
Hamilton (2005) Zero order correlation between pain and mood 
repair 
Hierarchical linear modeling to predict the 
prospective relationship between pain and 
negative affect using mood repair 
r=-.01 
 
B=-.005 for mood repair 
 
n.s. 
 
<.05 
 
Hamilton (2007) Zero order correlation between pain and mood 
repair 
 
Hierarchical linear modeling to predict 
differences in negative affect in response to pain 
using mood repair and the interaction of affect 
intensity and mood repair  
r=-0.01 
 
 
B=-0.001 for mood repair 
 
B=-0.023 for the interaction of affect intensity and mood 
repair 
n.s. 
 
n.s. 
 
<0.01 
Garland (2016) Zero order correlations between comorbid 
depression diagnosis and use of suppression as 
well as between pain severity and depressive 
mood and major depressive disorder 
Major depressive disorder and use of suppression:  
r=.24 
Pain severity:  
r=.44 for depressive mood 
r=.24 for major depressive disorder 
 
 
<.05 
 
Thomas (2006) Chi square to compare frequency of emotion 
suppression between patients with chronic pelvic 
pain and controls 
 
ANOVA to compare pain M and SD between 
those who suppressed emotions and the other 
groups (repressors, high anxious, low anxious) 
34.3% vs. 8.2%, χ2=24.68 
 
 
 
M=16.81, SD=5.8 (suppressors) M=9.96, SD=6.63 
(repressors) 
M=9.56, SD=8.44 (high anxious) 
M=6.03, SD=4.88 (low anxious) 
F(3,87)=10.41 
<.001 
 
 
 
 
<.005 
 
 
 
 
Response-
focused emotion 
regulation 
strategies 
 
Baker (2016) MANOVA to determine differences between 
participants in the normal range and those with 
clinically elevated emotional control values with 
regard to pain interference, pain self-efficacy, 
anxiety, depression and stress 
Pain interference: 
M=7.9, SD=1.6 for elevated values, M=6.2, SD=1.8 for 
normal values 
Pain self-efficacy: 
M=18.2, SD=10.7 for elevated values, M=24.9, SD=11.8 for 
normal values 
Anxiety, depression, stress: 
M=67.0, SD=27.7 for elevated values, M=40.1, SD=26.4 for 
normal values 
 
<.001 
 
 
<.05 
 
 
<.001 
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Response-
focused emotion 
regulation 
strategies (cont.) 
Burns (2015) Zero order correlations between anger inhibition, 
anger expression and pain intensity 
 
Hierarchical linear modeling to test concurrent 
and lagged relationships between anger 
expression, anger inhibition and pain and pain 
interference 
r=0.26 for anger expression and pain intensity 
r=0.3 for anger inhibition and pain intensity 
 
Anger expression: 
B=.02, SE=.02 for concurrent pain intensity 
B=.04, SE=.01 for pain intensity 3h after anger expression 
B=.02, SE=.02 for concurrent pain interference  
Anger inhibition: 
B=.02, SE=.01 for concurrent pain intensity 
B=.01, SE=.01 for pain intensity 3h after anger inhibition 
B=.05, SE=.01 for concurrent pain interference 
<.05 
<.01 
 
n.s. 
<.01 
n.s. 
 
n.s. 
n.s. 
<.01 
Connelly (2012) Hierarchical linear modeling to predict overall 
pain and functional limitations using greater 
variability in negative emotion levels and child 
self-report baseline emotion regulation 
B=55.68 ± 22.94 for pain using negative emotion variability  
B=12.93 ± 5.06 for functional limitations using negative 
emotion variability 
B=10.40 ± 11.42 for pain using child self-report 
B=2.32 ± 2.75 for functional limitations using child self-
report 
 
.02 
 
n.s. 
n.s. 
Hamilton (2012) Zero order correlations between self-perceived 
ability to amplify or reduce of emotions and the 
sensory dimension of pain experience or 
depression 
Amplification of emotions: 
r=-0.21 for the sensory dimension of pain experience 
r=-0.30 for depressive symptoms 
Reduction of emotions: 
r=-0.08 for the sensory dimension of pain experience 
r=-0.48 for depressive symptoms 
 
n.s. 
<.10 
 
n.s. 
<.01 
Van Middendorp 
(2005a) 
Structural equation model to determine 
percentage of variance accounted for by emotion 
regulation styles 
16% of variance of negative affect 
7% of variance of positive affect 
20% of variance of social functioning 
0% of variance of physical functioning and disease activity 
 
Van Middendorp 
(2005b) 
Effect sizes of gender differences regarding 
emotion regulation styles (ambiguity, control, 
orientation, expression) and physical functioning 
Ambiguity: d=.24 
Women: M=-.06, SD=.78 
Men: M=.16, SD=.76 
Control: d=0.10 
Women: M=-.03, SD=.78 
Men: M=.08, SD=.67 
Orientation: d=0.69 
Women: M=.14, SD=.75 
Men: M=-.39, SD=.64 
Expression: d=0.13 
Women: M=.04, SD=.80 
Men: M=-.12, SD=.80 
Physical functioning: d=0.59 
Women: M=-.10, SD=.92 
Men: M=.28, SD=.83 
 
.07  
 
 
.51 
 
 
.00 
 
 
.33  
 
 
.00 
Antecedent- and 
response-focused 
emotion 
regulation 
strategies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Middendorp 
(2008) 
Zero order correlations between cognitive 
reappraisal, expressive suppression and mental 
distress, pain, and fatigue 
Cognitive reappraisal: 
r=-.09 for mental distress 
r=.06 for pain 
r=.06 for fatigue 
Expressive suppression: 
r=.21 for mental distress 
r=.08 for pain 
r=.05 for fatigue 
 
n.s. 
n.s. 
n.s. 
 
<.001 
n.s. 
n.s. 
Wong (2013) Zero order correlations between expressive 
suppression, cognitive reappraisal and pain 
intensity, pain-related disability and pain 
catastrophizing 
Expressive suppression: 
Pain intensity° 
Pain-related disability° 
Cognitive reappraisal: 
Pain intensity° 
Pain-related disability* 
Pain catastrophizing: 
r=-0.14 for cognitive reappraisal 
r=0.37 for expressive suppression 
r=0.39 for pain intensity 
r=0.34 for pain-related disability 
 
n.s. 
n.s. 
 
n.s. 
n.s. 
 
<.05 
<.01 
<.01 
<.01 
Antecedent- and 
response-focused 
emotion 
regulation 
strategies (cont.) 
Tsao (2014) Zero order correlations between cognitive 
reappraisal, expressive suppression and pain  
 
Sequential logistic regression with blood type 
and pain as step 1 variables and emotional 
suppression and somatization as step 2 variables.  
r=-.06 for cognitive reappraisal and pain 
r=-.07 for expressive suppression and pain  
 
 
B=.22, OR=1.25 for emotional suppression 
n.s. 
n.s. 
 
.04 
Geenen (2012) Zero order correlations of cognitive reappraisal, 
expressive suppression, emotion expression and 
disease impact 
Disease impact:  
Cognitive reappraisal° 
Expressive suppression: r=.18 
Emotion expression: r=-.18 
 
n.s. 
<.001   
<.001    
 
Agar-Wilson (2012) Zero order correlation between efficacy in 
emotion regulation and pain-related disability  
 
Hierarchical multiple regression analyses to 
predict negative affect and quality of life using 
efficacy in emotion regulation. 
 
 
r=-.14 
 
 
Negative affect: 
b=-.21, sr2=-18, t=-2.40 
Quality of life: 
b=.26, sr2=.20, t=2.89 
n.s. 
 
 
.018 
 
<.005 
 
* No results of other MPI subscales or other pain measures were given.  
° No further information was provided for not significant results in these papers. 
Abbreviations  
n.s.: not significant; B= unstandardized Beta-values; b=standardized Beta-values 
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Abstract 
 
Objectives  
Stressful life events have been associated with adjustment problems in adolescence in cross-
sectional studies. Using a longitudinal cohort, we examined the influence of these events and 
predefined covariates on adjustment problems in adolescence, and compared internalizing and 
externalizing trajectories among children with many vs. few stressful life events. 
Methods  
Data were obtained from the Study of Early Child Care and Youth Development. 1,364 children 
and their families were followed from child’s birth until age 15. Adjustment problems at age 15 
were defined as high (>60 T-score) internalizing and/or externalizing problems on the Youth 
Self-Report and Child Behavior Checklist. Stressful life events were evaluated at 54 months, in 
3rd and 5th grade. Categories created by mixture model analyses for covariates were used in 
logistic regressions to predict adolescent-reported adjustment problems.   
Results  
Mothers reported higher rates of adjustment problems than adolescents (21.1% vs. 16.3%; 
p<0.0001). Adjustment problems were associated with more stressful life events (OR=1.7, 
p=0.0042), male gender (OR=1.9, p=0.001), and child’s high emotional reactivity (OR=1.6, 
p=0.01). Analysis using mother report of adjustment problems showed the same predictors, as 
well as lower maternal education level (OR=3.5, p=0.0003), child’s friendship quality (OR=0.4, 
p=0.005), and paternal depression (OR=2.1, p=0.0165). Higher internalizing and externalizing T-
scores were apparent in children with more stressful life events from the age of 2 onwards 
(Ps<0.0001).   
Conclusions  
After adjusting for multiple covariates, stressful life events during childhood predicted 
adjustment problems at age 15. Our results suggest that emotional reactivity and paternal 
depression play a significant role in the development of adjustment problems in adolescence. 
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Introduction 
Stressful life events, such as physical, sexual, or emotional abuse, neglect, exposure to 
violence, mental illness, incarceration, substance abuse in the family, parental absence due to 
divorce or separation, and low socioeconomic status1 present a risk factor to healthy 
development in children and adolescents. Previous research on the impact of stressful life events 
in childhood has linked them to depression and anxiety,2 delinquent behavior,3 and somatic 
health.4  In addition, stressful life events have been found to be associated with rumination and 
emotional dysregulation.5 Early stressful life events pose a risk for maladaptive development 
when they accumulate over time or if they occur during sensitive developmental periods.6 
However, most previous studies have used cross-sectional designs, often focused solely on one 
type of life event, and examined few mediators or moderators that might increase or decrease the 
risk of adverse outcomes following life events. One of the few longitudinal studies that looked at 
the impact of social support on the relationship between stressful life events and internalizing 
and externalizing behavior within a year found a main effect for stressful life events as a 
predictor for problematic behaviors in adolescent girls only.7 Another longitudinal study looked 
at gender differences within the relationship between stressful life events and depressive 
symptoms and again found this relationship to be significant for girls only.8 A review paper 
found stressful life events to predict both internalizing and externalizing symptoms, with a 
stronger association for internalizing symptoms.9 However, further elucidation of the exact 
mechanisms leading to these associations is warranted.  
In our study, several potential risk and protective factors are taken into consideration. The 
choice of these factors is based on research on resilience10 and differential susceptibility,11 and 
includes individual-level and family-level risk factors, namely mother-child attachment, child 
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temperament, child emotional reactivity, child peer relationship, maternal separation anxiety, 
father-child and mother-child relationship, parental relationship, and maternal and paternal 
depression.  
Past research has introduced the concepts of resilience and differential susceptibility. The 
idea of resilience states that among those children growing up under adverse circumstances, 
some grow up to be healthy, while others show an impaired functioning, i.e., symptoms of 
psychopathology, and/or low levels of academic or social achievements.10 In a pioneering 
longitudinal study, a birth cohort from the island of Kauai, Hawaii, was followed from the 
prenatal period to young adulthood.12 This study found that some children developed into 
competent adults despite growing up in adverse circumstances. The research that followed this 
initial study found some factors that resilient children seemed to share, such as average or better 
IQ, social and academic competences, at least one stable attachment figure, sensitive parenting, 
and good regulation of behavior and emotion.13 However, resilience has also been defined as 
arising from “ordinary human adaptive processes,”10 highlighting that it is neither a hereditary 
trait, nor some extraordinary set of skills, but rather a series of adaptive processes. 
While the concept of resilience is part of the diathesis-stress framework that describes 
protective processes and individual differences in response to adversity, the model of differential 
susceptibility is not restricted to such negative effects of contextual adversity.14 Rather, 
differential susceptibility states that some individuals are more susceptible to both negative and 
positive exposures, as well as developmental experiences11. Additionally, people differ 
fundamentally in how they perceive and process their environment: some are generally more 
sensitive, while others are generally less sensitive.15 For example, increased sensitivity is 
associated with difficult infant temperament, negative emotionality, candidate genes (e.g. 5-
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HTTLPR, MAOA), and high physiological stress reactivity, but will only develop into 
vulnerability when combined with an adverse environment.11 If combined with a supportive 
environment, the presence of sensitivity features is likely to lead to positive outcomes.14  
Using a prospective, longitudinal dataset, and taking the findings from research on 
resilience and differential susceptibility into account, we were interested in early determinants of 
child behavior, and influences of individual (such as child temperament and child emotional 
reactivity) and family factors (such as parent-child interaction, parental depression, and parental 
intimacy) on the relationship between early exposure to stressful life events and clinical 
elevation for adjustment problems in adolescence.  
One variable that can be classified both on the individual- (with regard to the child) and 
family-level (with regard to the mother-child relationship) is attachment. Early attachment 
quality is known to be an important influence on many aspects of child development.16 
Attachment is conceptualized through the mother-child interaction and can be classified into 
three main groups17: Securely attached children use their mother as a secure base from which 
they explore and where they return. Insecurely attached children show either dominantly 
ambivalent or anxious-avoidant behavior.18 Results from a longitudinal study that classified 
children into attachment groups at 1 year of age and assessed them again to test for the presence 
of psychopathology at 17.5 years of age found that belonging to one of the insecure groups was 
the main significant predictor of anxiety disorders in adolescence.19 Previous studies in children 
have found that possessing at least one stable and dependable attachment figure, low emotional 
reactivity, a flexible temperament, and having good peer relationships can be protective against 
adverse consequences of early insecure attachment experiences.20  
	
	
6	
	
Insecure attachment is related and may contribute to high maternal separation anxiety, a 
family-level variable which is defined as a mother’s increased concern and apprehension when 
separated from their children.21 Maternal separation anxiety is an important psychological 
construct that shapes maternal behavior, and has implications for both the child’s emotional 
development and the mother’s mental health.22 Higher levels of maternal separation anxiety are 
specifically related to increased levels of depressive symptoms and feelings of being a less 
effective mother.23 Perceived difficult child temperament can increase maternal separation 
anxiety.24 Other risk factors for maternal separation anxiety include low socioeconomic status,25 
which is also considered a risk factor for children’s mental health problems.26 
Several family-level variables have been shown to be potentially protective against 
adverse child outcomes and might mitigate the negative effect of stressful life events. One of 
them is the father-child relationship. The role of the father-child relationship is often overlooked, 
even though a positive father-child relationship is considered a protective factor against risky 
behavior in adolescence.27 In contrast, paternal depression is significantly related to child’s 
internalizing and externalizing symptomatology.28 A father’s involvement in a child’s life has 
shown to decrease a child’s conduct problems, hyperactivity, emotional problems, and peer 
problems.29 However, families with high levels of inter-parental conflict often show a decrease 
in fathers’ involvement.30 Moreover, high levels of inter-parental conflict can disrupt the child’s 
feeling of emotional security, which can contribute to difficulties in regulating emotional arousal 
and impact psychological adjustment.31 Continuous marital conflict,32 as well as both maternal 
and paternal psychopathology,29 hence can increase the risk for adjustment problems in children 
and adolescents.  
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Past research has shown that both the number and the timing of stressful life events can 
have an impact on child development.33 For the purpose of this study, we decided to look at the 
impact of stressful life events in three different ways: (I) to categorize the number of stressful life 
events a child experienced as either “many” or “few”, (II) to create a timing variable to reflect 
the time points at which the child experienced stressful life events, and (III) to create different 
categories of stressful life events, with regard to the domain they were related to, namely to 
parent/family physical or mental health and well-being; to parental work, school, or financial 
stability; to emotional aspects of relationships; or to change in family structure, routine, and 
caregiving. As an outcome measure, we use adjustment problems in adolescence. This was 
defined as either high internalizing and/or high externalizing symptoms on the Youth Self 
Report. High, in this case, means more than one standard deviation above the mean, a 
classification typically used in clinics.34 As internalizing and externalizing symptoms are often 
comorbid in childhood and adolescence,35 we decided to take them together to define the 
presence of adjustment problems. 
Our study prospectively evaluates the influence of stressful life events in childhood on 
the presence of clinical elevation of adjustment problems at age 15. We tested a number of 
family- and individual-level covariates that possibly influence this association, relying on 
previous research in the field of resilience and differential susceptibility, and analyzed the impact 
of stressful life events from various perspectives. This study adds to the literature on the 
detrimental health effects of early stressful life events in children and adolescents. We 
simultaneously evaluate how multiple individual- and family-level factors can influence the 
presence of adverse outcomes, such as clinical elevation of adjustment problems following 
stressful life events in a prospective cohort of children. The aims of our study are threefold: (1) 
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to test the influence of stressful life events (total number, type, and timing of stressful life events) 
on clinical elevation of adjustment problems in adolescence, (2) to examine the effect of 
predefined family- and individual-level covariates on the found associations, and (3) to compare 
internalizing and externalizing behavior trajectories throughout childhood and adolescence 
between children with “many” and “few” stressful life events.   
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Methods  
Sample  
We used data the Eunice Kennedy Shriver National Institute of Child Health and Development 
(NICHD) collected for the Study of Early Child Care and Youth Development (SECCYD). 
Participants were recruited from different hospitals and university centers across 10 locations in 
the United States at the time of child’s birth in 1991 and followed until age 15 
(https://secc.rti.org). The NICHD catchment population was defined as all babies (and their 
families) born in the hospitals participating in the study during the period of recruitment. The 
sample was selected by a conditional random sampling plan, designated to ensure that the 
recruited families included (i) mothers who planned to go to work or school full-time, part-time 
or stay at home during the child the first year, and (ii) reflected the demographic diversity of the 
sites. The major exclusion criteria were: (a) mothers younger than 18 years at the time of 
childbirth, (b) families that did not anticipate remaining in the catchment area for at least 3 years, 
(c) Children with obvious disabilities at birth or who remained in the hospital more than 7 days 
postpartum, and (d) mothers not sufficiently conversant in English.    
The final sample of this longitudinal study included 1.364 children and their families. 
Throughout the course of the study, the main study investigators invested considerable time and 
substantial effort in creating procedures that allow them to argue that whatever site effects are 
found are actually present due to real differences (e.g., due to demography, economy, or any of a 
vast number of unmeasured factors) and not by site procedural differences (NICHD technical 
note #9 in data report sheet). 
The institutional review boards of all participating institutions approved this study. Data were 
provided to us pre-processed as totals or summary values for different measurement scores; all 
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analyses were done in a de-identified manner. Figure 1 shows all measures and data points used 
in the study. 
 
Outcome: Adjustment Problems  
Our primary outcome was clinical elevation of adjustment problems at age 15 years. We used the 
well-validated subscales of the Child Behavior Checklist36 (CBCL), rated by the mother, and the 
Youth Self Report37 (YSR), a self-report for adolescents derived from the CBCL. The CBCL is a 
standardized form parents complete to describe their child’s behavioral and emotional problems. 
A series of descriptions of behaviors (around 100 items, depending on the age-group) are rated 
on a 3-point scale from 0 (not true of the child) to 2 (very true of the child or often true) for the 
past six months. Reported test-retest reliability in all subscales is good (r=0.71-0.93; p<0.0001).  
For this study, we focused on two broad groups of syndromes provided by the YSR and the 
CBCL: internalizing problems, which combines social withdrawal, somatic complaints, and 
anxiety/depression scales; and externalizing problems, which combines delinquent and 
aggressive behavior scales.36 The presence of high internalizing or externalizing problems was 
defined as having a T-score >60 (one standard deviation above the mean) for each scale.37 The 
primary outcome variable, clinical elevation of adjustment problems, was defined as the presence 
of high internalizing and/or externalizing problems at age 15 years, as rated by adolescents’ self 
report on the YSR.   
Main predictor: Stressful Life Events  
The study child’s mother completed an adapted version of the Life Experience Survey38 at three 
time points during childhood: 54 months, in 3rd grade, and 5th grade. At each time point, mothers 
reported if each of 57 evaluated stressful life events had occurred during the last year, reported 
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test-retest reliability is moderated (r=0.56-0.8). The list of events included routine happenings 
(such as a wedding in the extended family), major events (such as separation of parents), and 
catastrophic events (such as the death of a family member). This questionnaire aimed to provide 
an overview of events that the child’s family may have experienced, and that could have had an 
impact on the child and family well-being as well as on the quality of parenting.      
Similar to previous research,39 we first categorized the total number of stressful life events as 
either “many” (upper quartile of a total number of stressful life events), or “few” (lower three 
quartiles of the total number of stressful life events) at each time point. Next, we created a 
timing/chronicity variable to reflect the time points at which the child was in the upper quartile: 
(i) early: at 54 months and in 3rd grade (n =38); (ii) late: in 3rd and 5th grade (n = 65); (iii) single 
exposure (n=314); (iv) never (n = 513); and (v) always (n=51). We then created four categories 
of stressful life events: (i) parent/family physical or mental health and well-being (21 questions); 
(ii) parental work, school, or financial stability (16 questions); (iii) emotional aspects of 
relationships (16 questions); and (iv) change in family structure, routine, and caregiving (15 
questions). We averaged the number of stressful life events in each category across time points 
and defined “many” scores as belonging to the top quartile for each category.  
Covariates  
We included child gender (male or female), race/ethnicity (white or non-white [American Indian, 
Eskimo, Aleut; Asian or Pacific Islander; Black or Afro-American]; other), maternal education 
(years of education; categorized as (i) No high school degree (<12y); (ii) High school degree 
(12y); (iii) Bachelor’s degree (13 to 16 y); (iv) Post graduate studies (>16y)), and total income-
to-needs ratio (3 items that assess financial stress, 1 item asking how many people are supported; 
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and 2 items to assess sources of income, and the amount of income from these sources) at first 
month after birth as the primary demographic covariates. Additionally, we included individual- 
(i.e., concerning the child only) and family-level (i.e., concerning the child and the child’s 
family) covariates that have been shown to modulate the effect of stressful life events on 
adjustment problems.  
The following measures were collected on ≥2 time points during the study. We created summary 
variables (compound or trajectory variables, see Statistical analysis) as follows: 
Mother-child attachment (individual and family level; 2 time points): The Strange Situation18 
measure has been validated by several studies in the first year of life, it measures the 
organization of child attachment. The videotapes of 3 episodes of separation and reunion of 
mother and child are reviewed and coded by trained personnel. The organization of the child 
attachment and exploratory behaviors, especially in the reunion episodes, is analyzed and the 
mother-child attachment is then classified into one of the three major classifications: secure, 
insecure-avoidant, and insecure-ambivalent. For our analyses, children were classified as (i) 
always secure, (ii) always insecure, (iii) increasingly secure, and (iv) increasingly insecure.  
Child temperament (individual level; 2 time points): The Early Infant Temperament 
Questionnaire40 is a 39-item questionnaire that evaluates mother’s perception of the activity, 
adaptability, approach, mood, and intensity of the child. Reported test-retest reliability range 
from 0.48 to 0.80 across questionnaire subscales. Items are rated on a 1- to 6-point scale from 
"almost never" to “almost always."  Mean (3.3) and SD (0.7) at one month and six months were 
used to calculate changes in child temperament as (i) increasingly (six months value > one month 
value +0.7), or (ii) decreasingly difficult temperament (six months value < one month value -
0.7), and (iii) no change. 
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Child emotional reactivity (individual level; 4 time points): Mothers completed a composite 
measure for emotional reactivity41 that evaluates their perception of how their child expresses 
emotions in response to events. Reported test-retest reliability range from 0.74 to 0.78 across 
timepoints. Respondents were asked to rate their child’s frequency of display of emotions on a 5-
point scale from 1 (“never”) to 5 (“always”). Our model identified two trajectories (i) high vs. (ii) 
low emotional reactivity. 
Child friendship quality (individual level; 5 time points): The Friendship Quality 
Questionnaire/My Best Friend & Me42 evaluates the child’s perceptions of the previously 
identified best friendship he/she has. Reported test-retest reliability range from 0.63 to 0.93 
across timepoints. The 21-item questionnaire utilizes a 5-point response scale ranging from 1 
(“not at all true”) to 5 (“really true”) to measure six qualitative aspects of the friendship: 
validation and caring, conflict resolution, conflict and betrayal, help and guidance, 
companionship and recreation, and intimate exchange. Our model identified four trajectories: (i) 
Stable high, (ii) medium and decreasing, (iii) medium and increasing, and (iv) low but increasing 
friendship quality. 
Maternal separation anxiety (family level; 4 time points): The Maternal Separation Anxiety 
Scale43 is a 21-item questionnaire that evaluates mother’s level of worry, sadness, and guilt when 
separated from the infant. Reported internal consistency reliability ranged from 0.91 to 0.93. 
Each item is rated on a 5-point Likert scale ranging from 1 (“strongly disagree”) to 5 (“strongly 
agree”). Our model identified two trajectories: (i) low and (ii) high maternal separation anxiety.  
Parent-child interaction (family level; 5 time points): The Parent-Child Interaction Task44 is rated 
from 15-min videotapes of free play between parent and child. Our model identified four 
trajectories for the maternal sensitivity subscale: (i) increasing, (ii) stable-low, (iii) stable-middle, 
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and (iv) stable-high maternal sensitivity; and two trajectories for paternal sensitivity: (i) high vs. 
(ii) low. 
Parental intimacy (family level; 9 time points): The Personal Assessment of Intimacy in 
Relationships45 is a 36-item questionnaire that evaluates the degree of five areas of intimacy that 
an individual perceives he/she has with his/her partner. Internal consistency reliability ranged 
from 0.91 to 0.93 across samples We used the emotional intimacy subscale. Our model identified 
two trajectories for mother’s and father’s perception of intimacy in their relationship. We 
categorized the agreement between parents as (i) high and (ii) low intimacy agreement, and (iii) 
intimacy disagreement. 
Maternal depression (family level; 11 time points) and paternal depression (family level; 6 time 
points): The Center for Epidemiologic Studies Depression Scale46 evaluates depressive 
symptomatology for non-clinical samples. Reported test-retest reliability is 0.57. Respondents 
rate the frequency of 20 symptoms of depression during the past week. Response categories are 
"rarely or none of the time (less than one day)", "some or a little of the time (1-2 days)", 
"occasionally or a moderate amount of time (3-4 days) 11, and "most or all of the time (5-7 
days)”. Our model identified three trajectories (i) low, (ii) borderline significant, and (iii) 
clinically significant maternal and paternal depression. 
 
Statistical analysis 
All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC), hypotheses were two-
tailed. Descriptive statistics were calculated for all demographics and study characteristics; we 
assumed no normality and used non-parametric tests for continuous variables. Chi-squares and 
Wilcoxon's test were used to assess unadjusted associations of individual stressful life events, 
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summary stressful life events variables, and all the covariates with adjustment problems in 
adolescence. 
For the covariates assessed at ≥2 time points (see Covariates), we used the SAS PROC TRAJ 
procedure. This procedure is a group-based trajectory modeling that assumes there is a certain 
number of discrete underlying groups in the population47 (Supplemental Material S1 provides 
more detailed information).  
Multiple logistic regressions analyses were used to evaluate the association of adjustment 
problems in adolescence (dependent variable) and the total number of stressful life events 
(independent variable) while controlling for sociodemographic variables. The models were re-
run using all the stressful life events categorical variables and stressful life events 
timing/chronicity as independent variables. Finally, models including individual- and family-
level covariates were run. The final models presented in the manuscript included only variables 
that showed significance in the individual or family-level models. Adjusted odds ratios (ORs) 
and their 95% confidence intervals (CIs) were calculated for all models. Final model’s 
significance values were Bonferroni-adjusted for multiple comparisons and p-values <0.01 were 
considered significant. 
Linear mixed models were used to evaluate differences in CBCL internalizing and externalizing 
trajectories over time between children with “many” and “few” stressful life events. This model 
intrinsically consists of two components: subject-specific and population-specific models, while 
accounting for correlation at each level 48. Missing data can be handled readily by this technique.  
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Results  
Table 1 shows the sociodemographic characteristic of the population, covariates, and bivariate 
associations with adjustment problems as rated by adolescent self-report (information about 
adjustment problems rated by the mother is presented in the Supplemental Materials Table 1). Of 
the 1.364 children and families enrolled in the study, information from the YSR at age 15 years 
was available for 956 subjects. Some differences between those with complete data at age 15 
years compared to those not included in the analysis were found. Those with complete data on 
adjustment problems had a higher income-to-needs ratio (median=2.5, IQR: 1.4-3.9 vs. 
median=1.8, IQR: 0.8-3.2, p<0.001) and the percentage of females was higher (50.1% vs. 44.1%, 
p=0.043). There was no difference in ethnicity (81.4% vs. 78.2%, p=0.17). 
A significant difference between mother- and adolescent-reports were found for the internalizing 
(11.0% vs. 11.3%, p<0.001) and externalizing (10.3% vs. 14.3%, p<0.001) subscales. This 
difference was also found in the ratings of adjustment problems (26.3% vs. 21.1%, p<0.001). All 
selected covariates, except change in temperament, showed a significant association with 
mother-reported adjustment problems in adolescence in the unadjusted analysis (Supplemental 
Material S2). However, for child-reported adjustment problems, only emotional reactivity 
(p=0.002), and maternal (p=0.004) and paternal depression (p=0.006) were found to be 
significant (Table 1). 
Detailed information about individual stressful life events at each evaluated time point and their 
association with adjustment problems separated by mother- and child-report are provided in the 
Supplemental Material (S3). Common stressful life events significantly associated with 
adjustment problems at all three time points were: Arguments/conflicts with husband/partner, 
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major changes in the emotional closeness (increasing or decreasing) of family members, and 
problems with child (e.g., school, discipline, etc.). Table 2 shows the prevalence and unadjusted 
association of all stressful life events with adjustment problems. Overall, children with 
adjustment problems at age 15 reported a higher total number of stressful life events 
(median=24, IQR:15-30 vs. median=19, IQR:12-27, p<0.001).  
Families of children with “few” total number of stressful life events differed from those with 
“many” with regard to some key sociodemographic variables, such as maternal education level 
(13% vs. 8% didn’t have a high school degree and 11% vs. 17% completed graduate studies; 
p=0.015), lower median income-to-needs ratio (median=1.84, IQR: 0.9-3.1 vs. median=2.52, 
IQR: 1.4-4.0 p<0.001), more arguments and conflicts with husband/partner (at 54m: 57.5% vs. 
28.0%, p<0.001; 3rd grade: 53.6% vs. 23.6%, p<0.001; 5th grade: 47.7 vs. 23.0%, p<0.001), more 
family violence (at 54m: 5% vs. 1.1%, p<0.001; 3rd grade: 5.6% vs. 0.7%, p<0.001; 5th grade: 
2.6% vs. 0.81, p=0.023) and living in violent neighborhoods (at 54m: 11.5% vs.  3.9%, p<0.001; 
3rd-grade: 9.4% vs. 2.1%, p<0.001; 5th-grade: 5.3% vs. 0.9%, p<0.001). 
Variables significantly associated with adjustment problems in adolescence were: total 
number of stressful life events, gender, maternal education level, emotional reactivity, friendship 
quality, and paternal depression (Table 3, Model 1). There were no significant associations 
between stressful life events timing/chronicity and adjustment problems (Table 3, Model 2). 
Stressful life events categorized as parent/family physical or mental health and well-being were 
associated with mother-report of adjustment problems, but not with child-report. Stressful life 
events categorized as emotional aspects of relationships were significantly associated with child-
reported adjustment problems, and marginally significant with mother-reported adjustment 
problems (Table 3, Model 3). Of note, each additional stressful life event increased the odds ratio 
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(OR) for adjustment problems in adolescence. Children with “many” versus those with “few” 
stressful life events had significantly higher odds of adjustment problems in adolescence 
(OR=1.7, p=0.004). All information on the models analyzed using mother-report can be found in 
the Supplemental Material (S4). 
Results from the model that included only children with “many” stressful life events 
showed that mother-rated adjustment problems were associated only with high child emotional 
reactivity scores (OR=3.8, p=0.003); and child-rated adjustment problems were marginally 
associated with child’s father or mother’s husband/partner living in the same household at child’s 
birth (OR=2.5, p=0.015).  
On the other hand, results from the model including only children with “few” stressful 
life events showed that mother-rated adjustment problems were associated with maternal 
education at child’s birth (high school education vs. graduate studies; OR=3.3, p=0.002), high 
child emotional reactivity (OR=2.0, p=0.006), and child’s report of low and increasing vs. 
medium and increasing friendship quality (OR=2.9, p=0.014). Child-rated adjustment problems 
were associated with paternal clinically significant versus low depression scores (OR=3.5, 
p=0.001).  
Finally, Figure 1 depicts the mixed regression trajectories for internalizing and 
externalizing scores over time with significant differences between children with “many” and 
“few” stressful life events (ps<0.001 for both trajectories).  
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Discussion  
This study evaluated the influence of stressful life events in childhood on clinical elevation of 
adjustment problems at age 15 as well as the role of individual- and family-level covariates. We 
tested the influence of a number of covariates derived from research on resilience and differential 
susceptibility and examined the influence of stressful life events on adjustment problems in 
adolescence from numerous perspectives: the effect of individual stressful life events, total 
number of stressful life events across childhood, stressful life event type (by life domain), and 
timing/chronicity of stressful life event exposure. Additionally, we compared internalizing and 
externalizing trajectories of children with “few” and ”many” stressful life events.  
Our study resulted in several main findings. First, we found that mother- and child-report 
of adjustment problems in adolescence differ. This is in line with findings from a previous study 
showing that parents and children generally agree on the presence of symptoms, but not 
necessarily on the level/intensity of symptoms.49 Achenbach et al. reported an average 
correlation between self- and parent-report on behavioral and emotional problems across 
childhood and adolescence to be as low as r=0.22.50 In our study, adolescents rated themselves 
higher on the YSR than their mothers did on the CBCL. Previous research has shown that self-
ratings of internalizing problems are consistently higher than ratings by other informants (such as 
parents or teachers) and this agreement decreases when subjects get older. The opposite was 
found for externalizing problems, where the agreement is larger and increases with age.51 
Next, we found experiencing “many” stressful life events to be the single most important 
predictor of adjustment problems, even after controlling for sociodemographic variables and 
multiple individual- and family-level covariates. The increased risk associated with every 
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additional stressful life event was significant. This result supports the cumulative risk model 52 
that highlights the importance of the number of adverse childhood experiences (which includes 
stressful life events and other factors, such as socioeconomic status) in the development of 
adjustment problems, especially externalizing problems.53 Interestingly, we found that the timing 
of stressful life events was much less important than the total number of stressful life events 
across childhood. Another study that looked at stressful life events and obesity in the same study 
sample also came to this conclusion.39 Of note, the assessment of stressful life events started at 
4.5 years, so we could not examine their influence on earlier sensitive periods of development.6 
Stressful life events related to emotional aspects of relationships, such as conflicts within the 
(extended) family, divorce, and major change in the emotional closeness of family members 
were more important compared to other types of stressful life events. Although a change of 
attachment classification (i.e., increasingly secure after first being classified as insecurely 
attached and vice versa) showed significant univariate associations with adjustment problems, 
this association - contrary to our expectations - was not maintained as a predictive factor of 
adjustment problems after adjusting for other covariates (even though it showed a trend towards 
significance). This is surprising, given that mother-child attachment is considered a key 
component of early child development.16 Our results suggest that other factors such as stressful 
life events and child emotional reactivity may be more important in the development of 
adjustment problems. This is in line with the idea of differential susceptibility, in that more 
susceptible individuals are more affected by both positive and negative (i.e., stressful life events) 
environmental exposures11, and the more recently proposed idea of vantage sensitivity14. The 
model of vantage sensitivity describes individual differences in response to positive experiences. 
Responses to negative experiences are not captured in the model of vantage sensitivity – this is 
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in contrast to differential susceptibility, where individual differences to both positive and 
negative experiences are addressed. Interestingly, Pluess and Belsky identified negative 
emotionality as one behavioral endogenous susceptibility and vantage sensitivity factor.14  
For children with “few” stressful life events, paternal, but not maternal depression was 
the most significant risk factor for adjustment problems in adolescence. This is partly in line with 
Compas et al.,54 one of few studies that reported on both maternal and paternal depression and 
child outcomes over a nine-month period and found that both parents’ psychological symptoms 
are associated with an increase in adjustment problems in adolescence. Paternal depression is 
rarely assessed, although a meta-analysis has shown that when assessed, paternal depression is 
significantly related to child’s adjustment problems.28 Interestingly, in the analyses of individual 
CBCL subscales, paternal depression was significantly associated only with child’s self-reported 
anxiety/depression, an association that was not found for mother-report. Future studies should 
examine the specific influence of paternal depression on different areas of child adjustment 
problems. Finally, low and medium but increasing friendship quality served as a protective factor 
against adjustment problems for children with “few” stressful life events. This is in line with 
previous research suggesting that peer environment can present both a risk and a protective 
factor.55 
In the subsample of children with “many” stressful life events, we found only two 
protective factors: Child’s low emotional reactivity and absence of father (or mother’s 
husband/partner) living in the same household at child’s birth. The positive and large effect 
(OR=2.5) of not having a father or father-figure living in the same household at birth appears 
counter-intuitive. We found no assessed moderator or mediator that could explain this result. The 
fact that this was only assessed at childbirth makes its contribution difficult to understand. After 
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correcting for multiple comparisons, the result remains only borderline significant for the child-
report model (p=0.0152).  
The other protective factor we found was low emotional reactivity. The Emotional 
Security Theory32 proposes that in a conflict-laden environment, high emotional reactivity can 
serve as a sensible short-term coping strategy, as heightened emotional arousal helps to facilitate 
access to physical and psychological resources. Following the differential susceptibility model, 
high emotionality is considered a “plasticity marker” that can increase sensitivity to both positive 
and negative environmental exposures.14 In our sample, low emotional reactivity was a 
protective factor against adjustment problems for children with “many” stressful life events.  
Further, we looked at differences in internalizing and externalizing behavior trajectories 
among children with “many” and “few” stressful life events. Children with “many” stressful life 
events showed higher trajectories of internalizing and externalizing behaviors even before the 
first occurrence of stressful life events was assessed. Children with “many” stressful life events 
later on in life were born into significantly more stressful environments compared to those with 
“few” stressful life events, including lower maternal education, lower income, more arguments 
and conflicts within the family, more family violence, and living in dangerous neighborhoods. 
These results emphasize the need for targeted interventions for high-risk children in toxic stress 
environments. Children born in families and communities with low education and income levels 
are especially vulnerable to early stressful exposures, and in some cases, the cumulative burden 
of multiple risk factors in life may limit the benefit of protective factors and the effectiveness of 
intervention programs.1 
	
	
23	
	
Although internalizing and externalizing behaviors decreased for both groups over the 
course of the study, the group of children with “many” stressful life events decreased slower, and 
the difference at the final assessment was almost one standard deviation higher than those with 
“few” stressful life events. The steady decrease of both internalizing and externalizing behaviors 
conflicts with previous research that showed a decrease of externalizing, but an increase of 
internalizing behaviors in school-aged children over time.56 However, as data were collected 
until the age of 15, we might have missed a future reoccurring increase of internalizing 
behavior.2 
Our study has several strengths. First, we were able to use a prospective, longitudinal 
data set that followed children and their families over 15 years. Our main predictor, stressful life 
events, and our outcome measure, clinical elevation of adjustment problems, were both 
individually assessed at multiple time points, which reduces the risk of recall bias. Our 
methodology has several advantages, as the trajectory analysis not only deals well with missing 
data but also allows for a reduction of data without the loss of important information. We 
analyzed stressful life events by taking multiple factors into account (individual stressful life 
event, the total number of stressful life events across childhood, type and timing of stressful life 
event exposure). Further, thanks to the extensive amount of information collected in this dataset, 
we were able to assess the influence of multiple individual- and family-level covariates that we 
deemed important, based on previous research on resilience and differential susceptibility.  
Limitations of our study include that we had no child report of stressful life events, which 
means we could not determine if children and mothers agreed on their ratings of what they 
considered stressful. Moreover, all the information used in our study relied on self-report of 
participating mothers and children. Also, there was a considerable amount of missing data and 
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changes regarding the father figure over time (due to separation and divorce). As we used a 
community and not a clinical sample, our outcome, adjustment problems, represented differences 
within the norm and did only in rare cases exceed a clinical threshold. It is, therefore, uncertain 
whether our findings can be generalized to a clinical sample.   
Despite these limitations, our study indicates that early intervention for children in high-
risk environments addressing the emotional reactivity of the children, the appropriate 
establishment of friendships, and the assessment and treatment of paternal depression in 
preventing future psychopathology are of crucial importance. We highlight the need for early 
screening and detection of families and children in vulnerable situations or high-risk toxic 
environments. Further, specific interventions are warranted in order to reduce the number of 
stressful life events and to mitigate the impact that these events can have on children’s health, 
both in the short and long run. Future studies should gather longitudinal data into adulthood to 
observe the development of trajectories during the transition to adulthood. 	 	
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Figure Legends: 
Figure 1. Outcome measures and data points used in the study.   
Figure 2. Mixed regression models of internalizing and externalizing scores by upper quartile vs. 
lower three quartiles for the number of stressful life events. Bold lines represent the fix values 
and soft lines represent 95% confidence intervals. “Many” stressful life events: upper quartile of 
number of stressful life events; “Few” stressful life events: lower three quartiles of number of 
stressful life events. 
Table	1.	Demographics	and	bivariate	associations	with	clinical	elevation	for	adjustment	problems	
rated	by	self-report.	
Variable		
Clinical	elevation	
for	adjustment	
Problems					
(n=203)																									
%	
No	clinical	
elevation	for	
adjustment	
problems	
		(n=753)													
		%	 p-value	
Study	Child:	Female	 55.67	 48.61	 0.0742	
White	ethnicity		 75.86	 82.87	 0.1343	
Maternal	education	
	 	
	
No	high	school	degree	 9.36	 7.57	
0.2622	High	school	degree	 24.14	 18.86	
Bachelor's	degree		 51.72	 57.5	
Post-graduate	studies		 14.78	 16.07	
Father/mother’s	husband	or	partner	living	
in	the	same	household	
80.3	 88.71	 0.0016	
Income-to-needs	ratio		 2.0	(0.9-3.4)	 2.5	(1.5-4.0)	 0.0002	
	 	 	 	Mother-child	attachment		
	 	
	
Always	secure		 49.72	 51.03	
0.7933	Increasingly	secure		 19.89	 19.21	
Increasingly	insecure		 20.99	 18.48	
Always	insecure	 9.39	 11.29	
Temperament	changes		
	 	
	
Increasingly	difficult	temperament		 10.66	 8.24	
0.3979	Decreasingly	difficult	temperament		 15.74	 18.78	
No	change		 73.6	 72.97	
Maternal	separation	anxiety		
	 	
	
Low	 56.16	 62.15	 0.1204	
High		 43.84	 37.85	
Maternal	sensitivity		
	 	
	
Increasing	 3.94	 3.05	
0.0531	Stable	low		 6.4	 4.52	
Stable	middle		 33	 25.37	
Stable	high		 56.65	 67.07	
Paternal	sensitivity		
	 	
	
Low		 15.27	 15.01	 0.9256	
High		 84.73	 84.99	
Relationship	Intimacy	
	 	
	
Agree	high		 51.23	 52.19	
0.6879	Agree	low		 22.17	 19.52	
Disagree		 26.6	 28.29	
Emotional	reactivity	
	 	
	
Low		 36.45	 51	 0.0002	
High		 63.55	 49	
Friendship	quality	
	 	
	
High		 41.38	 43.29	
0.1469	Middle	decreasing		 11.33	 8.23	
Middle	increasing		 28.57	 34.13	
Low	but	increasing		 41.38	 14.34	
Maternal	depression		
	 	
	
Low		 42.86	 53.12	
0.0035	Borderline		 42.36	 38.78	
Clinically	significant		 14.78	 8.1	
Paternal	depression		
	 	
	
Low		 49.75	 59.23	
0.0058	Borderline		 37.44	 34	
Clinically	significant		 12.81	 6.77	
	
Significant	p-values	are	marked	in	bold	(p<0.05).	
“Clinical	elevation	for	adjustment	problems”	is	defined	as	the	presence	of	high	(>1 standard deviation 
above the mean)	internalizing	and/or	externalizing	problems	measured	by	the	Youth Self-Report	scale	at	
age	15.	
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Table	3.	Variables	associated	with	clinical	elevation	for	adjustment	problems	at	age	15,	rated	by	
adolescent	self-report.	
	
Adolescent	report		
Variable		 OR		 95%	CI	 p-value	
Model	1.		 	 	 	
Total	number	of	stressful	life	events	(continuous	variable,	
odds	per	additional	stressful	life	event)		 1.03	 (1.02-1.04)	 <.0001	
	 	 	 	Gender:	Male	vs.	female	 1.89	 (1.29-2.76)	 0.001	
Maternal	education	level	
	 	 	High	school	vs.	graduate	studies		 1.29	 (0.75-2.2)	 0.0963	
Bachelor's	vs.	graduate	studies		 0.83	 (0.51-1.36)	 0.0885	
	 	 	 	Individual-level	factors	 	 	 	
Emotional	Reactivity:		High	vs.	low	 1.59	 (1.12-2.26)	 0.0103	
Friendship	quality		
	 	 	High	vs.	low	but	increasing	 0.53	 (0.32-0.9)	 0.0212	
Middle	decreasing	vs.	low	but	increasing	 1.05	 (0.55-2)	 0.1074	
Middle	increasing	vs.	low	but	increasing	 0.56	 (0.33-0.95)	 0.0537	
Family-level	factors	 	 	 	
Attachment		 	 	 	
Always	insecure	vs	always	secure	 0.74	 (0.41-1.35)	 0.1811	
Became	insecure	vs.	always	secure		 1.15	 (0.73-1.8)	 0.4241	
Became	secure	vs.	always	secure	 1.18	 (0.75-1.86)	 0.3468	
Paternal	depression		
	 	 	Clinically	significant	vs.	low		 2.10	 (1.2-3.66)	 0.0165	
Borderline	vs.	low	 1.19	 (0.82-1.73)	 0.3344	
	 	 	 	
Model	2.	 	 	 	
Stressful	life	events	timing/chronicity		 	 	 	
Once	vs.	never	 1.51	 (1.01-2.27)	 0.1217	
Always	vs.	never	 3.20	 (1.66-6.2)	 0.0798	
Early	vs.	never	 1.59	 (0.67-3.78)	 0.5243	
Late	vs.	never		 4.04	 (2.02-8.06)	 0.0124	
	 	 	 	
Gender:	Male	vs.	female	 1.86	 (1.26-2.76)	 0.0019	
Maternal	education	level	 	 	 	
High	school	vs.	graduate	studies		 1.40	 (0.8-2.46)	 0.0599	
Bachelor's	vs.	graduate	studies		 0.88	 (0.53-1.47)	 0.1125	
	 	 	 	
Individual-level	factors	 	 	 	
Temperament	change		 	 	 	
Increasingly	difficult	vs.	no	change		 0.87	 (0.53-1.43)	 0.2625	
Decreasingly	difficult	vs.	no	change		 1.40	 (0.77-2.53)	 0.1911	
Emotional	Reactivity:		High	vs.	low	 1.51	 (1.04-2.17)	 0.0293	
Friendship	quality		 	 	 	
High	vs.	low	but	increasing	 0.51	 (0.29-0.87)	 0.0167	
Middle	decreasing	vs.	low	but	increasing	 0.96	 (0.49-1.89)	 0.2151	
Middle	increasing	vs.	low	but	increasing	 0.59	 (0.34-1.01)	 0.1595	
	
Family-level	factors	 	 	 	
Attachment		 	 	 	
Always	insecure	vs.	always	secure	 0.82	 (0.44-1.53)	 0.3199	
Became	insecure	vs.	always	secure		 1.04	 (0.64-1.69)	 0.9789	
Became	secure	vs.	always	secure	 1.34	 (0.84-2.15)	 0.1507	
Paternal	depression		 	 	 	
Clinically	significant	vs.	low		 2.24	 (1.24-4.03)	 0.0118	
Borderline	vs.	low	 1.19	 (0.8-1.76)	 0.2718	
	 	 	 	
Model	3.		 	 	 	
Stressful	life	events	categories	(high	total	scores)	 	 	 	
Health	and	wellbeing		 0.89	 (0.6-1.31)	 0.5432	
Work/school/finances	 1.00	 (0.66-1.52)	 0.9961	
Emotional	aspects	 2.19	 (1.46-3.29)	 0.0002	
Change	in	family	structure	 1.28	 (0.86-1.9)	 0.2295	
	 	 	 	
Gender:	Male	vs.	female	 1.90	 (1.29-2.79)	 0.0011	
Maternal	education	level	 	 	 	
High	school	vs.	graduate	studies		 1.16	 (0.67-2.01)	 0.2085	
Bachelor's	vs.	graduate	studies		 0.80	 (0.49-1.3)	 0.0973	
	 	 	 	
Individual-level	factors	 	 	 	
Emotional	reactivity:		High	vs.	low	 1.58	 (1.1-2.26)	 0.0123	
Friendship	quality		 	 	 	
High	vs.	low	but	increasing	 0.51	 (0.3-0.87)	 0.0257	
Middle	decreasing	vs.	low	but	increasing	 0.98	 (0.5-1.91)	 0.1454	
Middle	increasing	vs.	low	but	increasing	 0.52	 (0.31-0.89)	 0.04	
Family-level	factors	 	 	 	
Attachment		 	 	 	
Always	insecure	vs.	always	secure	 0.77	 (0.42-1.41)	 0.2365	
Became	insecure	vs.	always	secure		 1.08	 (0.68-1.71)	 0.6822	
Became	secure	vs.	always	secure	 1.22	 (0.77-1.94)	 0.2591	
Paternal	depression		 	 	 	
Clinically	significant	vs.	low		 2.15	 (1.23-3.76)	 0.0164	
Borderline	vs.	low	 1.24	 (0.85-1.81)	 0.4113	
Significant	p-values	are	marked	in	bold	(p<0.01).	
“Clinical	elevation	for	Adjustment	problems”	is	defined	as	the	presence	of	high	(>1 standard deviation 
above the mean)	internalizing	and/or	externalizing	problems	measured	by	the	Youth Self-Report	scale	at	
age	15.	
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1. Trajectory analysis  
The Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD) 
Study of Early Child Care and Youth Development (SECCYD) collected a wide range of 
variables at multiple time-points during four study phases over 15 years. In order to include the 
time factor of the follow-ups without increasing the complexity of our models, and with the aim 
of providing clear results in mind, we decided to use growth mixture modeling as a first step to 
create summary variables that could be included in posterior analyses. One advantage of these 
models is that they address the problem of varying time-points by clustering similar trajectories 
together and creating categorical indicators of each trajectory.   
Two variables were only assessed twice: Mother-child attachment (at 15 and 36 months of age) 
and child temperament (at one and six months of age). For variables assessed at more than 2 
time-points we used the SAS PROC TRAJ procedure. This procedure is a group-based trajectory 
modeling that assumes there is a certain number of discrete underlying groups in the population 
and that each group has its own prevalence, intercept, and slope (trajectory shape or change in 
BMI Z-score). Based on a calculated probability of belonging to a group, the model assigns the 
individual to the group to which the individual has the highest probability of belonging.1 This 
model is robust and allows missing data in the analysis, using all available data from each case to 
estimate the individual’s timeline. For all variables assessed at more than 2 time-points we 
started with models for four groups, then decreasing number of groups down to two groups. 
Polynomials were selected for each model, and we used Bayesian information criterion (BIC) 
scores and authors’ criteria to determinate the best fit of the model.2 Authors’ criteria means that 
we were especially interested in those groups that changed over time (i.e. from high to low or the 
opposite way), as we thought of trajectory change as a potential risk or protective mechanism 
across development.  
Maternal Separation Anxiety (assessed at one, six, 15 and 24 months): 
The Maternal Separation Anxiety Scale3 (MSAS) was completed by the study child’s mother at 4 
time-points during phase I of the study. The selected model resulted in two linear trajectories: (i) 
high vs. (ii) low maternal separation. BIC=-19072.  
 
  
Parent-child interaction (assessed at 54 months, 1st-, 3rd- and 5th-grade, and at age 15 years): 
The Parent-Child Interaction Task4 was observed at five time-points during the study. We used 
the maternal and paternal sensitivity composite measure, which includes parental supportive 
presence, respect for child’s autonomy, and parental reversed hostility. The selected model for 
maternal sensitivity resulted in four trajectories (one quadratic and three cubic trajectories): (i) 
increasing, (ii) stable low, (iii) stable middle, (iv) stable high (BIC=-9065).   
 
The selected model for paternal sensitivity resulted in two cubic trajectories: (i) high vs. (ii) low. 
(BIC=-6652).  
 
Parental intimacy (assessed at six, 15, 24, 54 months, 1st-, 3rd-, 5th-, and 6th grade, and at age 15 
years): 
The “Love and Relationships” subscale of the Personal Assessment of Intimacy in Relationships5 
was evaluated at nine time-points throughout the study. The selected model for pair agreement 
on shared intimacy resulted in two cubic trajectories: (i) high vs. (ii) low intimacy agreement for 
mother ratings (BIC=-7354). 
 
The selected model for intimacy resulted in two cubic trajectories (i) high vs. (ii) low intimacy 
agreement for father ratings (BIC=-6278).  
 
 
Child emotional reactivity (assessed in 3rd-, 4th-, 5th-, and 6th- grade): 
Two measures6,7 were completed by the study child’s mother at four time-points during the study 
to create a composite measure of child’s emotional reactivity. The selected model for emotional 
reactivity resulted in two cubic trajectories: (i) high vs. (ii) low emotional reactivity (BIC=-
12221). 
 
 
Friendship quality (assessed in 3rd-, 4th-, 5th-, and 6th- grade and at age 15 years): 
The Friendship  Quality Questionnaire/My Best Friend & Me8 was completed by the study child 
at five time-points. The selected model for child friendship quality resulted in four trajectories 
(one linear, one quadrantic and 2 cubic): (i) stable high friendship quality, (ii) middle and 
decreasing friendship quality, (iii) middle and increasing friendship quality, and (iv) low but 
increasing friendship quality (BIC=-4113). 
 
Maternal (assessed at one, six, 15, 24, 36, 54 months, 1st-, 3rd-, 5th-, 6th-grade and at age 15 years) 
and paternal depression (assessed at 54 months, 1st-, 3rd-, 5th-, 6th-grade and at age 15 years): 
The Center for Epidemiologic Studies Depression Scale9 was completed at eleven time-points by 
the study child’s  mother and at six time-points by the study child’s father. The selected model 
for maternal depression resulted in three cubic trajectories: (i) low, (ii) borderline, and (iii) 
clinically significant depression (BIC=-40507). 
 
The selected model paternal depression resulted in three cubic trajectories: (i) low, (ii) 
borderline, and (iii) clinically significant paternal depression. (BIC=-14010) 
 
sTable	1.	Demographics	and	bivariate	associations	with	clinical	elevation	for	adjustment	problems	
rated	by	mother	(n=973).	
Variable		
Total	(n=1364)										
%	
Clinical	
elevation	for	
adjustment	
problems					
(n=161)										
%	
No	clinical	
elevation	for	
adjustment	
problems						
(n=812)																							
%	 p-value	
Study	Child:	Female	 48.31	 54.66	 49.14	 0.2006	
White	ethnicity		 80.43	 79.5	 82.02	 0.1813	
Maternal	education	 		
	 	
	
No	high	school	degree	 10.2	 12.42	 7.14	
0.0004	High	school	degree	 21.06	 27.33	 18.84	
Bachelor's	degree		 54.22	 52.8	 56.4	
Post-graduate	studies		 14.53	 7.45	 17.61	
Father/mother’s	husband	or	partner	living	in	the	
same	household	
85.48	 80.75	 88.55	 0.0067	
Income-to-needs	ratio		 2.3	(1.1-3.7)	 2.0	(1.1-3.1)	 2.5	(1.5-4.0)	 <0.0001	
	
		
	 	 	Mother-child	attachment		 		
	 	
	
Always	secure		
49.41	
	 50.34	 50.75	
0.0807	Increasingly	secure		 19.78	 13.61	 21.12	
Increasingly	insecure		 19.78	 24.49	 17.56	
Always	insecure	 11.03	 11.56	 10.56	
Temperament	changes		 		
	 	
	
Increasingly	difficult	temperament		 8.91	 6.88	 8.84	
0.436	Decreasingly	difficult	temperament		 17.98	 21.25	 17.55	
No	change		 73.1	 71.88	 73.61	
Maternal	separation	anxiety		 		
	 	
	
Low	 58.14	 48.45	 63.42	 0.0004	
High		 41.86	 51.55	 36.58	
Maternal	sensitivity		 		
	 	
	
Increasing	 3.23	 3.73	 3.2	
0.0141	Stable	low		 4.33	 7.45	 4.19	
Stable	middle		 22.51	 34.78	 25.74	
Stable	high		 69.94	 54.05	 66.87	
Paternal	sensitivity		 		
	 	
	
Low		 12.24	 21.12	 13.79	 0.0174	
High		 87.76	 78.88	 86.21	
Relationship	Intimacy	 		
	 	
	
Agree	high		 58.36	 40.99	 54.8	 0.0029	
Agree	low		 16.86	 27.33	 18.1	
Disagree		 24.78	 31.68	 27.09	
Emotional	reactivity	 		
	 	
	
Low		 37.98	 27.33	 51.72	 <0.0001	
High		 62.02	 72.67	 48.28	
Friendship	quality	 		
	 	
	
High		 54.4	 44.72	 42.49	
0.0143	Middle	decreasing		 6.89	 11.8	 8.5	
Middle	increasing		 26.98	 22.98	 34.61	
Low	but	increasing		 11.73	 20.5	 14.41	
Maternal	depression		 		
	 	
	
Low		 52.2	 29.19	 55.91	
<0.0001	Borderline		 37.54	 48.45	 37.07	
Clinically	significant		 10.26	 22.36	 7.02	
Paternal	depression		 		
	 	
	
Low		 65.69	 46.56	 59.98	
0.0002	Borderline		 27.71	 38.51	 33.5	
Clinically	significant		 6.6	 14.91	 6.53	
Significant	p-values	are	marked	in	bold	(p<0.05).	
“Clinical	elevation	for	Adjustment	problems”	is	defined	as	the	presence	of	high	(>1 standard deviation 
above the mean)	internalizing	and/or	externalizing	problems	measured	by	the	Youth Self-Report	scale	at	
age	15.	
 
 
 
  
 sTable 2: Correlations between individual life events and clinical elevation for adjustment 
problems at age 15 
	  
Study Phase 2 at                  
54 Months  
Study Phase 3 at                
3rd Grade 
Study Phase 3 at                     
5th Grade 
		   n=1075 n=1024 n=1011 
Variable  
Yes 
(%)  No (%) 
Yes 
(%)  
No 
(%) 
Yes 
(%)  
No 
(%) 
Emotional Aspects of Relationships           
1 Argument or Conflict with Husband /Partner 35.16*Ɨ 64.84 31.38*Ɨ 68.62 29.5* 70.5 
2 Major Change of Emotional Closeness 
Between Family Members (Increased or 
Decreased) 
23.63*Ɨ 76.37 23.88*Ɨ 76.12 17.61* 82.39 
3 Arguments or Conflicts with In-laws or 
Other Family Members (Not Including 
Husband) 
19.24 80.76 17.22*Ɨ 82.78 14.13*Ɨ 85.87 
4 Separated from Husband/Partner (Due To 
Work, Travel, Etc.) 12.09 87.91 8.41
Ɨ 91.59 6.33 93.67 
5 Trouble with In-Laws 11.8 88.2 10.25Ɨ 89.75 6.45 93.55 
6 Change of Family Situation of Close 
Relative (e.g., Sister’s Divorce or Marriage) 9.94 90.06 9.92
* 90.08 6.63 93.37 
7 Arguments or Conflicts with Close Friend 8.65* 91.35 7.88* 92.12 7.12* 92.88 
8 Broke Up with Boyfriend/Partner 6.41*Ɨ 93.59 5.74* 94.26 5.93* 94.07 
9 Marital Separation (Due to Conflict) 5.86 94.14 6.26* 93.74 4.45 95.55 
10 Gunshots or Violence in Neighborhood 5.76*Ɨ 94.24 3.99*Ɨ 96.01 2.08 97.92 
11 Aftermath of Divorce (e.g., Change in 
Visiting, Continued Conflict) 5.20 94.8 6.54 93.46 4.85 95.15 
12 Marriage 4.09 95.91 3.99 96.01 3.95 96.05 
13 Divorce 3.07 96.93 4.00Ɨ 96.00 3.56 96.44 
14 Marital Reconciliation 2.97* 97.03 1.95 98.05 2.19 97.81 
15 Reconciliation with Boyfriend/Partner 2.51*Ɨ 97.49 2.24* 97.76 1.98* 98.02 
16 Family Violence or Abuse 2.04Ɨ 97.96 1.95Ɨ 98.05 1.29 98.71 
Parent or Family Physical or Mental Health and Well-Being       17 Had Psychological Counseling or Therapy 
For Self 11.98 88.02 11.41
*Ɨ 88.59 12.69* 87.31 
18 Took Prescription Drugs for at Least One 
Month to Help with Mental Problems 6.41
* 93.59 11.59*Ɨ 88.41 13.55* 86.45 
19 Took Non-Prescription Drugs for at Least 
One Month to Help with Mental Problems 0.56 99.44 2.34 97.66 1.78
* 98.22 
20 Had Family Psychological Counseling or 
Therapy For Marital or Family or Child 
Problems 
 
11.21* 88.79 11.77* 88.23 
21 Had Psychological Counseling or Therapy 
for Study Child 8.19
*Ɨ 91.81 7.53*Ɨ 92.47 
22 Study Child Took Prescription Drugs 
Regularly to Help with Mental Problem(s) 2.91
*Ɨ 97.09 3.17* 96.83 
23 Major Personal Injury or Illness 6.41 93.59 6.68 93.32 9.41* 90.59 
 Serious Illness of Grandparent 12.61 87.39 9.56 90.44 8.13 91.87 
24 Serious Illness of Mother  8.40* 91.60 8.86 91.14 6.36 93.64 
 Serious Illness of Father 7.17 92.83 9.24* 90.76 7.55 92.45 
 Serious Illness of Child 6.20 93.80 5.90* 94.10 5.07 94.93 
 Serious Illness of Spouse  4.51 95.49 5.30* 94.70 4.66 95.34 
 Serious Illness of Sister/Brother  4.41 95.59 4.63 95.37 4.07 95.93 
25 Serious Illness or Injury of a Close Friend 5.67 94.33 6.15 93.85 5.84* 94.16 
26 Death of Husband/Partner 0.09 99.91 0.39 99.61 0.6 99.4 
 Death of Grandparent  10.62 89.38 10.30Ɨ 89.70 6.45 93.55 
 Death of Father  2.63 97.37 3.77 96.23 2.78 97.22 
 Death of Mother  1.38 98.62 3.16 96.84 1.49 98.51 
 Death of Sister/Brother  0.88 99.12 0.99 99.01 1.19 98.81 
 Death of Child  0.50 99.50 - - 0.40 99.60 
27 Death of Close Friend 6.41 93.59 6.82* 93.18 5.34 94.66 
Family Structure, Routine and Caregiving Change         28 Child Started School 42.55 57.45 20.96 79.04 12.75 87.25 
29 Problem with Child(ren) (e.g., School, 
Discipline, Etc.) 31.10
* 68.9 38.42*Ɨ 61.58 32.74*Ɨ 67.26 
30 Major Change in Social Activities, e.g., 
Parties, Movies, Visiting (Increasing or 
Decreasing) 
25.33*Ɨ 74.67 19.57* 80.43 15.71* 84.29 
31 Major Change in Church Activities 
(Increased or Decreased Attendance) 22.30 77.70 18.19 81.81 14.84
* 85.16 
32 Change of Residence 22.10*Ɨ 77.90 19.32* 80.68 12.21 87.79 
33 Major Change in Usual Type and/or Amount 
of Recreation 20.52
* 79.48 18.99* 81.01 14.94* 85.06 
34 Pregnancy 18.14 81.86 10.6 89.4 6.23Ɨ 93.77 
35 Gained a New Member of Household (i.e. 
Family Member or Friend Moved In, Etc.) 17.50 82.50 13.04 86.96 12.27
* 87.73 
36 Major Change in Living Conditions 
(Building New Home, Remodeled, Etc.) 16.73 83.27 19.16 80.84 15.91 84.09 
37 Birth or Adoption of A Child 11.57 88.43 7.68 92.32 4.15 95.85 
38 Change in Mode of Daily Transportation 
(e.g., Bus Route, Car, Carpool, Etc.) 8.45 91.55 8.66 91.34 6.20 93.80 
39 Change in Child Custody 
Arrangements/Visitations 6.04
*Ɨ 93.96 5.93* 94.07 4.35Ɨ 95.65 
40 Needed to Care for Aging Family Member 5.58Ɨ 94.42 10.51 89.49 9.50 90.50 
41 Had a Miscarriage 3.92 96.08 2.82 97.18 1.19 98.81 
42 Had an Abortion 1.30 98.70 1.27 98.73 0.59 99.41 
Parental Work, School or Financial Stability         43 Outstanding Personal Achievement 44.09 55.91 40.23 59.77 32.15 67.85 
44 Change in Work Situation (Different Work 
Responsibility, Working Conditions, 
Working Hours, Etc.) or New Job 
43.77 56.23 39.57 60.43 38.83 61.17 
45 Major Change in Financial Status (A Lot 
Better or A Lot Worse) 35.04
* 64.96 35.12 64.88 31.09 68.91 
46 Change in Husband's/Partner's Work (Loss 
Of Job, Beginning New Job, Increased 
Responsibility, Longer Hours, Etc.) 
32.34 67.66 28.85 71.15 25.62 74.38 
47 Borrowed Less Than $10,000 (For Car, T.V., 
School Loan, Etc.) 18.31 81.69 19.49 80.51 16.30 83.70 
48 Borrowed More Than $10,000 (For Home, 
Business, Etc.) 17.49 82.51 22.47 77.53 21.80
Ɨ 78.20 
49 Return to Work 15.26 84.74 12.45Ɨ 87.55 10.54 89.46 
50 
Future of Husband's/Partner's Job is Insecure 13.02 86.98 11.61 88.39 14.03 85.97 
51 Minor Law Violation (e.g., Traffic Tickets) 11.44 88.56 13.72 86.28 12.25 87.75 
52 Returned/Began 
College, Graduate School Or Professional 
Training 
11.27* 88.73 8.09 91.91 7.82 92.18 
53 Stopped Working Outside the Home 9.85 90.15 7.78 92.22 6.62Ɨ 93.38 
54 Trouble With Employer (In Danger of 
Losing Job, Being Suspended, Demoted, 
Etc.) 
5.67 94.33 5.06Ɨ 94.94 5.83* 94.17 
55 Fired or Laid Off From Job 4.74 95.26 5.06Ɨ 94.94 5.34Ɨ 94.66 
56 Completed Formal Schooling 4.18 95.82 3.99 96.01 2.96 97.04 
57 Husband/Partner Detained In Jail For Law 
Violation 1.95 98.05 2.33
* 97.67 1.88* 98.12 
58 Foreclosure on Mortgage Loan 0.56 99.44 1.07* 98.93 1.28 98.72 
	
Significantly associated with clinical elevation for adjustment problems rated by Mother* and/or self-
report Ɨ on a bi-variate analysis (p<0.05)   
	“Clinical	elevation	for	Adjustment	problems”	is	defined	as	the	presence	of	high	(>1 standard deviation 
above the mean)	internalizing	and/or	externalizing	problems	measured	by	the	Youth Self-Report	scale	at	
age	15. 
		
	
	 	
sTable	3.	Variables	associated	with	clinical	elevation	for	clinical	elevation	for	adjustment	problems	at	
age	15,	rated	by	mother.		
	
Mother	report	
Variable		 OR		 95%	CI	 p-value	
Model	1.		 	 	 	
Total	number	of	stressful	life	events	(continuous	
variable,	odds	per	additional	stressful	life	event)		 1.05	 (1.03-1.06)	 <.0001	
	 	 	
		
Gender:	Male	vs.	female	 1.57	 (1.03-2.39)	 0.0375	
Maternal	education	level	
	 	
		
High	school	vs.	graduate	studies		 3.49	 (1.7-7.17)	 0.0003	
Bachelor's	vs.	graduate	studies		 2.09	 (1.05-4.16)	 0.6122	
	 	 	
		
Individual-level	factors	 	 	 	
Emotional	Reactivity:		High	vs.	low	 2.41	 (1.59-3.64)	 <.0001	
Friendship	quality		
	 	
		
High	vs.	low	but	increasing	 0.56	 (0.32-0.98)	 0.3166	
Middle	decreasing	vs.	low	but	increasing	 0.83	 (0.41-1.68)	 0.3021	
Middle	increasing	vs.	low	but	increasing	 0.40	 (0.22-0.73)	 0.0054	
Family-level	factors	 	 	 	
Attachment		 	 	 		
Always	insecure	vs	always	secure	 0.92	 (0.49-1.73)	 0.8974	
Became	insecure	vs.	always	secure		 1.37	 (0.84-2.22)	 0.049	
Became	secure	vs.	always	secure	 0.65	 (0.37-1.14)	 0.073	
Paternal	depression		
	 	
		
Clinically	significant	vs.	low		 2.00	 (1.09-3.68)	 0.0313	
Borderline	vs.	low	 1.12	 (0.74-1.7)	 0.2925	
	 	 	 	
Model	2.	 	 	 	
Stressful	life	events	timing/chronicity		 	 	 		
Once	vs.	never	 2.41	 (1.52-3.8)	 0.3055	
Always	vs.	never	 3.69	 (1.79-7.62)	 0.4126	
Early	vs.	never	 4.74	 (1.98-11.32)	 0.1606	
Late	vs.	never		 4.95	 (2.34-10.48)	 0.0744	
	 	 	 		
Gender:	Male	vs.	female	 1.68	 (1.08-2.6)	 0.0203	
Maternal	education	level	 	 	 		
High	school	vs.	graduate	studies		 4.01	 (1.89-8.54)	 0.0002	
Bachelor's	vs.	graduate	studies		 2.32	 (1.13-4.78)	 0.5380	
	 	 	 	
Individual-level	factors	 	 	 	
Temperament	change		 	 	 		
Increasingly	difficult	vs.	no	change		 1.50	 (0.9-2.48)	 0.0087	
Decreasingly	difficult	vs.	no	change		 0.43	 (0.18-1)	 0.0159	
Emotional	Reactivity:		High	vs.	low	 2.50	 (1.63-3.83)	 <.0001	
Friendship	quality		 	 	 		
High	vs.	low	but	increasing	 0.65	 (0.36-1.17)	 0.4895	
Middle	decreasing	vs.	low	but	increasing	 0.93	 (0.44-1.96)	 0.2904	
Middle	increasing	vs.	low	but	increasing	 0.46	 (0.24-0.86)	 0.0119	
Family-level	factors	 	 	 	
Attachment		 	 	 		
Always	insecure	vs.	always	secure	 1.07	 (0.56-2.03)	 0.7807	
Became	insecure	vs.	always	secure		 1.53	 (0.92-2.55)	 0.0264	
Became	secure	vs.	always	secure	 0.61	 (0.33-1.1)	 0.0265	
Paternal	depression		 	 	 		
Clinically	significant	vs.	low		 1.84	 (0.96-3.51)	 0.0689	
Borderline	vs.	low	 1.08	 (0.7-1.67)	 0.3277	
	 	 	 	
Model	3.		 	 	 	
Stressful	life	events	categories	(high	total	scores)	 	 	 		
Health	and	wellbeing		 1.91	 (1.27-2.88)	 0.0019	
Work/school/finances	 1.02	 (0.65-1.6)	 0.9285	
Emotional	aspects	 1.73	 (1.11-2.7)	 0.0157	
Change	in	family	structure	 1.41	 (0.91-2.16)	 0.1232	
	 	 	 		
Gender:	Male	vs.	female	 1.64	 (1.07-2.5)	 0.0235	
Maternal	education	level	 	 	 		
High	school	vs.	graduate	studies		 3.72	 (1.8-7.68)	 0.0002	
Bachelor's	vs.	graduate	studies		 2.11	 (1.06-4.2)	 0.6937	
	 	 	 		
Individual-level	factors	 	 	 	
Emotional	reactivity:		High	vs.	low	 2.41	 (1.59-3.65)	 <.0001	
Friendship	quality		 	 	 		
High	vs.	low	but	increasing	 0.62	 (0.35-1.09)	 0.5977	
Middle	decreasing	vs.	low	but	increasing	 0.85	 (0.41-1.76)	 0.3287	
Middle	increasing	vs.	low	but	increasing	 0.39	 (0.21-0.72)	 0.0027	
Family-level	factors	 	 	 	
Attachment		 	 	 		
Always	insecure	vs.	always	secure	 1.03	 (0.55-1.94)	 0.8844	
Became	insecure	vs.	always	secure		 1.43	 (0.87-2.33)	 0.0562	
Became	secure	vs.	always	secure	 0.68	 (0.38-1.19)	 0.0686	
Paternal	depression		 	 	 		
Clinically	significant	vs.	low		 2.11	 (1.14-3.89)	 0.021	
Borderline	vs.	low	 1.12	 (0.73-1.71)	 0.2475	
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IMPORTANCE Depressive disorders (DDs), anxiety disorders (ADs), obsessive-compulsive
disorder (OCD), and posttraumatic stress disorder (PTSD) are commonmental disorders in
children and adolescents.
OBJECTIVE To examine the relative efficacy and safety of selective serotonin reuptake
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and placebo for the
treatment of DD, AD, OCD, and PTSD in children and adolescents.
DATA SOURCES PubMed, EMBASE, PsycINFO,Web of Science, and Cochrane Database from
inception through August 7, 2016.
STUDY SELECTION Published and unpublished randomized clinical trials of SSRIs or SNRIs in
youths with DD, AD, OCD, or PTSDwere included. Trials using other antidepressants
(eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded.
DATA EXTRACTION AND SYNTHESIS Effect sizes, calculated as standardizedmean differences
(Hedges g) and risk ratios (RRs) for adverse events, were assessed in a random-effects model.
MAIN OUTCOMES ANDMEASURES Primary outcomes, as defined by authors on
preintervention and postintervention data, mean change data, and adverse event data, were
extracted independently bymultiple observers following PRISMA guidelines.
RESULTS Thirty-six trials were eligible, including 6778 participants (3484 [51.4%] female;
mean [SD] age, 12.9 [5.1] years); 17 studies for DD, 10 for AD, 8 for OCD, and 1 for PTSD.
Analysis showed that SSRIs and SNRIs were significantly more beneficial compared with
placebo, yielding a small effect size (g = 0.32; 95% CI, 0.25-0.40; P < .001). Anxiety disorder
(g = 0.56; 95% CI, 0.40-0.72; P < .001) showed significantly larger between-group effect
sizes than DD (g = 0.20; 95% CI, 0.13-0.27; P < .001). This difference was driven primarily by
the placebo response: patients with DD exhibited significantly larger placebo responses
(g = 1.57; 95% CI, 1.36-1.78; P < .001) compared with those with AD (g = 1.03; 95% CI,
0.84-1.21; P < .001). The SSRIs produced a relatively large effect size for ADs (g = 0.71; 95%
CI, 0.45-0.97; P < .001). Compared with participants receiving placebo, patients receiving an
antidepressant reported significantly more treatment-emergent adverse events (RR, 1.07;
95% CI, 1.01-1.12; P = .01 or RR, 1.49; 95% CI, 1.22-1.82; P < .001, depending on the reporting
method), severe adverse events (RR, 1.76; 95% CI, 1.34-2.32; P < .001), and study
discontinuation due to adverse events (RR, 1.79; 95% CI, 1.38-2.32; P < .001).
CONCLUSIONS AND RELEVANCE Comparedwith placebo, SSRIs and SNRIs aremore beneficial
than placebo in children and adolescents; however, the benefit is small and disorder specific,
yielding a larger drug-placebo difference for AD than for other conditions. Response to
placebo is large, especially in DD. Severe adverse events are significantly more commonwith
SSRIs and SNRIs than placebo.
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.2432
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D epressivedisorders (DDs), anxietydisorders (ADs), ob-sessive-compulsive disorder (OCD), and posttrau-matic stressdisorder (PTSD) are among themost com-
monmental disorders in children and adolescents.1 They are
major public health concerns and predict long-term risk for
various adverse outcomes.2 Thus, early diagnosis and proper
treatment is of critical importance. Selective serotonin reup-
take inhibitors (SSRIs) are first-line pharmaceutical treat-
ments for these disorders, whereas serotonin-norepineph-
rine reuptake inhibitors (SNRIs) are considered second- or
third-line treatments, given the limited available trial data to
support their use.3Thismeta-analysis compares thedifferen-
tial efficacy of thesedrugs across thedisorders forwhich they
are primarily prescribed in a pediatric population and also as-
sessesdifferences in response toplaceboand inadverseevents.
Since the release of fluoxetine hydrochloride in the mid-
1980s, the number of SSRIs and SNRIs has grown substan-
tially.However, theiruse in childrenandadolescents is still de-
bated, thus indicatinganeed formore research into their safety
and efficacy and the comparative efficacy of the newer SNRIs
vs SSRIs.4 Recent meta-analyses generate many questions
about the overall benefits vs costs of using SSRIs to treat ma-
jordepression in childrenandadolescents.5The small amount
of research on SNRIs for pediatric DD has hadmixed results.3
One meta-analysis on pediatric depression found that, al-
though SSRIs differed significantly from placebo, SNRIs and
tricyclic antidepressants did not.6
Althoughmost prior reviews andmeta-analyses of the ef-
fects of SSRIs and SNRIs focused on pediatric DD, consider-
able data also exist on pediatric AD and OCD. The latter stud-
ies suggest thatmost SSRIs have a favorable risk-benefit ratio,
whereas there are insufficient data for the remaining SSRIs.3
There have been relatively few studies on SNRIs for pediatric
AD, despite the fact that the only US Food and Drug Adminis-
tration (FDA)–approvedagent for pediatricAD, duloxetinehy-
drochloride, is an SNRI. To our knowledge, no double-blind,
randomized clinical trials of SNRIs for pediatricOCDhadbeen
conducted as of2016, and limiteddatahavebeen reported for
SSRIs and SNRIs in pediatric PTSD.7
Research on safety and tolerability indicates a high risk of
developing treatment-emergent adverse events (TEAEs)—
most prominently headache and nausea—during treatment
withanantidepressant inpediatricDD.6Severeadverseevents
(SAEs), such as an increased risk of suicidal thoughts and be-
havior, inadults andyouth receivingantidepressantshavealso
beenreported,8 leadingto the implementationofaboxedwarn-
ing on the labels of all antidepressants for pediatric use by the
FDA in 2004, although adoption of the warning remains
controversial.9 In addition, to date no recent meta-analyses
have focusedonhowpediatric adverse effect profiles of SSRIs,
SNRIs, and placebo might differ across disorders.
Finally, there is agrowingbodyof literatureconcerning the
role of placebo effects in studies of SSRIs and SNRIs, based on
large placebo responses in studies of antidepressants in both
adult andpediatric samples.10Factors suchas contactwith re-
search staff may lead to large placebo response rates in pedi-
atric DD11 andmay explainmuchof the variability in pediatric
antidepressant trials.12 For adultswith DD, a genuine placebo
effect has been demonstrated, as the combination of placebo
andsupportive carehasbeenshowntobemorebeneficial than
supportive care alone.13 Conversely, patients in the placebo
groupalsodemonstrateTEAEs.6However,howresponsetopla-
cebo differs across disorders or other study design features in
pediatrics remains understudied.
Toourknowledge,only 1other reviewormeta-analysishas
examined the use of SSRIs and SNRIs across pediatric DD, AD,
OCD,andPTSD.14However, thatearlierstudyisnowadecadeold
andpredates 11primarystudies (n = 2068) that fulfill our inclu-
sioncriteria.Theearlier reviewalsodidnot includeanystudies
onduloxetine,which iscurrently theonlymedicationapproved
for pediatric AD. We therefore conducted an updated and ex-
tendedreviewtoassess theefficacyandsafetyof thesedrugsfor
treatment of DD, AD, OCD, and PTSD, along with between-
disordervariation indrugandplaceboresponses.Psychological
therapiesarenotpartof thismeta-analysis.However,amorere-
cent reviewhascomparedpsychological therapiesaloneand in
combinationwithantidepressantmedication fordepression in
children and adolescents.15
Methods
Search Strategy and Study Selection
The study was conducted in accordance with the PRISMA
statement.16,17WesearchedPubMed,EMBASE,PsycInfo,Coch-
rane, andWebof Science from inceptionuntil August 7, 2016;
clinicaltrials.gov; and fda.gov and checked references of the
included studies as well as previous reviews. Additional in-
formation on search terms is presented in the eAppendix 1 in
the Supplement. In total, this search returned 4899 articles
(eFigure 1 in theSupplement).Thescreeningandselectionpro-
cess was conducted independently by 3 of us (C.L., H.K., and
S.R.Z.). We included randomized, double-blind, placebo-
controlled trials of SSRIs and SNRIs in children and adoles-
cents younger than 18 years, including studies that examined
Key Points
Question Is there a scientific justification to prescribe selective
serotonin reuptake inhibitors and serotonin-norepinephrine
reuptake inhibitors for children and adolescents, based on what is
known about their efficacy and safety?
Findings In a systematic review andmeta-analysis including 36
trials (6778 participants), selective serotonin reuptake inhibitors
and serotonin-norepinephrine reuptake inhibitors were
significantly more beneficial compared with placebo in treating
common pediatric psychiatric disorders, yet also led to
significantly more treatment-emergent and severe adverse
events, such as suicide ideation and suicide attempts, as well as
study discontinuation due to adverse events. Themagnitude of
the effect and adverse event profiles were disorder dependent.
Meaning There is some evidence for the benefit of selective
serotonin reuptake inhibitors and serotonin-norepinephrine
reuptake inhibitors in children and adolescents, but owing to the
higher risk for severe adverse events, a cautious and individual
cost-benefit analysis is of importance.
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drug vs placebo, both in the context of a psychosocial inter-
vention, in which case the combination group was extracted
only if no comparison of drug and placebo alone was given.
Participantswere requiredtohaveadiagnosisofaDD,AD,OCD,
or PTSD, based onDSM-III,DSM-III-R, orDSM-IV-TR criteria.
Comorbiditywasallowed,and informationaboutcomorbiddis-
orders was extracted.
Case reports, comments, letters, gray literature, and re-
views were excluded. Non–second-generation antidepres-
sants (eg,monoamineoxidase inhibitors, tricyclic antidepres-
sants) were also excluded.18 Boston Children’s Hospital
provided approval for the study.
Methodologic Quality Assessment
Twoofus (C.L.andS.R.Z.) independently ratedthequalityof in-
cluded studies based on theCochraneRisk of Bias Assessment
Tool,19withfinalqualityratingsbasedonconsensus.Riskofbias
wasassessed in individual studies (eTable 1 in theSupplement)
and across studies (eFigure 2 in the Supplement).
OutcomeMeasures and Data Extraction
Theprimaryoutcomeasdefinedbyauthorswas chosenas the
soleoutcomemeasure foreachstudy.Preinterventionandpost-
intervention data or mean change data had to be available.
Outcomes had to be reported on a well-validated, disorder-
specific scale (eg, Children's Depression Rating Scale–
Revised, Multidimensional Anxiety Scale for Children, and
Children'sYale-BrownObsessiveCompulsiveScale)oronagen-
eral severity scale (ie, Clinical Global Impression–Severity
Scale). We included only continuous outcome data, since di-
chotomizing continuous scores into categorical outcomedata
leads to a loss of information, reduces power, and creates an
artificial boundary.20,21Wedidnot extract data from improve-
ment scales, suchas theClinicalGlobal Impression-Global Im-
provementScale.Repeatedattemptsweremade tocontact the
authors of studies with incomplete or insufficient data. Two
studies22,23 did not include SDs or SEs, and they were im-
puted by way of the leaving-1-out method.24
Data were extracted independently by 3 of us (C.L., H.K.,
and S.R.Z.). Discrepancies were resolved by consensus. Ex-
tracteddata includeddemographic information,dropout rates,
adverseevents, safety information, andbaselineandendpoint
assessment points. Data from open-label extensions or fol-
low-up after the predesignated end pointwere not extracted.
Statistical Analysis
Threeeffect sizeswerecalculatedforeach includedstudy.First,
drug-placebo difference response was assessed as the differ-
ence inmean change scores between the antidepressants and
placebo. Thedrug andplacebo responseswere assessedas the
meanchange scoresofpreanalysesvspostanalyses in thedrug
and placebo groups, respectively. Effect sizes were calcu-
lated as Hedges g.25 We chose to use random-effects models
rather than fixed-effects models because the studies that we
included were heterogeneous and the number of studies for
the subanalyseswere relatively small.26Heterogeneitywasas-
sessedbycalculating theQ statistic,27 the τ2, and the I2, a trans-
formation ofQ that indicates the proportion of observed vari-
ance that can be attributed to heterogeneity rather than
sampling error.28 The τ2 offers an estimate of the variance
among trueeffect sizes.29Effect sizedifferencesbetween sub-
groups were analyzed using a mixed-effects model.30 Publi-
cation bias was assessed visually by means of funnel plots31
and formally by means of the fail-safe N32 and the Begg ad-
justed-rank correlation test.33Weestimated the sensitivity of
publication bias, using the trim-and-fill method.34
Moderatoranalyseswereconducted for6continuousmod-
erators (treatment duration, publication year, illness duration,
age of onset, number of sites, and baseline severity) and 4 cat-
egoricalmoderators (placebo lead-in, comorbidity, region, and
primary funding source). Details of the applied statistical ap-
proaches are provided in eAppendix 2 in the Supplement.
To evaluate the risk of adverse events in the antidepres-
sant andplacebogroups, risk ratios (RRs) forTEAEs, SAEs, and
studydiscontinuationdue to adverse events across trialswere
calculated in a random-effects model. The RRs of SAEs were
basedon thepercentage of patientswith SAEs. RegardingRRs
of TEAEs, 2 commonly used reporting methods were com-
pared: percentage of patients with TEAEs in each group and
mean number of TEAEs per patient across all reported symp-
toms. Comprehensive Meta-Analysis, version 3 (Biostat) and
R, version 3.2.1 (RFoundation)wereused for calculations and
analyses.
Results
Our search identified35publishedand 1unpublished random-
ized, double-blind trials7,22,23,35-67 including 6778 partici-
pants (3484 [51.4%]female;mean[SD]age, 12.9 [5.1] years) that
compared an SSRI or an SNRI against placebo in patients
younger than 18 years with a diagnosis of AD (n = 10), DD
(n = 17), OCD (n = 8), or PTSD (n = 1) (eFigure 1 in the Supple-
ment). One study reported 2 trials thatwere treated indepen-
dently for analyses55 and another compared a drug plus psy-
chosocial intervention group vs a placebo plus psychosocial
intervention group andwas therefore excluded from thedrug
and placebo response analyses.59Characteristics of the 36 in-
cluded trials are presented in eTable 1 in the Supplement, and
details regarding heterogeneity and publication bias can be
found in the eTable 2, eAppendix 3, eFigure 2, and eFigure 3
in the Supplement.
Thecombinedanalysisbetweengroupsacrossalldisorders
yieldeda small drug-placebodifference (g = 0.32;95%CI,0.25
to0.40;P < .001). Inthebetween-groupanalysisstratifiedbydis-
order, AD (g = 0.56; 95% CI, 0.40 to 0.72; P < .001) and OCD
(g = 0.39; 95%CI, 0.25 to 0.54; P < .001) did not differ signifi-
cantly from each other (P = .14), but both yielded significantly
higher (ADvsDD:P < .001andOCDvsDD:P = .02)drug-placebo
differences than the DD group (g = 0.20; 95% CI, 0.13 to 0.27;
P < .001) (Figure 1). Excluding the unpublished study in the
DDgroup47 ledtoanegligiblechangeineffectsize.Between-drug
analysisyieldedthesmallesteffectsizes forcitalopram(g = 0.18;
95%CI,−0.18 to0.54;P = .33) and escitalopram (g = 0.18;95%
CI,0.01to0.34;P = .03)andthelargesteffectsizeforfluvoxamine
(g = 0.68;95%CI,−0.05 to 1.41;P = .07).However,owing to the
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Figure 1. Between-Group Analyses Stratified by Disorder
–2.00 1.00 2.000
Hedges g
–1.00
Favors Placebo Favors Drug
Hedges gSource
Depressive disorders
SE (95% CI)
SSRI
0.05Atkinson et al,48 2014 0.17 (–0.27 to 0.38)
0.07Emslie et al,49 2014 0.19 (–0.29 to 0.44)
0.34PIR112487,47 2011 0.27 (–0.18 to 0.87)
0.21Emslie et al,45 2009 0.11 (–0.01 to 0.43)
SNRI
0.00Atkinson et al,48 2014 0.17 (–0.33 to 0.33)
0.17Emslie et al,49 2014a 0.19 (–0.20 to 0.54)
0.22Emslie et al,49 2014a 0.19 (–0.15 to 0.58)
0.20Emslie et al,44 2007 0.11 (–0.02 to 0.42)
0.35Findling et al,46 2009 0.39 (–0.42 to 1.11)
0.00von Knorring et al,43 2006 0.13 (–0.25 to 0.26)
0.14Wagner et al,23 2006 0.12 (–0.10 to 0.38)
Anxiety disorders
SSRI
0.53Birmaher et al,52 2003 0.23 (0.08 to 0.99)
1.11da Costa et al,57 2013 0.45 (0.23 to 2.00)
0.47Melvin et al,59 2017 0.31 (–0.14 to 1.07)
1.06RUPP,50 2001 0.19 (0.69 to 1.43)
0.72Wagner et al,53 2004 0.18 (0.49 to 0.95)
1.48Rynn et al,51 2001 0.47 (0.56 to 2.39)
0.32Walkup et al,56 2008 0.18 (–0.04 to 0.68)
0.08Berard et al,41 2006 0.13 (–0.18 to 0.33)
0.05Emslie et al,42 2006 0.14 (–0.22 to 0.33)
0.37Wagner et al,22 2004 0.15 (0.07 to 0.67)
0.40March et al,40 2004 0.17 (0.07 to 0.72)
0.19Wagner et al,39 2003 0.11 (–0.02 to 0.39)
0.52Emslie et al,38 2002 0.14 (0.25 to 0.80)
0.21Keller et al,37 2001 0.15 (–0.08 to 0.51)
0.60Emslie et al,36 1997 0.21 (0.19 to 1.00)
0.21Simeon et al,35 1990 0.36 (–0.49 to 0.91)
0.21Subtotal 0.04 (0.13 to 0.29)
0.16Subtotal 0.08 (0.01 to 0.31)
SNRI
0.48Strawn et al,58 2015 0.12 (0.24 to 0.73)
0.38March et al,54 2007 0.12 (0.15 to 0.62)
0.49Rynn et al,55 2007b 0.16 (0.17 to 0.81)
0.26Rynn et al,55 2007b 0.16 (–0.05 to 0.57)
0.71Subtotal 0.13 (0.45 to 0.97)
Obsessive-compulsive disorder
SSRI
0.00Storch et al,67 2013c 0.45 (–0.89 to 0.89)
0.14Storch et al,67 2013c 0.51 (–0.85 to 1.13)
0.44Geller et al,66 2004 0.14 (0.15 to 0.72)
0.40POTS,65 2004 0.32 (–0.24 to 1.04)
0.24Liebowitz et al,64 2002 0.30 (–0.35 to 0.83)
0.49Geller et al,62 2001 0.21 (0.07 to 0.91)
0.31Riddle et al,63 2001 0.18 (–0.04 to 0.67)
0.42March et al,61 1998 0.15 (0.13 to 0.70)
0.78Riddle et al,60 1992 0.54 (–0.28 to 1.84)
0.39Subtotal 0.08 (0.25 to 0.54)
0.16Subtotal 0.20 (–0.23 to 0.56)
Posttraumatic stress disorder
SSRI
0.16Robb et al,7 2010 0.20 (–0.23 to 0.56)
0.41Subtotal 0.07 (0.27 to 0.54)
Because there was only 1 study,
posttraumatic stress disorder was not
included in the overall analysis. POTS
indicates Pediatric OCD Treatment
Study; RUPP, Research Unit on
Pediatric Psychopharmacology
Anxiety Study Group; SNRI,
serotonin-norepinephrine reuptake
inhibitor; SSRI, selective serotonin
reuptake inhibitor.
a One study reported 2 different
dosages of duloxetine.
bOne study reported 2 trials that
were treated independently for
analyses.
c One study examined 2 forms of
dosing. One treatment armwas
sertraline at standard dosing and
the second treatment armwas
sertraline titrated slowly.
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smallnumberof studiesand large95%CI, theeffect size for flu-
voxaminewas not significant.
In the between-group analysis stratified by drug cat-
egory, SSRIs and SNRIs did not differ significantly in the DD
group (Q = 0.431; P = .51), but SSRIs were significantly better
than SNRIs in theADgroup (Q = 4.161;P = .04). No studies in-
vestigated the use of SNRIs in OCD.
The within-drug group analysis stratified by disorder
yielded no significant difference (P = .07) between studies of
AD (g = 1.68; CI, 1.56-1.79; P < .001) and DD (g = 1.85; 95% CI,
1.7-2.0; P < .001), yet both yielded significantly larger drug
responses (P < .001) than studies of OCD (g = 1.01; 95% CI,
0.88-1.14; P < .001). When stratified by drug, duloxetine
yielded the largest response (g = 1.95; 95% CI, 1.73-2.18;
P < .001) and fluvoxamine the smallest response (g = 1.22;
95% CI, 0.41-2.02; P = .003); however, the difference
between those 2 drugs was not significant (Q = 3.021;
P = .08). The combined analysis across all disorders for the
within-group analysis yielded a drug response of g = 1.65
(95% CI, 1.52-1.78; P < .001). The SSRIs and SNRIs did not
differ significantly in both the DD group (Q = 2.351; P = .13)
and the AD group (Q = 0.341; P = .56).
The within-placebo group analysis stratified by disorder
yieldeda largeplaceboresponse for studiesofDD(g = 1.57;95%
CI, 1.36-1.78;P < .001),whichwassignificantly larger (P < .001)
than the placebo response in studies of AD (g = 1.03; 95% CI,
0.84-1.21;P < .001).Themoderateplaceboresponse in theOCD
group (g = 0.63; 95% CI, 0.47-0.79; P < .001) was signifi-
cantly lower than in both the DD (P < .001) and AD (P = .002)
groups (Figure 2). The combined analysis across all disorders
for thewithin-group analysis yielded a placebo response size
of g = 1.23 (95%CI, 1.06-1.39; P < .001).
Adverse Event Analysis
Twenty-six trials reported thepercentage of patientswithTE-
AEs (reporting method 1), 26 trials reported the mean num-
ber of TEAEs per patient across symptoms (reportingmethod
2), and 15 trials reported both reporting methods. The 2 re-
porting methods differed significantly (across all 52 trials:
P = .002;within the 15 studies reportingboth reportingmeth-
ods: P = .045), indicating higher RRs with reporting method
2. Patients takinganantidepressant reportedsignificantlymore
TEAEs (reportingmethod 1: RR, 1.07;95%CI, 1.01-1.12;P = .01;
reportingmethod 2: RR, 1.49;95%CI, 1.22-1.82;P < .001) and
SAEs (RR, 1.76;95%CI, 1.34-2.32;P < .001) comparedwithpla-
cebo. No significant differences in TEAEs or SAEswere found
betweenSSRIs andSNRIs.TheRRs forTEAEsstratifiedbydrug
anddisorder aredisplayed inTable 1. Discontinuationof treat-
ment due to adverse events was significantly more common
in the antidepressant group comparedwith theplacebogroup
(RR, 1.79; 95% CI, 1.38-2.32; P < .001). The RRs for study dis-
continuationandSAEsstratifiedbydruganddisorder are sum-
marized inTable 2.Mean rates of TEAEs, SAEs, and studydis-
continuation can be found in eTable 3 in the Supplement.
Moderator Analysis
Univariate analyses indicated larger effect sizes as a function
for earlier trials, fewer sites, longer illness duration, and non-
industry funding.However,noneof themoderatorswas found
to be significant in a multivariate meta-regression (eAppen-
dix 3 and eTables 4-6 in the Supplement).
Discussion
Our meta-analysis addresses the response and safety profile
of SNRIs, SSRIs, and placebo in pediatric DD, AD, OCD, and
PTSD. Results indicate that SSRIs and SNRIs aremore benefi-
cial than placebo in treating these commonly diagnosed con-
ditions inchildrenandadolescents.However, theoverall drug-
placebodifference is small andvaries significantlybydisorder,
with a larger response in AD than DD, especially for SSRIs
(g = 0.71;95%CI,0.45-0.97;P < .001). This difference indrug-
placebodifference response ismainly due to a higher placebo
response in pediatricDD. Furthermore, patientswithOCDex-
hibit a significantly smaller response to both drug treatment
and placebo treatment compared with AD and DD.
The small effect size between SSRIs and SNRIs vs placebo
in pediatric DD might be owing to the lack of a clear depres-
sionphenotype.Thiswasapparent inDSM-5 field trials onma-
jor depressive disorder (MDD), which found a low test-retest
reliability (κ = 0.28) forchildren,adolescents,andadults.68Fur-
thermore, there is high comorbiditybetweenpediatricDDand
other disorders, especially AD. A recent review on the use of
SSRIs and SNRIs in pediatric populations reported that ap-
proximately 25% of patients with MDD had a comorbid AD.3
In our meta-analysis, although not all included studies re-
ported comorbidity rates, those doing so reported comorbid-
ity rates in AD ranging between 6% and 56% in patients with
DD.Yet, attempts by theDSM-5workgroup to create a “mixed
anxiety and depression disorder” resulted in an unaccept-
Figure 2. Drug and Placebo Effect Size by Disorder Category
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Because there was only 1 study, posttraumatic stress disorder (PTSD) was not
included in subgroup analyses. Responses to selective serotonin reuptake
inhibitors (SSRIs) were significantly larger in depressive disorders (DDs) and
anxiety disorders (ADs) compared with obsessive-compulsive disorder (OCD)
(both P < .001). The placebo response was significantly larger in DDs compared
with ADs (P < .001) and OCD (P < .001) and significantly larger in ADs compared
with OCD (P < .002). SNRI indicates serotonin-norepinephrine reuptake
inhibitor.
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able rate of test-retest reliability (κ = −0.004) when tested in
the DSM-5 field trials.68
Although it appears that the response to placebo is ro-
bust in pediatric DD, children and adolescentswith ADs, who
Table 2. Risk Ratios of Study Discontinuation Due to Adverse Effects and SAEsa
Disorder and Intervention
Discontinuationb SAEc
No. of Trials RR (95% CI) P Value No. of Trials RR (95% CI) P Value
Overall
SSRI vs placebo 27 1.84 (1.38-2.44) <.001 17 1.71 (1.22-2.40) .002
SNRI vs placebo 6 1.56 (0.83-2.94) .17 7 2.10 (1.19-3.69) .01
Stratified by Disorder
DDs
SSRI vs placebo 14 1.40 (0.99-1.98) .06 11 1.72 (1.12-2.63) .01
SNRI vs placebo 3 2.95 (1.61-5.40) <.001 3 4.43 (1.73-11.32) .002
Combined vs placebo 17 1.66 (1.20-2.28) .002 14 1.99 (1.33-2.97) .001
ADs
SSRI vs placebo 5 3.45 (1.34-8.86) .01 2 2.22 (0.45-10.87) .33
SNRI vs placebo 3 0.78 (0.39-1.56) .48 4 1.37 (0.67-2.78) .39
Combined vs placebo 8 1.38 (0.73-2.60) .33 6 1.48 (0.77-2.83) .24
OCD
SSRI vs placebo 7 3.59 (1.89-6.84) <.001 3 1.35 (0.47-3.92) .58
SNRI vs placebo
PTSD
SSRI vs placebo 1 2.31 (0.47-11.49) .31 1 13.90 (0.81-238.36) .07
SNRI vs placebo
Abbreviations: ADs, anxiety disorders; DDs, depressive disorders;
OCD, obsessive-compulsive disorder; PTSD, posttraumatic stress disorder;
RR, risk ratio; SAEs, severe adverse events; SNRI, serotonin-norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
a Empty cells indicate that no data were available to compute any scores.
b Percentage of patients who discontinued the study owing to adverse events.
c Percentage of patients reporting SAEs.
Table 1. Risk Ratios of TEAEsa
Disorder and Intervention
Reporting Method 1 b Reporting Method 2 c
No. of Trials RR (95% CI) P Value No. of Trials RR (95% CI) P Value
Overall
SSRI vs placebo 19 1.07 (1.02-1.13) .006 24 1.52 (1.22-1.88) <.001
SNRI vs placebo 7 1.07 (0.94-1.22) .33 2 1.56 (0.48-5.04) .46
Stratified by Disorder
DDs
SSRI vs placebo 11 1.06 (0.98-1.14) .13 11 1.46 (1.03-2.07) .03
SNRI vs placebo 4 1.12 (0.84-1.50) .44
Combined vs placebo 15 1.06 (0.98-1.15) .13
ADs
SSRI vs placebo 3 1.23 (0.86-1.76) .25 4 1.39 (0.85-2.26) .19
SNRI vs placebo 3 1.06 (0.90-1.24) .49 2 1.56 (0.48-5.04) .46
Combined vs placebo 6 1.08 (0.97-1.21) .16 6 1.40 (0.93-2.12) .11
OCD
SSRI vs placebo 4 1.08 (0.96-1.21) .19 8 1.89 (1.23-2.88) .003
SNRI vs placebo
PTSD
SSRI vs placebo 1 1.00 (0.83-1.22) .97 1 1.28 (0.42-3.88) .67
SNRI vs placebos
Abbreviations: ADs, anxiety disorders; DDs, depressive disorders;
OCD, obsessive-compulsive disorder; PTSD, posttraumatic stress disorder;
RR, risk ratio; SNRI, serotonin-norepinephrine reuptake inhibitors SSRI,
selective serotonin reuptake inhibitor; TEAEs, treatment-emergent
adverse events.
a Empty cells indicate that no data were available to compute any scores.
b Percentage of patients reporting TEAEs.
c Mean number of TEAEs per patient across all reported symptoms.
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respond to pharmacologic treatment to the same degree as
thosewith DD, do not appear to exhibit such a robust placebo
response. While in line with older reviews in children,69 this
finding is in contrast to adult studies that found no signifi-
cantdifferences inplaceboeffect sizebetweendepressionand
anxiety.70 This contrast is not unique: placebo responses be-
tween children and adults differ significantly for binary out-
comes across a wide variety of diseases.71 One explanation
might be that children and adolescentswithmajorDDmaybe
more demoralized than patients with AD and are therefore
more sensitive to changes in hope and favorablemeanings.69
However, because no pediatric trial included a no-treatment
arm that could serve as a control for the natural course of the
disorders, the difference in placebo responsemay also reflect
differences in theprobabilityof spontaneous improvementbe-
tween the 2 pediatric disorders rather than differences in the
placebo effect. Owing to the small number of studies in chil-
dren,wecouldnot estimate thedrugandplacebo response for
the individual ADs, yet a recent adult study found drug and
placebo effect sizes to be roughly equivalent across ADs.72 In
pediatric patients, however, those with panic disorder seem
to experience a greater placebo response compared with pa-
tients with generalized AD or social phobia.73
Our results are very similar to those of a recent meta-
analysis of 5 decades of research on youth psychological
therapy,74 which found that mean effect sizes at posttreat-
mentwerestrongest forAD(g = 0.61),weakest forDD(g = 0.29),
and nonsignificant formultiproblem treatment (g = 0.15), in-
dicating a general difficulty in establishing a clinically rel-
evantbenefit in the treatmentofpediatricdepression.Thesub-
stantial placebo response in MDD indicates that depressed
children andadolescentsmight benefit from innovative treat-
mentmodalities that harness the power of the placebo effect
in an ethical fashion, including clinician contact11 and other
common factors, such as the patients’ expectations of im-
provement, their desire for relief, and the exposure to treat-
ment rituals. Placebo response also offers several implica-
tions for research design in antidepressant trials. Alternative
designs, suchas adiscontinuationdesign75orn-of-1 trials,76,77
might be recommendedwhenestablishing efficacy,78yet also
have their individual shortcomings.79 Differences between 2
medication groups could provide information about the
magnitudeof expectancy effects. In this regard, response and
remission rates to antidepressants have been shown tobe sig-
nificantly higher in comparator trials comparedwithplacebo-
controlled trials.80 Future instructive studies could incorpo-
ratedesigns inwhichpeoplewho respond toplacebocontinue
to receive placebo.
With regard toadverseevents, our finding thatpatients re-
ceiving any antidepressant reported more TEAEs, SAEs, and
study discontinuation compared with those receiving pla-
cebo is in line with other meta-analyses reporting increased
suicidality (odds ratio, 2.39;95%CI, 1.31-4.33),81 suicidal ide-
ation, and suicide attempts (riskdifference: antidepressant vs
placebo, 0.7%; 95% CI, 0.1%-1.3%)14 in children and adoles-
cents receiving SSRIs and SNRIs comparedwith placebo. This
finding is mainly due to the large amount of significant SSRI
studies, although patients receiving SNRIs reported signifi-
cantlymore SAEs than did those receiving placebo. Thus, our
results support concerns about the safety of antidepressants
in children and adolescents. Evaluating the mean number of
adverseeventsprovidesamoresensitivemeasure thantheper-
centageofpatientsexhibitingat least 1adverseeventandmight
be recommended as the primary reporting method in future
clinical trials.
Limitations
Our study has some limitations. First, none of the random-
ized clinical trials included directly compared effectiveness
acrossdisorders.Accordingly,wecouldonlymake indirect con-
clusionswith regard to disorder specificity. Second, although
ourmeta-analysis includedunpublished trials, reporting bias
could lead to an overly positive representation of findings in
the literature.82 In this regard,manyconcernshavebeen raised
about the accuracy of the data of 1 study in particular: Paxil
Study 329. A reanalysis of the original data found that parox-
etine did not show efficacy for MDD in adolescents and that
the initial study underplayed the drug’s potential to increase
suicidal thoughts amongadolescents.83Third, therewas vari-
ability in themean age and age distribution between studies,
which may have had an effect on results. Response to SSRIs
andSNRIshas been shown tobe lower in children than in ado-
lescents, in part related to a higher placebo response in
children.14 Fourth, the Begg and Eggers tests31,33 used to as-
sess publication bias are valid onlywhen there are 10 ormore
studies being evaluated, andourOCDgroup consisted of only
8 trials. However, no evidence of publication bias was found
in the respective funnel plot. The different reporting meth-
ods of adverse events led to subgroup analyses based on only
a few studies and should therefore be considered prelimi-
nary, requiring further investigation. Furthermore, restric-
tive inclusion criteria of clinical trials, such asnoninclusionof
comorbidity and a higher symptom severity threshold, make
it difficult to generalize results to real-world populations.84
Finally, because only 1 study met our inclusion criteria for
PTSD,7nocategorical analysis of SSRIs andSNRIs for the treat-
ment of pediatric PTSD was possible.
Conclusions
The main findings of this meta-analysis present multiple av-
enues for further analyses. First, the nearly identical re-
sponse rate for pediatric DD and AD deserves further investi-
gation and perhaps the revision of federal prescribing
guidelines for these 2 conditions. Although several SSRIs and
SNRIs have been approved for the treatment of pediatric DD
and OCD, only 1—duloxetine—has recently received FDA ap-
proval for treatment of pediatric ADs.85 Second, the substan-
tial differential response to both drug treatment and placebo
treatment in OCD compared with AD and DD highlights un-
derlyingdifferences in the etiologies andpathogeneses of the
disorders that may require additional interventions for pedi-
atric patients with OCD.86 It is our hope that a research do-
main criteria approach87 will help to elucidate the above-
mentionedpointsandcould leadtobetter treatmentoutcomes.
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Third, additional research into the factors that moderate the
efficacy of SSRIs and SNRIs in children is warranted, as is the
need formore comprehensive reporting of population and ill-
nessdetails (eg, age at onset, durationof illness) in clinical and
pragmatic trials. Finally, the significant variability in the as-
sessment and reporting of adverse events highlights the need
for a standardizedmethodof reportingTEAEsandSAEs.Given
thepotential for life-threatening events in young childrenand
adolescents, understanding the extent to which these medi-
cationsposeagenuine risk toyouth isurgent.Thisneedwould
allow future research to deviate from the current line of stud-
iesestimatingthemagnitudeanddifferencesbetweendrugand
placebo effects and focusmore on precisionmedicine-driven
questions, suchaswhichtreatmentorcombinationthereofmay
be most advantageous for certain patient subgroups in cer-
tain clinical settings.
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1. Search Terms 
 
1.1. PubMed 
 
"Depressive Disorder"[mesh] OR depression*[tiab] OR depressive[tiab] OR dysthymic[tiab] OR 
dysthymia*[tiab] OR "Anxiety Disorders"[Mesh] OR "Anxiety"[Mesh:noexp] OR anxiety[tiab] OR 
obsessive-compulsive[tiab] OR ocd[tiab] OR anankastic[tiab] OR phobic[tiab] OR phobia*[tiab] OR 
panic[tiab] OR stress disorder*[tiab] OR post traumatic stress[tiab] OR posttraumatic stress[tiab] OR 
post traumatic symptom*[tiab] OR posttraumatic symptom*[tiab] OR ptsd[tiab] 
 
"Serotonin Uptake Inhibitors"[Mesh] OR "Serotonin Uptake Inhibitors"[pa] OR serotonin reuptake 
inhibitor*[tiab] OR serotonin uptake inhibitor*[tiab] OR SSRI*[tiab] OR SRI*[tiab] OR serotonin 
norepinephrine reuptake inhibitor*[tiab] OR serotonin norepinephrine uptake inhibitor*[tiab] OR 
SNRI* OR venlafaxin*[tiab] OR desvenlafaxin*[tiab] OR effexor[tiab] OR pristiq[tiab] OR 
milnacipran[tiab] OR levomilnacipran[tiab] OR fetzima[tiab] OR savella[tiab] OR duloxetin*[tiab] OR 
cymbalta[tiab] OR sibutramine[tiab] OR citalopram[tiab] OR celexa[tiab] OR escitalopram[tiab] OR 
lexapro[tiab] OR fluoxetin*[tiab] OR prozac[tiab] OR sarafem[tiab] OR symbyax[tiab] OR 
fluvoxamin*[tiab] OR luvox[tiab] OR paroxetin*[tiab] OR paxil[tiab] OR brisdelle[tiab] OR 
sertralin*[tiab] OR zoloft[tiab] 
 
Child[MeSH Terms] OR Pediatrics[MeSH] OR child*[tiab] OR adolescen*[tiab] OR toddler*[tiab] OR 
teen*[tiab] OR boy[tiab] OR boys[tiab] OR girl*[tiab] OR pediatric[tiab] OR paediatric[tiab] OR 
puber*[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] OR prepuberty*[tiab] OR schoolchild*[tiab] 
OR school age*[tiab] OR preschool*[tiab] OR kindergar*[tiab] OR primary school*[tiab] OR 
secondary school*[tiab] OR elementary school*[tiab] OR high school*[tiab] OR highschool*[tiab] OR 
youth*[tiab] 
 
random*[tw] OR blind*[tiab] OR placebo*[tiab] OR trial[tiab] OR untreated[tiab] OR "not 
treated"[tiab] OR sham[tiab] 
 
1.2. Embase 
 
'depression'/exp OR depression*:ab,ti OR depressive:ab,ti OR dysthymic:ab,ti OR dysthymia*:ab,ti OR 
'anxiety disorder'/exp OR 'anxiety'/de OR anxiety:ab,ti OR obsessive-compulsive:ab,ti OR ocd:ab,ti OR 
anankastic:ab,ti OR phobic:ab,ti OR phobia*:ab,ti OR panic:ab,ti OR (stress NEXT/1 disorder*):ab,ti 
OR (('post traumatic' OR posttraumatic) NEXT/1 (stress OR symptom*)):ab,ti OR ptsd:ab,ti 
 
'serotonin uptake inhibitor'/exp OR  'serotonin noradrenalin reuptake inhibitor'/exp OR (('serotonin 
reuptake' OR 'serotonin uptake' OR 'serotonin norepinephrine reuptake' OR 'serotonin norepinephrine 
uptake') NEXT/1 inhibitor*):ab,ti OR ssri*:ab,ti OR snri*:ab,ti OR venlafaxin*:ab,ti OR 
desvenlafaxin*:ab,ti OR effexor:ab,ti OR pristiq:ab,ti OR milnacipran:ab,ti OR levomilnacipran:ab,ti 
OR fetzima:ab,ti OR savella:ab,ti OR duloxetin*:ab,ti OR cymbalta:ab,ti OR sibutramine:ab,ti OR 
citalopram:ab,ti OR celexa:ab,ti OR escitalopram:ab,ti OR lexapro:ab,ti OR fluoxetin*:ab,ti OR 
prozac:ab,ti OR sarafem:ab,ti OR symbyax:ab,ti OR fluvoxamin*:ab,ti OR luvox:ab,ti OR 
paroxetin*:ab,ti OR paxil:ab,ti OR brisdelle:ab,ti OR sertralin*:ab,ti OR zoloft:ab,ti 
 
'child'/exp AND 'pediatrics'/exp OR child*:ab,ti OR adolescen*:ab,ti OR toddler*:ab,ti OR teen*:ab,ti 
OR boy:ab,ti OR boys:ab,ti OR girl*:ab,ti OR pediatric:ab,ti OR paediatric:ab,ti OR puber*:ab,ti OR 
pubescen*:ab,ti OR prepubescen*:ab,ti OR prepuberty*:ab,ti OR schoolchild*:ab,ti OR (school 
NEXT/1 age*):ab,ti OR preschool*:ab,ti OR kindergar*:ab,ti OR ((primary OR secondary OR 
elementary OR high) NEXT/1 school*):ab,ti OR highschool*:ab,ti OR youth*:ab,ti 
 
random*:ab,de,ti OR blind*:ab,ti OR placebo*:ab,ti OR trial:ab,ti OR untreated:ab,ti OR 'not 
treated':ab,ti OR sham:ab,ti 
 
1.3. PsycInfo 
 
DE ("Major Depression" OR "Dysthymic Disorder" OR "Endogenous Depression" OR "Reactive 
Depression" OR "Recurrent Depression" OR "Treatment Resistant Depression" OR "Anxiety" OR 
"Acute Stress Disorder" OR "Generalized Anxiety Disorder" OR "Obsessive Compulsive Disorder" OR 
"Panic Disorder" OR "Phobias" OR "Posttraumatic Stress Disorder" OR "Panic Disorder" OR "Panic" 
OR "Panic Attack") OR TI (depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR 
	 3 
"obsessive-compulsive" OR ocd OR anankastic OR phobic OR phobia* OR panic OR "stress 
disorder*" OR "post traumatic stress" OR "posttraumatic stress" OR "post traumatic symptom*" OR 
"posttraumatic symptom*" OR ptsd) OR AB (depression* OR depressive OR dysthymic OR 
dysthymia* OR anxiety OR "obsessive-compulsive" OR ocd OR anankastic OR phobic OR phobia* 
OR panic OR "stress disorder*" OR "post traumatic stress" OR "posttraumatic stress" OR "post 
traumatic symptom*" OR "posttraumatic symptom*" OR ptsd)  
 
 
DE ("Serotonin Reuptake Inhibitors" OR "Chlorimipramine" OR "Citalopram" OR "Fluoxetine" OR 
"Fluvoxamine" OR "Paroxetine" OR "Zimeldine" OR "Serotonin Norepinephrine Reuptake Inhibitors" 
OR "Venlafaxine") OR TI ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* 
OR SRI* OR "serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake 
inhibitor*" OR SNRI* OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR 
levomilnacipran OR fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram 
OR celexa OR escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR 
fluvoxamin* OR luvox OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) OR AB 
("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR "serotonin 
norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR SNRI* OR 
venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran OR 
fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR 
escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR 
luvox OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) 
 
AG ("Childhood (birth-12 yrs)") OR TI (child* OR adolescen* OR toddler* OR teen* OR boy OR boys 
OR girl* OR pediatric OR paediatric OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR 
schoolchild* OR "school age*" OR preschool* OR kindergar* OR "primary school*" OR "secondary 
school*" OR "elementary school*" OR "high school*" OR highschool* OR youth*) OR AB (child* OR 
adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR paediatric OR puber* 
OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR "school age*" OR preschool* 
OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary school*" OR "high 
school*" OR highschool* OR youth*) 
 
DE (random*) OR TI (random* OR placebo* OR trial OR untreated OR sham) OR AB (random* OR 
placebo* OR trial OR untreated OR sham) 
Note: "not treated" is handled as a stop word so all records with treated are retrieved. 
 
1.4. Cochrane Central 
 
TI ("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR 
"serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR 
SNRI* OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran 
OR fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR 
escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR 
luvox OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) OR AB ("serotonin reuptake 
inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR "serotonin norepinephrine 
reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR SNRI* OR venlafaxin* OR 
desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran OR fetzima OR savella OR 
duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR escitalopram OR lexapro OR 
fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR luvox OR paroxetin* OR paxil 
OR brisdelle OR sertralin* OR zoloft) 
 
TI (depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-compulsive" 
OR ocd OR anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post traumatic 
stress" OR "posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic symptom*" OR 
ptsd) OR AB (depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-
compulsive" OR ocd OR anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post 
traumatic stress" OR "posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic 
symptom*" OR ptsd) 
 
TI (child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR 
paediatric OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR "school 
age*" OR preschool* OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary 
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school*" OR "high school*" OR highschool* OR youth*) OR AB (child* OR adolescen* OR toddler* 
OR teen* OR boy OR boys OR girl* OR pediatric OR paediatric OR puber* OR pubescen* OR 
prepubescen* OR prepuberty* OR schoolchild* OR "school age*" OR preschool* OR kindergar* OR 
"primary school*" OR "secondary school*" OR "elementary school*" OR "high school*" OR 
highschool* OR youth*) 
 
1.5. Web of Science 
 
TS=("serotonin reuptake inhibitor*" OR "serotonin uptake inhibitor*" OR SSRI* OR SRI* OR 
"serotonin norepinephrine reuptake inhibitor*" OR "serotonin norepinephrine uptake inhibitor*" OR 
SNRI* OR venlafaxin* OR desvenlafaxin* OR effexor OR pristiq OR milnacipran OR levomilnacipran 
OR fetzima OR savella OR duloxetin* OR cymbalta OR sibutramine OR citalopram OR celexa OR 
escitalopram OR lexapro OR fluoxetin* OR prozac OR sarafem OR symbyax OR fluvoxamin* OR 
luvox OR paroxetin* OR paxil OR brisdelle OR sertralin* OR zoloft) 
 
TS=(depression* OR depressive OR dysthymic OR dysthymia* OR anxiety OR "obsessive-
compulsive" OR ocd OR anankastic OR phobic OR phobia* OR panic OR "stress disorder*" OR "post 
traumatic stress" OR "posttraumatic stress" OR "post traumatic symptom*" OR "posttraumatic 
symptom*" OR ptsd) 
 
TS=(child* OR adolescen* OR toddler* OR teen* OR boy OR boys OR girl* OR pediatric OR 
paediatric OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR schoolchild* OR "school 
age*" OR preschool* OR kindergar* OR "primary school*" OR "secondary school*" OR "elementary 
school*" OR "high school*" OR highschool* OR youth*) 
 
TS=(random* OR placebo* OR trial OR untreated OR sham) 
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2. Study Selection 
 
sFigure 1. Flow Chart 
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3.3. Risk of Bias Assessment 
sFigure 2 
 
Note: The large amount of high risk in the “other risk of bias” category was mainly due to per protocol 
analysis rather than intent-to-treat analysis. 
0 20 40 60 80 100
Other Risk of Bias
Selective Reporting
Incomplete Outcome Data
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3.4. Funnel Plots Stratified by Disorder  
Anxiety Disorders 
 
 
Depressive Disorder 
 
 
Obsessive-Compulsive Disorder 
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4. Side Effects 
 
4.1 Mean Percentages and Numbers 
sTable 2a. Mean Percentages and Numbers of TEAEs  
 Reporting Method 1a  Reporting Method 2b 
    
Intervention 
No.  
Trials 
Mean  
Percentage 
Drug 
Mean  
Percentage 
Placebo 
 No.  
Trials 
Mean  
Number 
Drug 
Mean  
Number 
Placebo 
SSRI vs. 
Placebo 19 66.89% 56.84%  24 0.14 0.09 
SNRI vs. 
Placebo 7 62.09% 57.99%  2 0.13 0.09 
aPercent of patients reporting TEAEs.  
bMean number of TEAEs per patient across all reported symptoms. 		
sTable 2b. Mean Percentages of Discontinuation of Study due to TEAEs and SAEs and Mean Percentages 
of SAEs 
 Discontinuationc  SAEd 
    
Intervention 
No.  
Trials 
Mean  
Percentage 
Drug 
Mean  
Percentage 
Placebo 
 No.  
Trials 
Mean 
Percentage 
Drug 
Mean  
Percentage 
Placebo 
SSRI vs. 
Placebo 27 6.83% 3.46%  17 6.24% 3.42% 
SNRI vs. 
Placebo 6 6.80% 3.62%  7 4.75% 2.17% 
cPercent of patients who discontinued the study due to TEAEs and SAEs. 
dPercent of patients reporting SAEs.  
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5. Moderator Analyses 
 
5.1. Methods and Results for the Univariate Analyses – Continuous Variables 
 
Methods: Moderator analyses were conducted for six continuous moderators (treatment duration, 
publication year, illness duration, age of onset, number of sites, and baseline severity) for both the 
combined disorders group and individual disorders groups. We examined whether specific 
characteristics of the studies were related to the effect sizes (i.e., drug-placebo differences) in univariate 
analyses. Continuous variables were analyzed with a meta-regression analysis using method-of-
moments analyses in a random-effects model. The Z-statistic was used to test the significance of the 
slope. As various scales were used to assess baseline severity, we standardized the baseline and 
outcome values by dividing the mean values by the SD. 
 
Results: The relationship between effect size and publication year was significant in the combined 
analyses (Z=-2.36, p=.02), as well as in the DD subgroup analyses (Z=-2.26, p=.02), with recently 
published studies yielding smaller antidepressant-placebo differences. Further, the relationship between 
effect size and illness duration was significant in the combined analyses (Z=2.89, p=.004), indicating 
that children with a longer duration of illness exhibit greater response to antidepressants compared to 
placebo. Finally, number of sites was found to be significantly correlated to effect size in the combined 
analyses (Z=-2.98, p=.003), as well as in the DD subgroup analyses (Z=-2.16, p<.03), and the OCD 
subgroup analyses (Z=-2.16, p=.03), with number of study sites negatively associated with magnitude 
of differences between antidepressants and placebo. See sTable 2 for all calculations.  
 
5.2. Methods and Results for the Univariate Analyses – Categorical Variables 
 
Methods:	Moderator analyses were conducted for four categorical moderators (placebo lead-in, 
comorbidity, region, and primary funding source) for both the combined disorders group and individual 
disorders groups. Categorical variables were analyzed using a mixed-effects model We examined 
whether specific characteristics of the studies were related to the effect sizes (i.e., drug-placebo 
differences) in univariate analyses.  
 
Results: The relationship between effect size and primary funding source was significant in the 
combined analyses (p = .02), as well as in the DD subgroup analyses (p = .02). In both cases, studies 
that were funded by industry yielded significantly smaller effect sizes than those that reported public 
sources of funding only (e.g., NIMH). See sTable 3 for further details. 
 
5.3. Methods and Results for the Multivariate Metaregression Analysis 
 
Methods:	Given the relatively large number of moderator analyses, we decided to conduct a 
multivariate meta-regression. Effect sizes (i.e., dependent variable) were weighted by the sample size 
divided by s2 (i.e., n/var; (1)). Multivariate regression analyses were conducted in SPSS (Version 
21.0.0.2). 
 
This approach is in line with the methods adopted by Cuijpers (2-5). The model indicates the 
significance of each potential moderator while controlling for the others. To avoid collinearity among 
the predictors of the regression model, we first tested whether high correlations (i.e., correlations higher 
than 0.60) were found among the moderators that could be entered into the model. Three variables were 
found to have correlations higher than 0.60: the funding source correlated high with the number of sites 
(r = .698), treatment duration correlated high with illness duration (r = 0.62), and comorbidity 
correlated high with the number of sites (r = -0.75). We decided to use the number of sites (not funding 
source or comorbidity) and illness duration (not treatment duration) as predictors in the model. All 
remaining variables (i.e., illness duration, publication year, baseline severity, number of sites, age of 
onset, placebo lead-in, and study location) were included as predictors in the model. 
 
Results: None of the moderators were found to be significant in the multivariate meta-regression with 
weighted effect sizes. All results can be found in the sTable 4.  
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sTable 3. Continuous Univariate Moderator Analyses 
Moderator Z-Value p-Value 
 Overall 
Treatment Duration 0.57 .57 
Publication Year -2.36 .02 
Baseline Severity 0.20 .84 
Number of Sites -2.98 .003 
Illness Duration 2.89 .004 
Age of Onset -1.11 .27 
 Depressive Disorder 
Treatment Duration -1.12 .26 
Publication Year -2.26 .02 
Baseline Severity 1.21 .23 
Number of Sites -2.16 .03 
Illness Duration -0.01 1.00 
Age of Onset -0.31 .76 
 Obsessive-Compulsive Disorder 
Treatment Duration -0.47 .64 
Publication Year -0.88 .38 
Baseline Severity -0.33 .74 
Number of Sites -0.50 .62 
Illness Duration 0.45 .65 
Age of Onset N/Aa  
 Anxiety Disorders 
Treatment Duration -0.55 .58 
Publication Year -1.90 .06 
Baseline Severity -1.18 .24 
Number of Sites -1.84 .07 
Illness Duration 1.62 .11 
Age of Onset N/Ab  
  aOnly 1 Study 
  bNo Studies 
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sTable 4. Categorical Univariate Moderator Analyses 
Moderator 
Number of 
included 
studies Hedges g 95% CI Q-value I2 p-Value 
Overall 
Placebo lead-in    0.23  .63 
 No 28 0.35 0.25 - 0.46  64.30  
 Yes 13 0.31 0.17 - 0.45  8.66  
Comorbidity    2.47  .12 
 No  6 0.24 0.04 - 0.43  29.90  
 Yes 28 0.41 0.31 - 0.51  60.61  
Study location    1.94  .16 
 US only 27 0.38 0.28 - 0.48  50.10  
 Not US only 14 0.26 0.13 - 0.39  62.97  
Primary funding source    5.42  .02a 
 Industry only 27 0.26 0.19 - 0.33  37.91  
 Public only 11 0.48 0.31 - 0.64  2.97  
Depressive Disorder 
Placebo lead-in    2.71  .10 
 No 11 0.15 0.06 - 0.24  0.00  
 Yes 9 0.26 0.16 - 0.35  23.51  
Comorbidity    1.98  .16 
 No  3 0.12 -0.04 - 0.28  0.00  
 Yes 11 0.25 0.16 - 0.35  27.54  
Study location    2.61  .11 
 US only 10 0.25 0.16 - 0.35  15.15  
 Not US only 10 0.15 0.05 - 0.24  0.00  
Primary funding source    5.64  .02a 
 Industry only 18 0.18 0.11 - 0.25  0.00  
 Public only 2 0.46 0.24 - 0.68  0.00  
Obsessive-Compulsive Disorder 
Placebo lead-in    0.05  .83 
 No 7 0.41 0.22 - 0.60  0.00  
 Yes 2 0.38 0.15 - 0.60  0.00  
Comorbidity N/Ab      
Study location N/Ab      
Primary funding source    0.07  .79 
 Industry only 4 0.41 0.25 - 0.58  0.00  
 Public only 4 0.36 -0.03 - 0.74  0.00  
Anxiety Disorder 
Placebo lead-in    1.69  .19 
 No 9 0.69 0.47 - 0.91  71.87  
 Yes 2 0.37 -0.06 - 0.80  4.13  
Comorbidity    3.32  0.07 
 No  3 0.37 0.06 - 0.69  0.00  
 Yes 8 0.74 0.51 - 0.97  71.38  
Study location    0.00  0.96 
 US only 7 0.62 0.37 - 0.88  78.68  
 Not US only 4 0.63 0.28 - 0.99  9.85  
Primary funding source    0.31  0.58 
 Industry only 4 0.47 0.24 - 0.70  55.44  
 Public only 5 0.57 0.28 - 0.87  48.85  
aSignificant at the p<0.05 
level 
bNot enough variance 
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sTable 5. Multivariate Metaregression Analyses 
 B1 p 
Placebo lead-in -1.02 .90 
Study location 0.63 .59 
Illness Duration -1.23 .52 
Publication Year 0.47 .73 
Age of Onset -1.07 .50 
Number of Sites -0.58 .70 
Baseline Severity 0.14 .85 
 
 
 
 
 
 
 
  
																																																								1	Standarized Beta	
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